

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as Private Foundation

Do not enter social security numbers on this form as it may be made public. Go to www.irs.gov/Form990PF for instructions and the latest information.

2023

Form 990-PF

Department of the Treasury Internal Revenue Service

For calendar year 2023 or tax year beginning APR 1, 2023, and ending MAR 31, 2024

Name of foundation: THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST. A Employer identification number: 13-7184401. B Telephone number: 212-679-3600. C If exemption application is pending, check here... D 1. Foreign organizations, check here... D 2. Foreign organizations meeting the 85% test... E If private foundation status was terminated... F If the foundation is in a 60-month termination... H Check type of organization: Section 501(c)(3) exempt private foundation. I Fair market value of all assets at end of year: \$7,300,077.622. J Accounting method: Accrual.

Table with 5 columns: (a) Revenue and expenses per books, (b) Net investment income, (c) Adjusted net income, (d) Disbursements for charitable purposes. Rows include Revenue (1-12) and Operating and Administrative Expenses (13-26). Total revenue: 385,228,530. Total expenses: 600,086,342. Net investment income: 224,697,955.

**Application for Extension of Time To File an Exempt Organization  
Return or Excise Taxes Related to Employee Benefit Plans**

Department of the Treasury  
Internal Revenue Service

File a separate application for each return.  
Go to [www.irs.gov/Form8868](http://www.irs.gov/Form8868) for the latest information.

**Electronic filing (e-file).** You can electronically file Form 8868 to request up to a 6-month extension of time to file any of the forms listed below except for Form 8870, Information Return for Transfers Associated With Certain Personal Benefit Contracts. An extension request for Form 8870 must be sent to the IRS in a paper format (see instructions). For more details on the electronic filing of Form 8868, visit [www.irs.gov/e-file-providers/e-file-for-charities-and-non-profits](http://www.irs.gov/e-file-providers/e-file-for-charities-and-non-profits).

Caution: If you are going to make an electronic funds withdrawal (direct debit) with this Form 8868, see Form 8453-TE and Form 8879-TE for payment instructions.

All corporations required to file an income tax return other than Form 990-T (including 1120-C filers), partnerships, REMICs, and trusts must use Form 7004 to request an extension of time to file income tax returns.

**Part I - Identification**

<b>Type or Print</b>  <small>File by the due date for filing your return. See instructions.</small>	Name of exempt organization, employer, or other filer, see instructions. THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	Taxpayer identification number (TIN)  13-7184401
	Number, street, and room or suite no. If a P.O. box, see instructions. 230 PARK AVENUE, 659	
	City, town or post office, state, and ZIP code. For a foreign address, see instructions. NEW YORK, NY 10169	

Enter the Return Code for the return that this application is for (file a separate application for each return) 0 4

Application Is For	Return Code	Application Is For	Return Code
Form 990 or Form 990-EZ	01	Form 4720 (other than individual)	09
Form 4720 (individual)	03	Form 5227	10
Form 990-PF	04	Form 6069	11
Form 990-T (sec. 401(a) or 408(a) trust)	05	Form 8870	12
Form 990-T (trust other than above)	06	Form 5330 (individual)	13
Form 990-T (corporation)	07	Form 5330 (other than individual)	14
Form 1041-A	08		

• After you enter your Return Code, complete either Part II or Part III. Part III, including signature, is applicable only for an extension of time to file Form 5330.

• If this application is for an extension of time to file Form 5330, you must enter the following information.

Plan Name \_\_\_\_\_  
 Plan Number \_\_\_\_\_  
 Plan Year Ending (MM/DD/YYYY) \_\_\_\_\_

**Part II - Automatic Extension of Time To File for Exempt Organizations (see instructions)**

The books are in the care of NICHOLAS J. SCHIAVO, CFO  
230 PARK AVENUE, SUITE 659 - NEW YORK, NY 10169

Telephone No. 212-679-3600 Fax No. \_\_\_\_\_

- If the organization does not have an office or place of business in the United States, check this box
- If this is for a Group Return, enter the organization's four-digit Group Exemption Number (GEN) \_\_\_\_\_. If this is for the whole group, check this box . If it is for part of the group, check this box  and attach a list with the names and TINs of all members the extension is for.

**1** I request an automatic 6-month extension of time until FEBRUARY 18, 20 25, to file the exempt organization return for the organization named above. The extension is for the organization's return for:  
 calendar year 20 \_\_\_\_\_ or  
 tax year beginning APR 1, 20 23, and ending MAR 31, 20 24

**2** If the tax year entered in line 1 is for less than 12 months, check reason:  Initial return  Final return  
 Change in accounting period

<b>3a</b> If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions.	<b>3a</b>	\$	6,570,099.
<b>b</b> If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit.	<b>3b</b>	\$	9,523,536.
<b>c</b> <b>Balance due.</b> Subtract line 3b from line 3a. Include your payment with this form, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions.	<b>3c</b>	\$	0.

**For Privacy Act and Paperwork Reduction Act Notice, see instructions.**

Part II Balance Sheets		Attached schedules and amounts in the description column should be for end-of-year amounts only.		
		Beginning of year	End of year	
		(a) Book Value	(b) Book Value	(c) Fair Market Value
Assets	1 Cash - non-interest-bearing	85,800,732.	89,496,038.	89,496,038.
	2 Savings and temporary cash investments	143,734,047.	55,980,540.	55,980,540.
	3 Accounts receivable 604,736.			
	Less: allowance for doubtful accounts	680,960.	604,736.	604,736.
	4 Pledges receivable			
	Less: allowance for doubtful accounts			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons			
	7 Other notes and loans receivable			
	Less: allowance for doubtful accounts			
	8 Inventories for sale or use			
	9 Prepaid expenses and deferred charges	1,129,528.	1,033,231.	1,033,231.
	10a Investments - U.S. and state government obligations			
	b Investments - corporate stock STMT 10	512,806,017.	643,618,129.	643,618,129.
	c Investments - corporate bonds			
	11 Investments - land, buildings, and equipment: basis			
Less: accumulated depreciation				
12 Investments - mortgage loans				
13 Investments - other STMT 11	6,449,780,993.	6,446,813,297.	6,446,813,297.	
14 Land, buildings, and equipment: basis 10,532,026.				
Less: accumulated depreciation STMT 12 3,861,764.	6,890,319.	6,670,262.	6,670,262.	
15 Other assets (describe STATEMENT 13)	56,013,040.	55,861,389.	55,861,389.	
16 Total assets (to be completed by all filers - see the instructions. Also, see page 1, item I)	7,256,835,636.	7,300,077,622.	7,300,077,622.	
Liabilities	17 Accounts payable and accrued expenses	11,336,884.	11,499,434.	
	18 Grants payable	482,673,051.	564,121,729.	
	19 Deferred revenue			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable			
	22 Other liabilities (describe STATEMENT 14)	41,684,887.	45,857,428.	
23 Total liabilities (add lines 17 through 22)	535,694,822.	621,478,591.		
Net Assets or Fund Balances	Foundations that follow FASB ASC 958, check here <input checked="" type="checkbox"/> and complete lines 24, 25, 29, and 30.			
	24 Net assets without donor restrictions	6,721,140,814.	6,678,599,031.	
	25 Net assets with donor restrictions			
	Foundations that do not follow FASB ASC 958, check here <input type="checkbox"/> and complete lines 26 through 30.			
	26 Capital stock, trust principal, or current funds			
	27 Paid-in or capital surplus, or land, bldg., and equipment fund			
	28 Retained earnings, accumulated income, endowment, or other funds			
29 Total net assets or fund balances	6,721,140,814.	6,678,599,031.		
30 Total liabilities and net assets/fund balances	7,256,835,636.	7,300,077,622.		

Part III Analysis of Changes in Net Assets or Fund Balances

1 Total net assets or fund balances at beginning of year - Part II, column (a), line 29 (must agree with end-of-year figure reported on prior year's return)	1	6,721,140,814.
2 Enter amount from Part I, line 27a	2	-214,857,812.
3 Other increases not included in line 2 (itemize) UNREALIZED GAIN ON INVESTMENTS	3	186,800,511.
4 Add lines 1, 2, and 3	4	6,693,083,513.
5 Decreases not included in line 2 (itemize) SEE STATEMENT 9	5	14,484,482.
6 Total net assets or fund balances at end of year (line 4 minus line 5) - Part II, column (b), line 29	6	6,678,599,031.

**Part IV Capital Gains and Losses for Tax on Investment Income**

SEE ATTACHED STATEMENTS

(a) List and describe the kind(s) of property sold (for example, real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.)		(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a				
b				
c				
d				
e				
(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) ((e) plus (f) minus (g))	
a				
b				
c				
d				
e	576,339,287.	326,851,732.	132,680,049.	
Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69.			(i) Gains (Col. (h) gain minus col. (k), but not less than -0-) or Losses (from col. (h))	
(i) FMV as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any		
a				
b				
c				
d				
e			132,680,049.	
2 Capital gain net income or (net capital loss)	{ If gain, also enter in Part I, line 7 If (loss), enter -0- in Part I, line 7 ..... }		2	132,680,049.
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). See instructions. If (loss), enter -0- in Part I, line 8 .....	}		3	N/A

**Part V Excise Tax Based on Investment Income (Section 4940(a), 4940(b), or 4948 - see instructions)**

1a Exempt operating foundations described in section 4940(d)(2), check here <input type="checkbox"/> and enter "N/A" on line 1. Date of ruling or determination letter: _____ (attach copy of letter if necessary - see instructions)	1	3,123,302.
b All other domestic foundations enter 1.39% (0.0139) of line 27b. Exempt foreign organizations, enter 4% (0.04) of Part I, line 12, col. (b) .....		
2 Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-) .....	2	0.
3 Add lines 1 and 2 .....	3	3,123,302.
4 Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-) .....	4	0.
5 <b>Tax based on investment income.</b> Subtract line 4 from line 3. If zero or less, enter -0- .....	5	3,123,302.
6 Credits/Payments:		
a 2023 estimated tax payments and 2022 overpayment credited to 2023 .....	6a	9,523,536.
b Exempt foreign organizations - tax withheld at source .....	6b	0.
c Tax paid with application for extension of time to file (Form 8868) .....	6c	0.
d Backup withholding erroneously withheld .....	6d	0.
7 Total credits and payments. Add lines 6a through 6d .....	7	9,523,536.
8 Enter any <b>penalty</b> for underpayment of estimated tax. Check here <input checked="" type="checkbox"/> if Form 2220 is attached .....	8	0.
9 <b>Tax due.</b> If the total of lines 5 and 8 is more than line 7, enter <b>amount owed</b> .....	9	
10 <b>Overpayment.</b> If line 7 is more than the total of lines 5 and 8, enter the <b>amount overpaid</b> .....	10	6,400,234.
11 Enter the amount of line 10 to be: <b>Credited to 2024 estimated tax</b> 6,400,234. <b>Refunded</b> .....	11	0.

**Part VI-A Statements Regarding Activities**

	Yes	No
<b>1a</b> During the tax year, did the foundation attempt to influence any national, state, or local legislation or did it participate or intervene in any political campaign? .....		X
<b>b</b> Did it spend more than \$100 during the year (either directly or indirectly) for political purposes? See the instructions for the definition ..... If the answer is "Yes" to <b>1a</b> or <b>1b</b> , attach a detailed description of the activities and copies of any materials published or distributed by the foundation in connection with the activities.		X
<b>c</b> Did the foundation file <b>Form 1120-POL</b> for this year? .....		X
<b>d</b> Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year: (1) On the foundation. \$ _____ 0. (2) On foundation managers. \$ _____ 0.		
<b>e</b> Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax imposed on foundation managers. \$ _____ 0.		
<b>2</b> Has the foundation engaged in any activities that have not previously been reported to the IRS? .....		X
If "Yes," attach a detailed description of the activities.		
<b>3</b> Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes .....		X
<b>4a</b> Did the foundation have unrelated business gross income of \$1,000 or more during the year? .....	X	
<b>b</b> If "Yes," has it filed a tax return on <b>Form 990-T</b> for this year? .....	X	
<b>5</b> Was there a liquidation, termination, dissolution, or substantial contraction during the year? .....		X
If "Yes," attach the statement required by <i>General Instruction T</i> .		
<b>6</b> Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either: • By language in the governing instrument, or • By state legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the state law remain in the governing instrument? .....	X	
<b>7</b> Did the foundation have at least \$5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part XIV .....	X	
<b>8a</b> Enter the states to which the foundation reports or with which it is registered. See instructions. _____ <u>NY</u>		
<b>b</b> If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney General (or designate) of each state as required by <i>General Instruction G</i> ? If "No," attach explanation .....	X	
<b>9</b> Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 2023 or the tax year beginning in 2023? See the instructions for Part XIII. If "Yes," complete Part XIII .....		X
<b>10</b> Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing their names and addresses .....		X
<b>11</b> At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the meaning of section 512(b)(13)? If "Yes," attach schedule. See instructions <u>STATEMENT 16</u> <u>STATEMENT 17</u> <u>STMT 18</u> .....	X	
<b>12</b> Did the foundation make a distribution to a donor advised fund over which the foundation or a disqualified person had advisory privileges? If "Yes," attach statement. See instructions .....		X
<b>13</b> Did the foundation comply with the public inspection requirements for its annual returns and exemption application? .....	X	
Website address <u>HELMSLEYTRUST.ORG</u>		
<b>14</b> The books are in care of <u>NICHOLAS J. SCHIAVO, CFO</u> Telephone no. <u>212-679-3600</u> Located at <u>230 PARK AVENUE, SUITE 659, NEW YORK, NY</u> ZIP+4 <u>10169</u>		
<b>15</b> Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of <b>Form 1041</b> - check here <input type="checkbox"/> and enter the amount of tax-exempt interest received or accrued during the year ..... <b>15</b> N/A		
<b>16</b> At any time during calendar year 2023, did the foundation have an interest in or a signature or other authority over a bank, securities, or other financial account in a foreign country? .....	X	
See the instructions for exceptions and filing requirements for FinCEN Form 114. If "Yes," enter the name of the foreign country <u>SEE STATEMENT 15</u>		

**Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required**

File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.

	Yes	No
<b>1a</b> During the year, did the foundation (either directly or indirectly):		
(1) Engage in the sale or exchange, or leasing of property with a disqualified person? .....	X	
(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person? .....		X
(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person? .....	X	
(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person? .....	X	
(5) Transfer any income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)? .....		X
(6) Agree to pay money or property to a government official? ( <b>Exception.</b> Check "No" if the foundation agreed to make a grant to or to employ the official for a period after termination of government service, if terminating within 90 days.) .....		X
<b>b</b> If any answer is "Yes" to 1a(1)-(6), did <b>any</b> of the acts fail to qualify under the exceptions described in Regulations section 53.4941(d)-3 or in a current notice regarding disaster assistance? See instructions .....		X
<b>c</b> Organizations relying on a current notice regarding disaster assistance, check here <input type="checkbox"/>		
<b>d</b> Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that were not corrected before the first day of the tax year beginning in 2023? .....		X
<b>2</b> Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)):		
<b>a</b> At the end of tax year 2023, did the foundation have any undistributed income (Part XII, lines 6d and 6e) for tax year(s) beginning before 2023? .....		X
If "Yes," list the years _____, _____, _____, _____		
<b>b</b> Are there any years listed in 2a for which the foundation is <b>not</b> applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to <b>all</b> years listed, answer "No" and attach statement - see instructions.) .....	N/A	
<b>c</b> If the provisions of section 4942(a)(2) are being applied to <b>any</b> of the years listed in 2a, list the years here. _____, _____, _____, _____		
<b>3a</b> Did the foundation hold more than a 2% direct or indirect interest in any business enterprise at any time during the year? .....	X	
<b>b</b> If "Yes," did it have excess business holdings in 2023 as a result of (1) any purchase by the foundation or disqualified persons after May 26, 1969; (2) the lapse of the 5-year period (or longer period approved by the Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of the 10-, 15-, or 20-year first phase holding period? (Use Form 4720, Schedule C, to determine if the foundation had excess business holdings in 2023.) .....		X
<b>4a</b> Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes? .....		X
<b>b</b> Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2023? .....		X

Form 990-PF (2023)

**Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required** (continued)

	Yes	No
<b>5a</b> During the year, did the foundation pay or incur any amount to:		
(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?		X
(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?		X
(3) Provide a grant to an individual for travel, study, or other similar purposes?		X
(4) Provide a grant to an organization other than a charitable, etc., organization described in section 4945(d)(4)(A)? See instructions	X	
(5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?		X
<b>b</b> If any answer is "Yes" to 5a(1)-(5), did any of the transactions fail to qualify under the exceptions described in Regulations section 53.4945 or in a current notice regarding disaster assistance? See instructions		X
<b>c</b> Organizations relying on a current notice regarding disaster assistance, check here <input type="checkbox"/>		
<b>d</b> If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? SEE STATEMENT 20	X	
If "Yes," attach the statement required by Regulations section 53.4945-5(d).		
<b>6a</b> Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?		X
<b>b</b> Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? If "Yes" to 6b, file Form 8870.		X
<b>7a</b> At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?		X
<b>b</b> If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? N/A		
<b>8</b> Is the foundation subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuneration or excess parachute payment(s) during the year?	X	

**Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors**

**1 List all officers, directors, trustees, and foundation managers and their compensation.**

(a) Name and address	(b) Title, and average hours per week devoted to position	(c) Compensation (If not paid, enter -0-)	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 19		4376329	796034.	0.

**2 Compensation of five highest-paid employees (other than those included on line 1). If none, enter "NONE."**

(a) Name and address of each employee paid more than \$50,000	(b) Title, and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
AL Y. KIM - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	735,817.	187,033.	0.
MEENAKSHI C. LAKSHMAN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIR. OF STRATEGY & RESEARCH 40.00	728,700.	185,916.	0.
CHRISTOPHER J. RAPCEWICZ - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY	DIR. OF RISK MNGMT. & OPERATIONS 40.00	735,462.	167,904.	0.
MAUREEN E. RAYHILL - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF HUMAN RESOURCES 40.00	458,150.	96,071.	0.
BRIAN B. CHUN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	454,231.	80,661.	0.
<b>Total</b> number of other employees paid over \$50,000				104

**Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors** *(continued)*

**3 Five highest-paid independent contractors for professional services. If none, enter "NONE."**

(a) Name and address of each person paid more than \$50,000	(b) Type of service	(c) Compensation
CRESTVIEW III - 590 MADISON AVENUE, 36TH FLOOR, NEW YORK, NY 10022	INVESTMENT MANAGEMENT	3,690,235.
HIGHCLERE INTERNATIONAL INVESTORS - 2 MANCHESTER SQUARE, LONDON, UNITED KINGDOM W1U	INVESTMENT MANAGEMENT	1,729,940.
IFP GLOBAL FRANCHISE - LEVEL 1, 10 PORTMAN SQUARE, LONDON, UNITED KINGDOM W1H 6AZ	INVESTMENT MANAGEMENT	1,241,609.
MARATHON GLOBAL - ORION HOUSE, 5 UPPER ST MARTIN'S LANE, UNITED KINGDOM WC2H 9	INVESTMENT MANAGEMENT	880,955.
SILCHESTER INTL 780 3RD AVE #4201, NEW YORK, NY 10017	INVESTMENT MANAGEMENT	879,842.
<b>Total</b> number of others receiving over \$50,000 for professional services		53

**Part VIII-A Summary of Direct Charitable Activities**

List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.	Expenses
<b>1</b> FOR THE PRODUCTION OF WEBSITE, VIDEO AND OTHER DESIGN SUPPORT TO COMMUNICATE IMPACT IN FURTHERANCE OF THE FOUNDATION'S MISSION.	1,217,774.
<b>2</b> FOR TECHNICAL SUPPORT TO GRANTEES TO MEET THEIR STRATEGIC AND COMMUNICATIONS NEEDS TO DRIVE FURTHER IMPACT OF THEIR CHARITABLE WORK.	170,066.
<b>3</b> FOR CONVENING EXPERTS TO EXPLORE PROGRAM PRIORITIES, SHARE RESEARCH AND IDEAS, AND BRAINSTORM NEW AREAS OF IMPACT IN SUPPORT OF THE FOUNDATION'S MISSION.	249,368.
<b>4</b>	

**Part VIII-B Summary of Program-Related Investments**

Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2.	Amount
<b>1</b> STARTUP HEALTH T1D PRI LP - CATALYZING SEED AND EARLY STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS	2,500,000.
<b>2</b> THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHN'S DISEASE	880,756.
All other program-related investments. See instructions.	
<b>3</b>	
SEE STATEMENT 21	1,187,500.
<b>Total.</b> Add lines 1 through 3	4,568,256.



**Part IX Minimum Investment Return** (All domestic foundations must complete this part. Foreign foundations, see instructions.)

1 Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:			
a	Average monthly fair market value of securities .....	1a	6,913,612,076.
b	Average of monthly cash balances .....	1b	199,653,289.
c	Fair market value of all other assets (see instructions) .....	1c	429,267.
d	<b>Total</b> (add lines 1a, b, and c) .....	1d	7,113,694,632.
e	Reduction claimed for blockage or other factors reported on lines 1a and 1c (attach detailed explanation) .....	1e	0.
2	Acquisition indebtedness applicable to line 1 assets .....	2	0.
3	Subtract line 2 from line 1d .....	3	7,113,694,632.
4	Cash deemed held for charitable activities. Enter 1.5% (0.015) of line 3 (for greater amount, see instructions) .....	4	106,705,419.
5	<b>Net value of noncharitable-use assets.</b> Subtract line 4 from line 3 .....	5	7,006,989,213.
6	<b>Minimum investment return.</b> Enter 5% (0.05) of line 5 .....	6	350,349,461.

**Part X Distributable Amount** (see instructions) (Section 4942(j)(3) and (j)(5) private operating foundations and certain foreign organizations, check here  and do not complete this part.)

1	Minimum investment return from Part IX, line 6 .....	1	350,349,461.
2a	Tax on investment income for 2023 from Part V, line 5 .....	2a	3,123,302.
b	Income tax for 2023. (This does not include the tax from Part V.) .....	2b	189,633.
c	Add lines 2a and 2b .....	2c	3,312,935.
3	Distributable amount before adjustments. Subtract line 2c from line 1 .....	3	347,036,526.
4	Recoveries of amounts treated as qualifying distributions .....	4	7,742,969.
5	Add lines 3 and 4 .....	5	354,779,495.
6	Deduction from distributable amount (see instructions) .....	6	0.
7	<b>Distributable amount</b> as adjusted. Subtract line 6 from line 5. Enter here and on Part XII, line 1 .....	7	354,779,495.

**Part XI Qualifying Distributions** (see instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:			
a	Expenses, contributions, gifts, etc. - total from Part I, column (d), line 26 .....	1a	479,058,575.
b	Program-related investments - total from Part VIII-B .....	1b	4,568,256.
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes .....	2	570,169.
3 Amounts set aside for specific charitable projects that satisfy the:			
a	Suitability test (prior IRS approval required) .....	3a	
b	Cash distribution test (attach the required schedule) .....	3b	
4	<b>Qualifying distributions.</b> Add lines 1a through 3b. Enter here and on Part XII, line 4 .....	4	484,197,000.

Form 990-PF (2023)

**Part XII Undistributed Income** (see instructions)

	(a) Corpus	(b) Years prior to 2022	(c) 2022	(d) 2023
<b>1</b> Distributable amount for 2023 from Part X, line 7 .....				354,779,495.
<b>2</b> Undistributed income, if any, as of the end of 2023:				
<b>a</b> Enter amount for 2022 only .....			168,607.	
<b>b</b> Total for prior years:		0.		
<b>3</b> Excess distributions carryover, if any, to 2023:				
<b>a</b> From 2018 .....				
<b>b</b> From 2019 .....				
<b>c</b> From 2020 .....				
<b>d</b> From 2021 .....				
<b>e</b> From 2022 .....				
<b>f</b> Total of lines 3a through e .....	0.			
<b>4</b> Qualifying distributions for 2023 from Part XI, line 4: \$ 484,197,000.				
<b>a</b> Applied to 2022, but not more than line 2a ...			168,607.	
<b>b</b> Applied to undistributed income of prior years (Election required - see instructions) ...		0.		
<b>c</b> Treated as distributions out of corpus (Election required - see instructions) .....	0.			
<b>d</b> Applied to 2023 distributable amount .....				354,779,495.
<b>e</b> Remaining amount distributed out of corpus	129,248,898.			
<b>5</b> Excess distributions carryover applied to 2023 (If an amount appears in column (d), the same amount must be shown in column (a).) .....	0.			0.
<b>6</b> Enter the net total of each column as indicated below:				
<b>a</b> Corpus. Add lines 3f, 4c, and 4e. Subtract line 5 .....	129,248,898.			
<b>b</b> Prior years' undistributed income. Subtract line 4b from line 2b .....		0.		
<b>c</b> Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed .....		0.		
<b>d</b> Subtract line 6c from line 6b. Taxable amount - see instructions .....		0.		
<b>e</b> Undistributed income for 2022. Subtract line 4a from line 2a. Taxable amount - see instr. ...			0.	
<b>f</b> Undistributed income for 2023. Subtract lines 4d and 5 from line 1. This amount must be distributed in 2024 .....				0.
<b>7</b> Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3) (Election may be required - see instructions) .....	0.			
<b>8</b> Excess distributions carryover from 2018 not applied on line 5 or line 7 .....	0.			
<b>9</b> Excess distributions carryover to 2024. Subtract lines 7 and 8 from line 6a .....	129,248,898.			
<b>10</b> Analysis of line 9:				
<b>a</b> Excess from 2019 ...				
<b>b</b> Excess from 2020 ...				
<b>c</b> Excess from 2021 ...				
<b>d</b> Excess from 2022 ...				
<b>e</b> Excess from 2023 ...	129,248,898.			

**Part XIII Private Operating Foundations** (see instructions and Part VI-A, question 9) N/A

**1 a** If the foundation has received a ruling or determination letter that it is a private operating foundation, and the ruling is effective for 2023, enter the date of the ruling \_\_\_\_\_

**b** Check box to indicate whether the foundation is a private operating foundation described in section \_\_\_\_\_  4942(j)(3) or  4942(j)(5)

	Tax year				(e) Total
	(a) 2023	(b) 2022	(c) 2021	(d) 2020	
<b>2 a</b> Enter the lesser of the adjusted net income from Part I or the minimum investment return from Part IX for each year listed _____					
<b>b</b> 85% (0.85) of line 2a _____					
<b>c</b> Qualifying distributions from Part XI, line 4, for each year listed _____					
<b>d</b> Amounts included in line 2c not used directly for active conduct of exempt activities _____					
<b>e</b> Qualifying distributions made directly for active conduct of exempt activities. Subtract line 2d from line 2c _____					
<b>3</b> Complete 3a, b, or c for the alternative test relied upon:					
<b>a</b> "Assets" alternative test - enter:					
<b>(1)</b> Value of all assets _____					
<b>(2)</b> Value of assets qualifying under section 4942(j)(3)(B)(i) _____					
<b>b</b> "Endowment" alternative test - enter 2/3 of minimum investment return shown in Part IX, line 6, for each year listed _____					
<b>c</b> "Support" alternative test - enter:					
<b>(1)</b> Total support other than gross investment income (interest, dividends, rents, payments on securities loans (section 512(a)(5)), or royalties) _____					
<b>(2)</b> Support from general public and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii) _____					
<b>(3)</b> Largest amount of support from an exempt organization _____					
<b>(4)</b> Gross investment income _____					

**Part XIV Supplementary Information (Complete this part only if the foundation had \$5,000 or more in assets at any time during the year-see instructions.)**

**1 Information Regarding Foundation Managers:**  
**a** List any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than \$5,000). (See section 507(d)(2).)  
 NONE

**b** List any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.  
 NONE

**2 Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs:**  
 Check here  if the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds. If the foundation makes gifts, grants, etc., to individuals or organizations under other conditions, complete items 2a, b, c, and d.

**a** The name, address, and telephone number or email address of the person to whom applications should be addressed:

**b** The form in which applications should be submitted and information and materials they should include:

**c** Any submission deadlines:

**d** Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

**Part XIV** Supplementary Information *(continued)*

<b>3 Grants and Contributions Paid During the Year or Approved for Future Payment</b>				
Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution **	Amount
<b>a Paid during the year</b>				
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	2,053,426.
ACADEMISCH ZIEKENHUIS LEIDEN 2 ALBINUSDREEF LEIDEN, NETHERLANDS	N/A	GOV	SEE STATEMENT	230,038.
ACTION4DIABETES 9 PARKFIELD ROAD TAUNTON, UNITED KINGDOM	N/A	PC	PHILIPPINES T1D TASK FORCE	156,500.
ACUMEN AMERICA, LLC 40 WORTH STREET NEW YORK, NY 10013	N/A	PC	SEE STATEMENT	502,312.
ADI NEGEV-NAHALAT ERAN, R.A. MERHAVIM REGIONAL COUNCIL OFAKIM, ISRAEL	N/A	PC	REHABILITATION WARD EQUIPMENT PROJECT	150,000.
<b>Total</b>	SEE CONTINUATION SHEET(S)			<b>3a</b> 445,672,622.
<b>b Approved for future payment</b>				
INSTITUTE FOR MONITORING PEACE AND CULTURAL TOLERANCE IN SCHOOL EDUCATION 2 JABOTINSKY ST. RAMAT GAN, ISRAEL	N/A	PC	SEE STATEMENT	150,000.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD AUSTIN, TX 78746	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	1,446,574.
ACADEMISCH ZIEKENHUIS LEIDEN 2 ALBINUSDREEF LEIDEN, NETHERLANDS	N/A	GOV	SEE STATEMENT	238,910.
<b>Total</b>	SEE CONTINUATION SHEET(S)			<b>3b</b> 586,831,945.





**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SALE OF PUBLICLY TRADED SECURITIES	P		
b ACADIAN FRONTIER MARKETS	P		11/17/23
c ACADIAN FRONTIER MARKETS	P		03/01/24
d ACADIAN FRONTIER MARKETS	P		07/14/23
e ACADIAN FRONTIER MARKETS	P		06/02/23
f ACADIAN FRONTIER MARKETS	P		02/16/24
g ACADIAN FRONTIER MARKETS	P		02/09/24
h ACCEL GROWTH FD IV LP	P		05/02/23
i ACCEL GROWTH FD IV LP	P		12/01/23
j ACCEL GROWTH FD IV LP	P		06/05/23
k ACCEL GROWTH FD IV LP	P		05/31/23
l ACCEL GROWTH FD IV LP	P		06/15/23
m ACCEL GROWTH FD IV LP	P		12/14/23
n ACCEL GROWTH FD IV LP	P		09/11/23
o ACCEL GROWTH FD IV LP	P		08/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 41,971,866.		14,475,270.	27,496,596.
b 61,991.			61,991.
c 93,958.			93,958.
d 141,696.			141,696.
e 241,066.			241,066.
f 707,008.			707,008.
g 1,686,366.			1,686,366.
h 641,959.			641,959.
i 341,451.			341,451.
j 338,656.			338,656.
k 309,496.			309,496.
l 272,315.			272,315.
m 247,578.			247,578.
n 223,412.			223,412.
o 514,861.			514,861.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			27,496,596.
b			61,991.
c			93,958.
d			141,696.
e			241,066.
f			707,008.
g			1,686,366.
h			641,959.
i			341,451.
j			338,656.
k			309,496.
l			272,315.
m			247,578.
n			223,412.
o			514,861.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACCEL GROWTH FUND II LP	P		09/14/23
b ACCEL GROWTH FUND II LP	P		08/02/23
c ACCEL GROWTH FUND II LP	P		08/21/23
d ACCEL GROWTH FUND II LP	P		12/01/23
e ACCEL GROWTH FUND II LP	P		05/22/23
f ACCEL GROWTH FUND II LP	P		11/07/23
g ACCEL GROWTH FUND II LP	P		05/31/23
h ACCEL GROWTH FUND III LP	P		08/04/23
i ACCEL LEADERS FUND LP	P		03/21/24
j ACCEL LEADERS FUND LP	P		11/29/23
k ACCEL LEADERS FUND LP	P		12/08/23
l ACCEL LEADERS FUND LP	P		12/11/23
m ACCEL LEADERS FUND LP	P		08/04/23
n ACCEL LEADERS FUND LP	P		12/11/23
o ANDREESSEN HOROWITZ FD III LP	P		12/29/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 368,531.			368,531.
b 185,061.			185,061.
c 180,041.			180,041.
d 174,007.			174,007.
e 159,662.			159,662.
f 159,340.			159,340.
g 133,478.			133,478.
h 1,176,640.			1,176,640.
i 566,375.			566,375.
j 488,445.			488,445.
k 186,078.			186,078.
l 186,078.			186,078.
m 515,517.			515,517.
n		186,078.	-186,078.
o 16,437,071.			16,437,071.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			368,531.
b			185,061.
c			180,041.
d			174,007.
e			159,662.
f			159,340.
g			133,478.
h			1,176,640.
i			566,375.
j			488,445.
k			186,078.
l			186,078.
m			515,517.
n			-186,078.
o			16,437,071.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	



**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ANDREESSEN HOROWITZ FD III LP	P		07/14/23
b ANDREESSEN HOROWITZ FD III LP	P		03/29/24
c AH PARALLEL FUND III LP	P		12/29/23
d ANDREESSEN HOROWITZ FD IV LP	P		02/14/24
e AH PARALLEL FUND IV LP	P		02/14/24
f ANDREESSEN HOROWITZ LSV FD I	P		03/25/24
g ANDREESSEN HOROWITZ LSV FD I	P		03/25/24
h ANDREESSEN HOROWITZ LSV FD I	P		03/25/24
i ANDREESSEN HOROWITZ LSV FD I	P		03/25/24
j ANDREESSEN HOROWITZ FUND V LP	P		03/15/24
k ANDREESSEN HOROWITZ FUND V LP	P		03/15/24
l AH PARALLEL FUND V LP	P		03/15/24
m AH PARALLEL FUND V LP	P		03/15/24
n AH PARALLEL FUND V LP	P		03/15/24
o ANGELENO INVESTORS III	P		12/21/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 143,082.			143,082.
b 216,948.			216,948.
c 1,941,818.			1,941,818.
d 563,540.			563,540.
e 306,422.			306,422.
f 3,070,384.			3,070,384.
g 3,057,987.			3,057,987.
h		12,397.	-12,397.
i		3,057,987.	-3,057,987.
j 559,245.			559,245.
k 39,048.			39,048.
l 307,809.			307,809.
m 233.			233.
n		465.	-465.
o 2,192,741.			2,192,741.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			143,082.
b			216,948.
c			1,941,818.
d			563,540.
e			306,422.
f			3,070,384.
g			3,057,987.
h			-12,397.
i			-3,057,987.
j			559,245.
k			39,048.
l			307,809.
m			233.
n			-465.
o			2,192,741.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ARBORETUM VENTURES IV LP	P		10/19/23
b BLACKROCK US DEBT INDEX FUND B	P		02/06/24
c BLACKROCK US DEBT INDEX FUND B	P		05/24/23
d BLACKROCK US DEBT INDEX FUND B	P		08/09/23
e BLACKROCK US DEBT INDEX FUND B	P		10/30/23
f BLACKROCK US DEBT INDEX FUND B	P		12/18/23
g BLACKROCK US DEBT INDEX FUND B	P		12/11/23
h BLACKROCK US DEBT INDEX FUND B	P		12/04/23
i BLACKROCK US DEBT INDEX FUND B	P		11/27/23
j BLACKROCK US DEBT INDEX FUND B	P		11/20/23
k BLACKROCK US DEBT INDEX FUND B	P		11/13/23
l BLACKROCK US DEBT INDEX FUND B	P		11/06/23
m BLACKROCK US DEBT INDEX FUND B	P		11/01/23
n CHATHAM ASSET PARTNERS HIGH YIELD FUND LP	P		09/30/23
o CHATHAM CO INVEST	P		03/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 294,556.			294,556.
b 16,811.		15,711.	1,100.
c 19,874.		22,596.	-2,722.
d 20,186.		22,964.	-2,778.
e 20,087.		23,849.	-3,762.
f 10,000,000.		9,336,356.	663,644.
g 10,000,000.		9,517,648.	482,352.
h 10,000,000.		9,552,881.	447,119.
i 10,000,000.		10,338,558.	-338,558.
j 10,000,000.		11,283,926.	-1,283,926.
k 10,000,000.		11,452,818.	-1,452,818.
l 10,000,000.		11,477,585.	-1,477,585.
m 10,000,000.		11,676,991.	-1,676,991.
n 2,064.		1,048.	1,016.
o 72,486.		229,186.	-156,700.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			294,556.
b			1,100.
c			-2,722.
d			-2,778.
e			-3,762.
f			663,644.
g			482,352.
h			447,119.
i			-338,558.
j			-1,283,926.
k			-1,452,818.
l			-1,477,585.
m			-1,676,991.
n			1,016.
o			-156,700.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a CHATHAM CO INVEST	P		03/31/23
b COLLER INTERNATIONAL PARTNERS VI	P		09/22/23
c COLLER INTERNATIONAL PARTNERS VI	P		12/15/23
d COLLER INTERNATIONAL PARTNERS VI	P		03/27/24
e COLLER INTERNATIONAL PARTNERS VI	P		06/26/23
f COLLER INTERNATIONAL PARTNERS VI	P		11/10/23
g COLLER INTL PARTNERS VII LP	P		12/22/23
h COLLER INTL PARTNERS VII LP	P		05/18/23
i COLLER INTL PARTNERS VII LP	P		10/31/23
j COLLER INTL PARTNERS VII LP	P		09/28/23
k CRESTVIEW PARTNERS III LP	P		01/12/24
l CRESTVIEW PARTNERS IV LP	P		02/27/24
m EIG ENERGY FUND XVI LP	P		06/06/23
n EIG ENERGY FUND XVI LP	P		02/02/24
o EIG ENERGY FUND XVI LP	P		11/10/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 245,370.		72,486.	172,884.
b 161,048.			161,048.
c 256,134.			256,134.
d 278,766.			278,766.
e 315,000.			315,000.
f 628,652.			628,652.
g 274,598.			274,598.
h 935,000.			935,000.
i 1,540,000.			1,540,000.
j 1,974,500.			1,974,500.
k 2,492,866.			2,492,866.
l 6,168,962.			6,168,962.
m 45,902.			45,902.
n 119,599.			119,599.
o 911,617.			911,617.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			172,884.
b			161,048.
c			256,134.
d			278,766.
e			315,000.
f			628,652.
g			274,598.
h			935,000.
i			1,540,000.
j			1,974,500.
k			2,492,866.
l			6,168,962.
m			45,902.
n			119,599.
o			911,617.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ENERGY FUND XV-A LP	P		11/10/23
b EIG ENERGY FD XVII LP	P		09/28/23
c EIG ENERGY FD XVII LP	P		06/26/23
d EIG ENERGY FD XVII LP	P		08/15/23
e EIG ENERGY FD XVII LP	P		10/27/23
f EMERGENCE CAPITAL PARTNERS III	P		11/15/23
g PROJECT ELECTRON LP-TBU	P		12/06/23
h EPIRIS FUND II B LP	P		08/04/23
i EPIRIS FUND II B LP	P		11/07/23
j EPIRIS FUND II B LP	P		08/04/23
k EPIRIS FUND II B LP	P		02/06/24
l EPIRIS FUND II B LP	P		12/06/23
m EPIRIS FUND II B LP	P		06/22/23
n EPIRIS FUND III LP	P		03/07/24
o EPIRIS FUND III LP	P		12/18/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 84,929.			84,929.
b 74,382.			74,382.
c 172,069.			172,069.
d 172,171.			172,171.
e 185,641.			185,641.
f 2,029,399.			2,029,399.
g 43,582.			43,582.
h 5,816.			5,816.
i 9,600.			9,600.
j 13,026.			13,026.
k 15,550.			15,550.
l 20,426.			20,426.
m 31,955.			31,955.
n		3,301.	-3,301.
o 19,455.			19,455.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			84,929.
b			74,382.
c			172,069.
d			172,171.
e			185,641.
f			2,029,399.
g			43,582.
h			5,816.
i			9,600.
j			13,026.
k			15,550.
l			20,426.
m			31,955.
n			-3,301.
o			19,455.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a EPIRIS FUND III LP	P		10/12/23
b FDAF DISLOCATED I LP	P		01/05/23
c FORTISSIMO CAPITAL FUND IV LP	P		11/28/23
d FRAZIER LIFE SCIENCES IX LP	P		10/24/23
e FRAZIER LIFE SCIENCES IX LP	P		02/22/24
f FRAZIER LIFE SCI PUBLIC OVERAGE LP	P		07/21/23
g FRAZIER LIFE SCI PUBLIC OVERAGE LP	P		02/06/24
h FRAZIER LIFE SCI PUBLIC OVERAGE LP	P		03/25/24
i FRAZIER LIFE SCI PUBLIC FD LP	P		02/06/24
j FRAZIER LIFE SCI PUBLIC FD LP	P		12/15/23
k FRAZIER LIFE SCI PUBLIC FD LP	P		03/25/24
l FRAZIER LIFE SCI PUBLIC FD LP	P		08/16/23
m FRAZIER LIFE SCIENCES X LP	P		09/29/23
n FRAZIER LIFE SCIENCES X LP	P		01/08/24
o FRAZIER LIFE SCIENCES X LP	P		08/15/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 43,691.			43,691.
b		10,929,899.	-10,929,899.
c 2,670,500.			2,670,500.
d 348,083.			348,083.
e 562,691.			562,691.
f 116,033.			116,033.
g 401,071.			401,071.
h 859,141.			859,141.
i 205,532.			205,532.
j 324,214.			324,214.
k 834,039.			834,039.
l 1,099,199.			1,099,199.
m 99,208.			99,208.
n 355,152.			355,152.
o 571,281.			571,281.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			43,691.
b			-10,929,899.
c			2,670,500.
d			348,083.
e			562,691.
f			116,033.
g			401,071.
h			859,141.
i			205,532.
j			324,214.
k			834,039.
l			1,099,199.
m			99,208.
n			355,152.
o			571,281.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a FRAZIER LIFE SCIENCES XI LP	P		08/15/23
b FRAZIER LIFE SCIENCES XI LP	P		03/29/24
c GAVEA INVEST FD V PLUS B LP	P		09/06/23
d GENERAL ATLANTIC SERVICE COMPANY LLC	P		01/12/24
e GENERAL ATLANTIC SERVICE COMPANY LLC	P		09/01/23
f GENERAL ATLANTIC SERVICE COMPANY LLC	P		08/14/23
g GENERAL ATLANTIC SERVICE COMPANY LLC	P		08/07/23
h GENERAL ATLANTIC SERVICE COMPANY LLC	P		07/26/23
i GENERAL ATLANTIC SERVICE COMPANY LLC	P		09/20/23
j GENERAL ATLANTIC SERVICE COMPANY LLC	P		12/06/23
k GENERAL ATLANTIC SERVICE COMPANY LLC	P		05/03/23
l GA MANAGED ACCOUNT PROGRAM	P		07/31/23
m GA MANAGED ACCOUNT PROGRAM	P		07/26/23
n GA MANAGED ACCOUNT PROGRAM	P		08/17/23
o GA MANAGED ACCOUNT PROGRAM	P		02/20/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 221,313.			221,313.
b 240,824.			240,824.
c 294,147.			294,147.
d		560,323.	-560,323.
e		116,591.	-116,591.
f 5,090.			5,090.
g 35,517.			35,517.
h 89,476.			89,476.
i 675,902.			675,902.
j 780,032.			780,032.
k 12,238,639.			12,238,639.
l		285,850.	-285,850.
m		16,702.	-16,702.
n		15,953.	-15,953.
o		11,027.	-11,027.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			221,313.
b			240,824.
c			294,147.
d			-560,323.
e			-116,591.
f			5,090.
g			35,517.
h			89,476.
i			675,902.
j			780,032.
k			12,238,639.
l			-285,850.
m			-16,702.
n			-15,953.
o			-11,027.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GA MANAGED ACCOUNT PROGRAM	P		08/14/23
b GA MANAGED ACCOUNT PROGRAM	P		08/07/23
c GA MANAGED ACCOUNT PROGRAM	P		12/01/23
d GA MANAGED ACCOUNT PROGRAM	P		04/28/23
e GA MANAGED ACCOUNT PROGRAM	P		12/22/23
f GA MANAGED ACCOUNT PROGRAM	P		06/26/23
g GA MANAGED ACCOUNT PROGRAM	P		02/08/24
h GA MANAGED ACCOUNT PROGRAM	P		02/01/24
i GA MANAGED ACCOUNT PROGRAM	P		06/15/23
j GA MANAGED ACCOUNT PROGRAM	P		05/03/23
k GSO CAPITAL SOLUTIONS FD III LP	P		05/24/23
l GSO CAPITAL SOLUTIONS FD III LP	P		07/17/23
m GSO CAPITAL SOLUTIONS FD III LP	P		07/17/23
n GSO CAPITAL SOLUTION	P		08/25/23
o HIG BIOVENTURES II	P		09/29/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 2,400.			2,400.
b 2,691.			2,691.
c 100,250.			100,250.
d 109,987.			109,987.
e 230,515.			230,515.
f 280,928.			280,928.
g 352,328.			352,328.
h 2,602,251.			2,602,251.
i 2,628,414.			2,628,414.
j 12,298,199.			12,298,199.
k 40,637.			40,637.
l 2,206,780.		3,039,263.	-832,483.
m 2,206,780.		3,039,263.	-832,483.
n 2,599,898.		12,952,701.	-12,952,701.
o 2,599,898.			2,599,898.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			2,400.
b			2,691.
c			100,250.
d			109,987.
e			230,515.
f			280,928.
g			352,328.
h			2,602,251.
i			2,628,414.
j			12,298,199.
k			40,637.
l			-832,483.
m			-832,483.
n			-12,952,701.
o			2,599,898.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV Capital Gains and Losses for Tax on Investment Income**

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIG BRAZIL & LATIN AME PTNRS MASTER B LP	P		09/28/23
b HIG BRAZIL & LATIN AME PTNRS MASTER B LP	P		04/19/23
c HIG BRAZIL & LATIN AME PTNRS MASTER C LP	P		09/28/23
d HIG BRAZIL & LATIN AME PTNRS MASTER C LP	P		04/19/23
e HIG CAPITAL PARTNERS V L P	P		11/28/23
f HIG CAPITAL PARTNERS V L P	P		02/16/24
g HIG CAPITAL PARTNERS V L P	P		07/26/23
h H.I.G. GROWTH BUYOUTS & EQUITY FUND II L.P..	P		12/01/23
i H.I.G. GROWTH BUYOUTS & EQUITY FUND II L.P..	P		12/29/23
j H.I.G. GROWTH BUYOUTS & EQUITY FUND II L.P..	P		08/28/23
k H.I.G. GROWTH BUYOUTS & EQUITY FUND II L.P..	P		12/01/23
l HIG GROWTH B&EQ FD III LP	P		07/26/23
m HIG MIDDLE MKT LBO FD II LP	P		09/26/23
n HIG MIDDLE MKT LBO FD II LP	P		04/21/23
o HIGHCLERE INTL SMALL CAP FUND	P		10/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 370,738.			370,738.
b 1,105,465.			1,105,465.
c 370,738.			370,738.
d 1,105,465.			1,105,465.
e 769,340.			769,340.
f 2,174,116.			2,174,116.
g 2,445,695.			2,445,695.
h 174,007.			174,007.
i 337,752.			337,752.
j 670,766.			670,766.
k		174,007.	-174,007.
l 428,164.			428,164.
m 167,041.			167,041.
n 690,013.			690,013.
o 87,119.			87,119.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			370,738.
b			1,105,465.
c			370,738.
d			1,105,465.
e			769,340.
f			2,174,116.
g			2,445,695.
h			174,007.
i			337,752.
j			670,766.
k			-174,007.
l			428,164.
m			167,041.
n			690,013.
o			87,119.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3



**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGHCLERE INTL SMALL CAP FUND	P		11/30/23
b HIGHCLERE INTL SMALL CAP FUND	P		09/30/23
c HIGHCLERE INTL SMALL CAP FUND	P		05/31/23
d HIGHCLERE INTL SMALL CAP FUND	P		06/30/23
e HIGHCLERE INTL SMALL CAP FUND	P		02/29/24
f HIGHCLERE INTL SMALL CAP FUND	P		01/31/24
g HIGHCLERE INTL SMALL CAP FUND	P		08/31/23
h HIGHCLERE INTL SMALL CAP FUND	P		04/30/23
i HIGHCLERE INTL SMALL CAP FUND	P		12/31/23
j HIGHCLERE INTL SMALL CAP FUND	P		03/31/24
k HIGHCLERE INTL SMALL CAP FUND	P		07/31/23
l HIGHCLERE INTL SMID CAP FUND	P		10/31/23
m HIGHCLERE INTL SMID CAP FUND	P		09/30/23
n HIGHCLERE INTL SMID CAP FUND	P		05/31/23
o HIGHCLERE INTL SMID CAP FUND	P		11/30/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 94,205.			94,205.
b 95,900.			95,900.
c 96,735.			96,735.
d 98,466.			98,466.
e 98,589.			98,589.
f 99,042.			99,042.
g 99,346.			99,346.
h 99,834.			99,834.
i 100,113.			100,113.
j 101,098.			101,098.
k 101,460.			101,460.
l 42,927.			42,927.
m 44,717.			44,717.
n 45,669.			45,669.
o 46,271.			46,271.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			94,205.
b			95,900.
c			96,735.
d			98,466.
e			98,589.
f			99,042.
g			99,346.
h			99,834.
i			100,113.
j			101,098.
k			101,460.
l			42,927.
m			44,717.
n			45,669.
o			46,271.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGHCLERE INTL SMID CAP FUND	P		06/30/23
b HIGHCLERE INTL SMID CAP FUND	P		08/31/23
c HIGHCLERE INTL SMID CAP FUND	P		02/29/24
d HIGHCLERE INTL SMID CAP FUND	P		01/31/24
e HIGHCLERE INTL SMID CAP FUND	P		04/30/23
f HIGHCLERE INTL SMID CAP FUND	P		03/31/24
g HIGHCLERE INTL SMID CAP FUND	P		07/31/23
h HIGHCLERE INTL SMID CAP FUND	P		12/31/23
i HONGSHAN CAP GR FD III LP	P		02/01/24
j HONGSHAN CAP GR FD III LP	P		09/14/23
k HONGSHAN CAP GR FD III LP	P		03/14/24
l HONGSHAN CAP GR FD IV LP	P		01/11/24
m HONGSHAN CAP GR FD V LP	P		01/11/24
n HONGSHAN CAP GR FD V LP	P		06/13/23
o HONGSHAN CAP GR FD V LP	P		11/30/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 46,408.			46,408.
b 46,503.			46,503.
c 46,670.			46,670.
d 47,218.			47,218.
e 47,332.			47,332.
f 47,737.			47,737.
g 48,180.			48,180.
h 48,401.			48,401.
i 545,347.			545,347.
j 567,039.			567,039.
k 2,679,640.			2,679,640.
l 1,763,479.			1,763,479.
m 144,901.			144,901.
n 184,690.			184,690.
o 265,310.			265,310.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			46,408.
b			46,503.
c			46,670.
d			47,218.
e			47,332.
f			47,737.
g			48,180.
h			48,401.
i			545,347.
j			567,039.
k			2,679,640.
l			1,763,479.
m			144,901.
n			184,690.
o			265,310.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HONGSHAN CAP VENT FD IV LP	P		02/20/24
b HONGSHAN CAP VENT FD V LP	P		05/16/23
c HONGSHAN CAP VENT FD VII LP	P		08/28/23
d HONGSHAN CAP VENT FD VII LP	P		11/24/23
e IDG CHINA CAPITAL FUND III LP	P		05/05/23
f IDG CHINA CAPITAL FUND III LP	P		12/26/23
g IDG CHINA VENTURE CAP FD IV LP	P		09/27/23
h IDG CHINA VENTURE CAP FD IV LP	P		03/27/24
i IDG CHINA VENTURE CAP FD IV LP	P		12/26/23
j IDG-ACCEL CHINA GROWTH FUND III L.P.	P		12/28/23
k IDG-ACCEL CHINA GROWTH FUND III L.P.	P		09/21/23
l IRON POINT RE PARTNERS IV LP	P		08/31/23
m IRON POINT RE PARTNERS IV LP	P		10/31/23
n IRON POINT RE PARTNERS IV LP	P		04/28/23
o IRON POINT RE PARTNERS IV LP	P		12/29/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 460,581.			460,581.
b 256,791.			256,791.
c 140,494.			140,494.
d 392,473.			392,473.
e 112,939.			112,939.
f 162,581.			162,581.
g 1,164,005.			1,164,005.
h 3,280,128.			3,280,128.
i 8,618,234.			8,618,234.
j 753,350.			753,350.
k 903,149.			903,149.
l 54,545.			54,545.
m 311,033.			311,033.
n 929,694.			929,694.
o 1,037,775.			1,037,775.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			460,581.
b			256,791.
c			140,494.
d			392,473.
e			112,939.
f			162,581.
g			1,164,005.
h			3,280,128.
i			8,618,234.
j			753,350.
k			903,149.
l			54,545.
m			311,033.
n			929,694.
o			1,037,775.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a IRON POINT RE PARTNERS IV LP	P		07/31/23
b JERICHO CAPITAL INTERNATIONAL LTD	P		12/31/23
c JERICHO CAPITAL INTERNATIONAL LTD	P		12/31/23
d PEG SECONDARY PE INVESTORS III LP	P		06/13/23
e PEG SECONDARY PE INVESTORS III LP	P		12/26/23
f LA CAPITAL GLOBAL EQUITY FUND	P		05/31/23
g LA CAPITAL GLOBAL EQUITY FUND	P		10/31/23
h LA CAPITAL GLOBAL EQUITY FUND	P		04/30/23
i LA CAPITAL GLOBAL EQUITY FUND	P		09/30/23
j LA CAPITAL GLOBAL EQUITY FUND	P		06/30/23
k LA CAPITAL GLOBAL EQUITY FUND	P		08/31/23
l LA CAPITAL GLOBAL EQUITY FUND	P		11/30/23
m LA CAPITAL GLOBAL EQUITY FUND	P		07/31/23
n LA CAPITAL GLOBAL EQUITY FUND	P		12/31/23
o LA CAPITAL GLOBAL EQUITY FUND	P		01/31/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,616,034.			1,616,034.
b 9,222,102.		4,985,910.	4,236,192.
c 175,219,935.		94,732,298.	80,487,637.
d 291,623.			291,623.
e 468,454.			468,454.
f 13,133.			13,133.
g 13,309.			13,309.
h 13,441.			13,441.
i 13,625.			13,625.
j 13,794.			13,794.
k 13,982.			13,982.
l 14,189.			14,189.
m 14,231.			14,231.
n 14,721.			14,721.
o 15,051.			15,051.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			1,616,034.
b			4,236,192.
c			80,487,637.
d			291,623.
e			468,454.
f			13,133.
g			13,309.
h			13,441.
i			13,625.
j			13,794.
k			13,982.
l			14,189.
m			14,231.
n			14,721.
o			15,051.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a LA CAPITAL GLOBAL EQUITY FUND	P		02/29/24
b LA CAPITAL GLOBAL EQUITY FUND	P		03/31/24
c LACM WORLD SMALL CAP EQUITY FUND LP	P		10/31/23
d LACM WORLD SMALL CAP EQUITY FUND LP	P		05/31/23
e LACM WORLD SMALL CAP EQUITY FUND LP	P		04/28/23
f LACM WORLD SMALL CAP EQUITY FUND LP	P		09/29/23
g LACM WORLD SMALL CAP EQUITY FUND LP	P		06/30/23
h LACM WORLD SMALL CAP EQUITY FUND LP	P		11/30/23
i LACM WORLD SMALL CAP EQUITY FUND LP	P		08/31/23
j LACM WORLD SMALL CAP EQUITY FUND LP	P		07/31/23
k LACM WORLD SMALL CAP EQUITY FUND LP	P		01/31/24
l LACM WORLD SMALL CAP EQUITY FUND LP	P		12/29/23
m LACM WORLD SMALL CAP EQUITY FUND LP	P		02/29/24
n LACM WORLD SMALL CAP EQUITY FUND LP	P		03/28/24
o THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		02/29/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 15,537.			15,537.
b 16,041.			16,041.
c 12,889.			12,889.
d 12,928.			12,928.
e 13,394.			13,394.
f 13,511.			13,511.
g 13,854.			13,854.
h 14,025.			14,025.
i 14,061.			14,061.
j 14,442.			14,442.
k 15,243.			15,243.
l 15,310.			15,310.
m 15,837.			15,837.
n 16,458.			16,458.
o 77,811.		51,011.	26,800.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			15,537.
b			16,041.
c			12,889.
d			12,928.
e			13,394.
f			13,511.
g			13,854.
h			14,025.
i			14,061.
j			14,442.
k			15,243.
l			15,310.
m			15,837.
n			16,458.
o			26,800.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		01/31/24
b THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		12/29/23
c THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		07/31/23
d THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		11/30/23
e THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		08/31/23
f THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		06/30/23
g THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		09/29/23
h THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		05/31/23
i THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		04/28/23
j THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		10/31/23
k THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		03/28/24
l MHR LONGEVITY FUND LP	P		03/21/23
m MHR LONGEVITY FUND LP	P		06/01/23
n MHR LONGEVITY FUND LP	P		10/26/23
o MHR LONGEVITY FUND LP	P		08/15/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 75,832.		51,681.	24,151.
b 75,212.		51,924.	23,288.
c 74,306.		52,408.	21,898.
d 73,095.		52,717.	20,378.
e 73,301.		52,742.	20,559.
f 72,354.		53,169.	19,185.
g 70,779.		53,699.	17,080.
h 69,874.		54,220.	15,654.
i 69,683.		54,337.	15,346.
j 68,728.		54,553.	14,175.
k 79,980.		80,044.	-64.
l 3,381,794.		2,896,439.	485,355.
m 4,999,720.		4,274,989.	724,731.
n 5,999,703.		4,953,794.	1,045,909.
o 7,280,573.		6,044,903.	1,235,670.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			24,151.
b			23,288.
c			21,898.
d			20,378.
e			20,559.
f			19,185.
g			17,080.
h			15,654.
i			15,346.
j			14,175.
k			-64.
l			485,355.
m			724,731.
n			1,045,909.
o			1,235,670.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a MHR INSTITUTIONAL PTNRS IV LP	P		04/25/23
b MHR INSTITUTIONAL PTNRS IV LP	P		08/22/23
c ORBIMED ASIA PARTNERS III LP	P		03/07/24
d ORBIMED ISRAEL PTNRS II LP	P		04/21/23
e ORBIMED PRIVATE INVEST VI LP	P		12/14/23
f ORBIMED PRIVATE INVEST VI LP	P		01/10/24
g ORBIMED PRIVATE INVEST VI LP	P		01/10/24
h ORBIMED PRIVATE INVEST VI LP	P		03/22/24
i ORBIMED PRIVATE INVEST VI LP	P		06/08/23
j ORBIMED PRIVATE INVEST VI LP	P		04/27/23
k ORBIMED PRIVATE INVEST VI LP	P		12/14/23
l ORBIMED PRIVATE INVEST VI LP	P		02/15/24
m ORBIMED PRIVATE INVEST VII LP	P		03/26/24
n ORBIMED PRIVATE INVEST VIII LP	P		06/15/23
o ORBIMED PRIVATE INVEST VIII LP	P		03/12/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 59,327.			59,327.
b 846,247.			846,247.
c 4,004,245.			4,004,245.
d 1,171,332.			1,171,332.
e			0.
f			0.
g 105,137.			105,137.
h 118,065.			118,065.
i 127,931.			127,931.
j 262,761.			262,761.
k 313,400.			313,400.
l 361,361.			361,361.
m 1,303,634.			1,303,634.
n 1,496,878.			1,496,878.
o 2,663,109.			2,663,109.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			59,327.
b			846,247.
c			4,004,245.
d			1,171,332.
e			0.
f			0.
g			105,137.
h			118,065.
i			127,931.
j			262,761.
k			313,400.
l			361,361.
m			1,303,634.
n			1,496,878.
o			2,663,109.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a PEAK XV PARTNERS V	P		04/20/23
b PEAK XV PARTNERS V	P		12/22/23
c RIDGEWOOD ENERGY OIL & GAS FD III LP	P		06/26/23
d RIDGEWOOD ENERGY OIL & GAS FD III LP	P		03/22/24
e S CAPITAL LP	P		12/19/23
f SEQUOIA CAPITAL FUND	P		10/21/22
g SEQUOIA CAPITAL FUND	P		11/04/22
h SEQUOIA CAPITAL FUND	P		09/20/22
i SEQUOIA CAPITAL FUND	P		11/30/22
j SEQUOIA CAPITAL FUND	P		07/31/22
k SEQUOIA CAPITAL FUND	P		11/30/22
l SEQUOIA CAPITAL FUND	P		08/26/22
m SEQUOIA CAPITAL FUND	P		08/26/22
n SEQUOIA CAPITAL FUND	P		10/21/22
o SEQUOIA CAPITAL FUND	P		11/30/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 156,151.			156,151.
b 178,485.			178,485.
c 171,472.			171,472.
d 375,446.			375,446.
e 257,700.			257,700.
f 628,894.		524,759.	104,135.
g 626,904.		524,759.	102,145.
h 409,493.		333,938.	75,555.
i 212,708.		178,050.	34,658.
j 194,997.		159,018.	35,979.
k 94,986.		79,509.	15,477.
l 58,499.		47,705.	10,794.
m 25,798.		21,038.	4,760.
n 25,213.		21,038.	4,175.
o 25,133.		21,038.	4,095.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			156,151.
b			178,485.
c			171,472.
d			375,446.
e			257,700.
f			104,135.
g			102,145.
h			75,555.
i			34,658.
j			35,979.
k			15,477.
l			10,794.
m			4,760.
n			4,175.
o			4,095.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3



**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL FUND	P		01/31/23
b SEQUOIA CAPITAL FUND	P		12/31/22
c SEQUOIA CAPITAL FUND	P		03/31/23
d SEQUOIA CAPITAL FUND	P		09/30/23
e SEQUOIA CAPITAL FUND	P		03/31/23
f SEQUOIA CAPITAL FUND	P		08/26/22
g SEQUOIA CAPITAL FUND	P		10/21/22
h SEQUOIA CAPITAL FUND	P		11/30/22
i SEQUOIA CAPITAL FUND	P		12/31/22
j SEQUOIA CAPITAL FUND	P		01/31/23
k SEQUOIA CAPITAL FUND	P		05/15/23
l SEQUOIA CAPITAL FUND	P		12/31/23
m SEQUOIA CAPITAL FUND	P		10/31/23
n SEQUOIA CAPITAL FUND	P		08/26/22
o SEQUOIA CAPITAL FUND	P		07/31/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 24,796.		21,038.	3,758.
b 24,796.		21,038.	3,758.
c 24,035.		21,038.	2,997.
d 7,122.		7,114.	8.
e 21,038.		20,947.	91.
f 21,038.		20,951.	87.
g 21,038.		20,951.	87.
h 21,038.		20,951.	87.
i 21,038.		20,951.	87.
j 21,038.		20,951.	87.
k 20,909.		22,926.	-2,017.
l 35,610.		35,881.	-271.
m 42,053.		42,007.	46.
n 47,705.		47,508.	197.
o 43,950.		47,547.	-3,597.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			3,758.
b			3,758.
c			2,997.
d			8.
e			91.
f			87.
g			87.
h			87.
i			87.
j			87.
k			-2,017.
l			-271.
m			46.
n			197.
o			-3,597.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL FUND	P		04/28/23
b SEQUOIA CAPITAL FUND	P		02/21/24
c SEQUOIA CAPITAL FUND	P		01/31/24
d SEQUOIA CAPITAL FUND	P		11/30/23
e SEQUOIA CAPITAL FUND	P		08/31/23
f SEQUOIA CAPITAL FUND	P		06/16/23
g SEQUOIA CAPITAL FUND	P		11/06/23
h SEQUOIA CAPITAL FUND	P		06/30/23
i SEQUOIA CAPITAL FUND	P		11/30/22
j SEQUOIA CAPITAL FUND	P		12/31/23
k SEQUOIA CAPITAL FUND	P		09/19/23
l SEQUOIA CAPITAL FUND	P		02/29/24
m SEQUOIA CAPITAL FUND	P		05/15/23
n SEQUOIA CAPITAL FUND	P		02/01/24
o SEQUOIA CAPITAL FUND	P		02/29/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 43,950.		48,414.	-4,464.
b 53,400.		53,837.	-437.
c 63,079.		63,559.	-480.
d 63,079.		63,631.	-552.
e 63,079.		67,155.	-4,076.
f 63,079.		68,241.	-5,162.
g 71,220.		71,762.	-542.
h 71,220.		77,049.	-5,829.
i 79,509.		79,181.	328.
j 79,509.		80,114.	-605.
k 87,900.		87,805.	95.
l 89,000.		89,728.	-728.
m 87,900.		96,380.	-8,480.
n 106,800.		107,612.	-812.
o 142,440.		143,605.	-1,165.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			-4,464.
b			-437.
c			-480.
d			-552.
e			-4,076.
f			-5,162.
g			-542.
h			-5,829.
i			328.
j			-605.
k			95.
l			-728.
m			-8,480.
n			-812.
o			-1,165.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV Capital Gains and Losses for Tax on Investment Income**

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL FUND	P		04/30/23
b SEQUOIA CAPITAL FUND	P		07/31/22
c SEQUOIA CAPITAL FUND	P		09/19/23
d SEQUOIA CAPITAL FUND	P		11/30/22
e SEQUOIA CAPITAL FUND	P		03/31/24
f SEQUOIA CAPITAL FUND	P		02/21/24
g SEQUOIA CAPITAL FUND	P		02/21/24
h SEQUOIA CAPITAL FUND	P		09/20/22
i SEQUOIA CAPITAL FUND	P		02/01/24
j SEQUOIA CAPITAL FUND	P		03/31/24
k SEQUOIA CAPITAL FUND	P		11/17/23
l SEQUOIA CAPITAL FUND	P		11/06/23
m SEQUOIA CAPITAL FUND	P		07/31/23
n SEQUOIA CAPITAL FUND	P		10/21/22
o SEQUOIA CAPITAL FUND	P		11/04/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 142,440.		156,161.	-13,721.
b 159,018.		158,361.	657.
c 174,920.		174,730.	190.
d 178,050.		177,315.	735.
e 178,000.		179,455.	-1,455.
f 213,660.		215,407.	-1,747.
g 318,036.		320,636.	-2,600.
h 333,938.		332,559.	1,379.
i 356,100.		359,011.	-2,911.
j 391,710.		394,913.	-3,203.
k 397,545.		400,568.	-3,023.
l 508,858.		512,728.	-3,870.
m 477,054.		516,097.	-39,043.
n 524,759.		522,592.	2,167.
o 524,759.		522,592.	2,167.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			-13,721.
b			657.
c			190.
d			735.
e			-1,455.
f			-1,747.
g			-2,600.
h			1,379.
i			-2,911.
j			-3,203.
k			-3,023.
l			-3,870.
m			-39,043.
n			2,167.
o			2,167.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL FUND	P		03/22/24
b SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		12/14/23
c SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		12/08/23
d SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		12/04/23
e SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		11/30/23
f SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/28/23
g SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/27/23
h SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/08/23
i SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		03/01/24
j SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		01/11/24
k SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		09/27/23
l SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		03/05/24
m SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/07/23
n SEQUOIA CAP GBL GR FD	P		03/01/24
o SEQUOIA CAP GBL GR FD	P		03/05/24

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,160,831.		1,170,322.	-9,491.
b 1,578,466.			1,578,466.
c 1,491,943.			1,491,943.
d 1,471,819.			1,471,819.
e 1,466,554.			1,466,554.
f 1,434,034.			1,434,034.
g 1,376,040.			1,376,040.
h 1,353,030.			1,353,030.
i 615,323.			615,323.
j 425,044.			425,044.
k 170,131.			170,131.
l 294,498.			294,498.
m 400,047.			400,047.
n 763,899.			763,899.
o 260,781.			260,781.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			-9,491.
b			1,578,466.
c			1,491,943.
d			1,471,819.
e			1,466,554.
f			1,434,034.
g			1,376,040.
h			1,353,030.
i			615,323.
j			425,044.
k			170,131.
l			294,498.
m			400,047.
n			763,899.
o			260,781.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP GBL GR FD	P		09/27/23
b SEQUOIA CAP GBL GR FD	P		05/23/23
c SEQUOIA CAP GBL GROWTH FD II	P		01/11/24
d SEQUOIA CAP GBL GROWTH FD II	P		11/20/23
e SEQUOIA CAP GBL GROWTH FD II	P		11/13/23
f SEQUOIA CAP GBL GROWTH FD II	P		11/07/23
g SEQUOIA CAP GBL GROWTH FD II	P		08/08/23
h SEQUOIA CAP GBL GROWTH FD II	P		09/05/23
i SEQUOIA CAP GBL GROWTH FD II	P		08/29/23
j SEQUOIA CAP GBL GROWTH FD II	P		09/27/23
k SEQUOIA CAP GBL GROWTH FD II	P		03/05/24
l SEQUOIA US E EXPANSION FUND I	P		12/31/22
m SEQUOIA CAP US GR FD VIII LP	P		02/08/24
n SEQUOIA CAP US GR FD VIII LP	P		01/30/24
o SEQUOIA CAP US GR FD VIII LP	P		12/14/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 306,458.			306,458.
b 484,514.			484,514.
c 1,238,639.			1,238,639.
d 790,194.			790,194.
e 766,541.			766,541.
f 758,718.			758,718.
g 719,783.			719,783.
h 711,141.			711,141.
i 695,494.			695,494.
j 164,365.			164,365.
k 484,298.			484,298.
l		287,317.	-287,317.
m 248,987.			248,987.
n 35,306.			35,306.
o 388,842.			388,842.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			306,458.
b			484,514.
c			1,238,639.
d			790,194.
e			766,541.
f			758,718.
g			719,783.
h			711,141.
i			695,494.
j			164,365.
k			484,298.
l			-287,317.
m			248,987.
n			35,306.
o			388,842.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VII LP	P		12/14/23
b SEQUOIA CAP US GROWTH FD VII LP	P		12/08/23
c SEQUOIA CAP US GROWTH FD VII LP	P		12/04/23
d SEQUOIA CAP US GROWTH FD VII LP	P		11/30/23
e SEQUOIA CAP US GROWTH FD VII LP	P		06/28/23
f SEQUOIA CAP US GROWTH FD VII LP	P		06/27/23
g SEQUOIA CAP US GROWTH FD VII LP	P		06/08/23
h SEQUOIA CAP US GROWTH FD VII LP	P		08/08/23
i SEQUOIA CAP US GROWTH FD VII LP	P		11/20/23
j SEQUOIA CAP US GROWTH FD VII LP	P		11/13/23
k SEQUOIA CAP US GROWTH FD VII LP	P		11/07/23
l SEQUOIA CAP US GROWTH FD VII LP	P		08/08/23
m SEQUOIA CAP US GROWTH FD VII LP	P		09/05/23
n SEQUOIA CAP US GROWTH FD VII LP	P		08/29/23
o SEQUOIA CAP US GROWTH FD VII LP	P		06/07/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 490,651.			490,651.
b 489,349.			489,349.
c 483,019.			483,019.
d 481,363.			481,363.
e 471,133.			471,133.
f 452,890.			452,890.
g 445,652.			445,652.
h 361,878.			361,878.
i 277,360.			277,360.
j 266,861.			266,861.
k 264,138.			264,138.
l 250,583.			250,583.
m 247,574.			247,574.
n 242,127.			242,127.
o 208,725.			208,725.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			490,651.
b			489,349.
c			483,019.
d			481,363.
e			471,133.
f			452,890.
g			445,652.
h			361,878.
i			277,360.
j			266,861.
k			264,138.
l			250,583.
m			247,574.
n			242,127.
o			208,725.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VII LP	P		05/22/23
b SEQUOIA CAP US GROWTH FD VII LP	P		05/17/23
c SEQUOIA CAP US GROWTH FD VII LP	P		08/07/23
d SEQUOIA CAP US GR FUND IX LP	P		12/05/23
e SEQUOIA CAP US GROWTH FD VI LP	P		08/25/23
f SEQUOIA CAP US GROWTH FD VI LP	P		08/30/23
g SEQUOIA CAP US GROWTH FD VI LP	P		08/16/23
h SEQUOIA CAP US GROWTH FD VI LP	P		08/22/23
i SEQUOIA CAP US GROWTH FD VI LP	P		08/21/23
j SEQUOIA CAP US GROWTH FD VI LP	P		09/05/23
k SEQUOIA CAP US GROWTH FD VI LP	P		11/20/23
l SEQUOIA CAP US GROWTH FD VI LP	P		11/13/23
m SEQUOIA CAP US GROWTH FD VI LP	P		11/07/23
n SEQUOIA CAP US GROWTH FD VI LP	P		08/08/23
o SEQUOIA CAP US GROWTH FD VI LP	P		09/05/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 169,544.			169,544.
b 158,500.			158,500.
c		1,308.	-1,308.
d 109,870.			109,870.
e 704,494.			704,494.
f 684,604.			684,604.
g 507,592.			507,592.
h 486,637.			486,637.
i 486,637.			486,637.
j 405,664.			405,664.
k 259,879.			259,879.
l 242,794.			242,794.
m 240,337.			240,337.
n 228,109.			228,109.
o 225,395.			225,395.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			169,544.
b			158,500.
c			-1,308.
d			109,870.
e			704,494.
f			684,604.
g			507,592.
h			486,637.
i			486,637.
j			405,664.
k			259,879.
l			242,794.
m			240,337.
n			228,109.
o			225,395.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VI LP	P		08/29/23
b SEQUOIA CAP US GROWTH FD VI LP	P		03/01/24
c SEQUOIA CAP US GROWTH FD VI LP	P		09/05/23
d SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/16/23
e SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/22/23
f SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/21/23
g SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/25/23
h SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/30/23
i SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		09/05/23
j SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		11/20/23
k SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		11/13/23
l SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		11/07/23
m SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/08/23
n SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		09/05/23
o SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		08/29/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 220,481.			220,481.
b 195,805.			195,805.
c		405,664.	-405,664.
d 1,542,538.			1,542,538.
e 1,483,792.			1,483,792.
f 1,483,792.			1,483,792.
g 1,435,175.			1,435,175.
h 1,413,082.			1,413,082.
i 1,245,562.			1,245,562.
j 713,589.			713,589.
k 671,663.			671,663.
l 665,176.			665,176.
m 632,892.			632,892.
n 625,726.			625,726.
o 612,752.			612,752.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			220,481.
b			195,805.
c			-405,664.
d			1,542,538.
e			1,483,792.
f			1,483,792.
g			1,435,175.
h			1,413,082.
i			1,245,562.
j			713,589.
k			671,663.
l			665,176.
m			632,892.
n			625,726.
o			612,752.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3



**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		09/05/23
b THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		03/28/24
c THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		12/29/23
d THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		02/29/24
e THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		01/31/24
f THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		07/31/23
g THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		11/30/23
h THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		08/31/23
i THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		09/30/23
j THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		06/30/23
k THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		04/28/23
l THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		10/31/23
m THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		05/31/23
n SPDR S&P 500 ETF TRUST	P		12/04/23
o STARWOOD GLOBAL OPP FD XI LP	P		12/15/23

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a		1,245,562.	-1,245,562.
b	77,882.	56,580.	21,302.
c	76,640.	59,264.	17,376.
d	75,760.	59,365.	16,395.
e	75,792.	59,390.	16,402.
f	74,806.	59,763.	15,043.
g	73,114.	59,975.	13,139.
h	73,207.	60,050.	13,157.
i	72,128.	60,243.	11,885.
j	71,467.	60,479.	10,988.
k	71,068.	60,630.	10,438.
l	69,126.	60,882.	8,244.
m	68,852.	61,106.	7,746.
n	25,091,453.	25,566,371.	-474,918.
o	386,971.		386,971.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			-1,245,562.
b			21,302.
c			17,376.
d			16,395.
e			16,402.
f			15,043.
g			13,139.
h			13,157.
i			11,885.
j			10,988.
k			10,438.
l			8,244.
m			7,746.
n			-474,918.
o			386,971.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a VENTURE LENDING & LEASING VII LLC	P		06/06/23
b VENTURE LENDING & LEASING VIII LLC	P		06/06/23
c ACADIAN FRONTIER MARKETS	P		
d ACADIAN FRONTIER MARKETS	P		
e ACADIAN FRONTIER MARKETS	P		
f ACADIAN FRONTIER MARKETS	P		
g ACADIAN FRONTIER MARKETS	P		
h ACADIAN FRONTIER MARKETS	P		
i ACADIAN FRONTIER MARKETS	P		
j ACADIAN FRONTIER MARKETS	P		
k ACADIAN FRONTIER MARKETS	P		
l ACADIAN FRONTIER MARKETS	P		
m ACADIAN FRONTIER MARKETS	P		
n ACADIAN FRONTIER MARKETS	P		
o ACADIAN FRONTIER MARKETS	P		

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 541,673.			541,673.
b 599,367.			599,367.
c		3,149,477.	-3,149,477.
d		187,389.	-187,389.
e		10,180.	-10,180.
f		139,443.	-139,443.
g		490,824.	-490,824.
h		45,353.	-45,353.
i		502,258.	-502,258.
j		45,698.	-45,698.
k		598,000.	-598,000.
l		46,322.	-46,322.
m		3,056,144.	-3,056,144.
n		46,183.	-46,183.
o		77,786.	-77,786.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			541,673.
b			599,367.
c			-3,149,477.
d			-187,389.
e			-10,180.
f			-139,443.
g			-490,824.
h			-45,353.
i			-502,258.
j			-45,698.
k			-598,000.
l			-46,322.
m			-3,056,144.
n			-46,183.
o			-77,786.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACADIAN FRONTIER MARKETS	P		
b ACADIAN FRONTIER MARKETS	P		
c ACADIAN FRONTIER MARKETS	P		
d ACADIAN FRONTIER MARKETS	P		
e ACADIAN FRONTIER MARKETS	P		
f ACADIAN FRONTIER MARKETS	P		
g ACADIAN FRONTIER MARKETS	P		
h ACADIAN FRONTIER MARKETS	P		
i ACADIAN FRONTIER MARKETS	P		
j ACADIAN FRONTIER MARKETS	P		
k ACADIAN FRONTIER MARKETS	P		
l ACADIAN FRONTIER MARKETS	P		
m ACADIAN FRONTIER MARKETS	P		
n ACADIAN FRONTIER MARKETS	P		
o ACADIAN FRONTIER MARKETS	P		

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a		46,472.	-46,472.
b		120,255.	-120,255.
c		74,636.	-74,636.
d		92,393.	-92,393.
e		1,705.	-1,705.
f		26,772.	-26,772.
g		3,852.	-3,852.
h		46,005.	-46,005.
i		142,267.	-142,267.
j		135,500.	-135,500.
k		4,140.	-4,140.
l		54,177.	-54,177.
m		3,297.	-3,297.
n		730.	-730.
o		631.	-631.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			-46,472.
b			-120,255.
c			-74,636.
d			-92,393.
e			-1,705.
f			-26,772.
g			-3,852.
h			-46,005.
i			-142,267.
j			-135,500.
k			-4,140.
l			-54,177.
m			-3,297.
n			-730.
o			-631.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV** Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACADIAN FRONTIER MARKETS	P		
b ACADIAN FRONTIER MARKETS	P		
c ACADIAN FRONTIER MARKETS	P		
d ACADIAN FRONTIER MARKETS	P		
e ACADIAN FRONTIER MARKETS	P		
f ACADIAN FRONTIER MARKETS	P		
g ACADIAN FRONTIER MARKETS	P		
h ACADIAN FRONTIER MARKETS	P		
i ACADIAN FRONTIER MARKETS	P		
j ACADIAN FRONTIER MARKETS	P		
k ACADIAN FRONTIER MARKETS	P		
l ACADIAN FRONTIER MARKETS	P		
m GENERAL ATLANTIC SERVICE COMPANY LLC	P		
n GENERAL ATLANTIC SERVICE COMPANY LLC	P		
o GENERAL ATLANTIC SERVICE COMPANY LLC	P		

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a		136.	-136.
b		1,927.	-1,927.
c	60,704.		60,704.
d	20,977.		20,977.
e	26,896.		26,896.
f	521,242.		521,242.
g	1,260.		1,260.
h	62,366.		62,366.
i	1,118.		1,118.
j	43,755.		43,755.
k	1.		1.
l	1,870.		1,870.
m		2,205.	-2,205.
n	31,869.		31,869.
o	286,390.		286,390.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			-136.
b			-1,927.
c			60,704.
d			20,977.
e			26,896.
f			521,242.
g			1,260.
h			62,366.
i			1,118.
j			43,755.
k			1.
l			1,870.
m			-2,205.
n			31,869.
o			286,390.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	

**Part IV Capital Gains and Losses for Tax on Investment Income**

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a CRESTVIEW PARTNERS III LP	P		
b HIG MIDDLE MKT LBO FD II LP	P		
c HIG MIDDLE MKT LBO FD II LP	P		
d GENERAL ATLANTIC SERVICE COMPANY LLC	P		
e CRESTVIEW PARTNERS IV LP	P		
f HIG MIDDLE MKT LBO FD III LP	P		
g ACADIAN FRONTIER MARKETS	P		
h GSO III	P		
i GSO III AIV-1	P		
j GSO III AIV-2	P		
k GSO III AIV-3	P		
l GSO III AIV-5	P		
m GSO III AIV-6	P		
n ACADIAN FRONTIER MARKETS	P		
o K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE	P		

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 27,043.			27,043.
b 2,245,125.			2,245,125.
c 552,608.			552,608.
d 56,092.			56,092.
e 22,328.			22,328.
f 100,602.			100,602.
g		24,965,982.	-24,965,982.
h 234,621.			234,621.
i		515,966.	-515,966.
j		484,356.	-484,356.
k		463,790.	-463,790.
l		711,774.	-711,774.
m		39,883.	-39,883.
n		227,186.	-227,186.
o			-116,807,506.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			27,043.
b			2,245,125.
c			552,608.
d			56,092.
e			22,328.
f			100,602.
g			-24,965,982.
h			234,621.
i			-515,966.
j			-484,356.
k			-463,790.
l			-711,774.
m			-39,883.
n			-227,186.
o			-116,807,506.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 } .....	2	132,680,049.
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8 .....	3	N/A

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	494,612.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	556,499.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY	168,556.
ALEH - HELP FOR THE SPECIAL CHILD 111 ABARBANEL ST BNEI BRAK, ISRAEL	N/A	PC	EMERGENCY EQUIPMENT	50,000.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	267,835.
ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC 1825 EYE STREET NW, 401 WASHINGTON, DC 20006	N/A	SOI	COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING (CGM)	500,000.
ALVIN AILEY DANCE FOUNDATION, INC. THE JOAN WEILL CENTER FOR DANCE NEW YORK, NY 10019	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
<b>Total from continuation sheets</b>				<b>442,580,346.</b>

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	CREATION OF EMERGENCY MEDICAL AIR-RAID SHELTER	150,000.
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	694,034.
AMC MEDICAL RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	50,570.
AMC MEDICAL RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN	1,607,013.
AMC MEDICAL RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	DEVELOPMENT AND VALIDATION OF AN EPIGENETIC BIOMARKER THAT PREDICTS TREATMENT SUCCESS AND ALLOWS PERSONALIZED MANAGEMENT IN CROHNS DISEASE	197,373.
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022-2024	51,040.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	981,349.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)	278,350.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)	337,310.
AMERICAN FRIENDS OF MAGEN DAVID ADOM 20 WEST 36TH STREET NEW YORK, NY 10018	N/A	PC	EMERGENCY SUPPORT FOR MAGEN DAVID ADOM	152,000.
AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE 4930 DEL RAY AVE BETHESDA, MD 20814	N/A	PC	AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	74,768.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE IOWA	2,105,298.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH	4,194,494.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	286,146.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MONTANA AND POST-ACUTE STROKE CARE QUALITY STANDARDS FIELD TESTING	1,024,257.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA	723,366.
AMERICAN SAMOA MEDICAL CENTER AUTHORITY P.O. BOX LBJ PAGO PAGO, AS 96799	N/A	GOV	MRI AT LBJ TROPICAL MEDICAL CENTER	1,878,805.
AMERICANS FOR BEN-GURION UNIVERSITY 1001 AVENUE OF THE AMERICAS, 19TH FLOOR NEW YORK CITY, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
AMERICANS FOR BEN-GURION UNIVERSITY 1001 AVENUE OF THE AMERICAS, 19TH FLOOR NEW YORK CITY, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	20,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	749,599.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	367,129.
ARAD MUNICIPALITY 6 HAPALMACH STREET ARAD, ISRAEL	N/A	GOV	ARAD OCCUPATIONAL REHABILITATION CENTER	183,236.
ARAD MUNICIPALITY 6 HAPALMACH STREET ARAD, ISRAEL	N/A	GOV	EMERGENCY FUNDING FOR SAFETY AND SECURITY EQUIPMENT	166,407.
ASIAN HEALTH CARE FOUNDATION 6-3-661, SOMAJIGUDA HYDERABAD, INDIA	N/A	PC	IMPROVING ACCESS TO DIAGNOSTICS FOR CROHN'S DISEASE PATIENTS LIVING BELOW THE POVERTY LINE IN SOUTHERN INDIA	83,381.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM	831,327.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	IMPROVE THE MANAGEMENT OF DIABETES (ESPECIALLY T1D) AND THE SUPPORT TO PEOPLE AFFECTED BY THE DISEASE IN BURKINA FASO, MALI, AND THE UNION OF COMOROS	475,984.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.	410,936.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,500,000.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,000,000.
BALLAD RESEARCH INSTITUTE 3525 JOHN HOPKINS COURT SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS	325,801.
BANNER HEALTH FOUNDATION 2901 N. CENTRAL AVENUE PHOENIX, AZ 85012	N/A	PC	BANNER HEALTH WYOMING ULTRASOUND REVITALIZATION PROJECT	1,869,864.
BAR ILAN UNIVERSITY MAX VE-ANNA WEBB ST. RAMAT GAN, ISRAEL	N/A	PC	THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY	3,216,875.
BARZILAI MEDICAL CENTER HAHISTADROUT ST 2 ASHKELON, ISRAEL	N/A	GOV	EMERGENCY FUNDING FOR EQUIPMENT	776,930.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	566,062.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	520,313.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	532,841.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	TRUCULTURE SAMPLE ANALYSIS FOR TN22 HCQ	297,957.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	809,757.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	131,733.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	EMERGENCY PREPAREDNESS FOR BEN GURION UNIVERSITY OF THE NEGEV	450,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CD	938,641.
BERKSHIRE THEATRE GROUP INC 111 SOUTH STREET PITTSFIELD, MA 01201	N/A	PC	GENERAL OPERATING SUPPORT FOR THE DAVID AND SUSIE AUERBACH REHEARSAL STUDIO	17,500.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL	797,851.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,060,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	940,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	149,166.
BIGHORN VALLEY HEALTH CENTER, INC. 10 4TH STREET WEST, SUITE B HARDIN, MT 59034	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	260,119.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC CODY ULTRASOUND PROJECT	172,365.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	EXPANDING ECMO SERVICES AT BILLINGS CLINIC	620,341.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW, #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES	622,296.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	2,000,000.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	1,740,266.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	1,975,490.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,480,533.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	1,740,267.
BNAI ZION MEDICAL CENTER 47 GOLOMB ST. HAIFA, ISRAEL	N/A	GOV	PURCHASE OF A CT SCANNER FOR BNAI ZION MEDICAL CENTER	1,300,000.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	197,208.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	64,655.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABETESWISE FOR EXERCISE	344,015.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABDOCS NATIONAL K12: SUPPLEMENT	402,980.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	1,006,531.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,483,787.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	836,979.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT)	341,879.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D	379,194.
BOSTON SYMPHONY ORCHESTRA, INC. 301 MASSACHUSETTS AVENUE BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	34,997.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA	1,915,763.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	2,648,126.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO TOMORROW'S TREATMENTS IN CROHN'S DISEASE	1,230,080.
CAMPBELL COUNTY HOSPITAL DISTRICT 501 SOUTH BURMA AVE. GILLETTE, WY 82717	N/A	PC	CAMPBELL COUNTY HEALTH ULTRASOUND PROJECT	599,884.
CANDID 32 OLD SLIP, 24TH FLOOR NEW YORK, NY 10005	N/A	PC	GENERAL OPERATING SUPPORT	25,974.
CARDIFF UNIVERSITY 30-36 NEWPORT RD WALES, UNITED KINGDOM	N/A	PC	T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	944,873.
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITAT MUNCHEN MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES	655,603.
CASTLE ROCK SPECIAL HOSPITAL DISTRICT 1400 UINTA DRIVE GREEN RIVER, WY 82935	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	117,688.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	EXPANDING COMMUNITY RECOVERY AND RESILIENCE	1,617,611.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,845,255.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	202,791.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	200,041.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSES TO SARS-COV-2 VACCINATION IN A DIVERSE INFLAMMATORY BOWEL DISEASE POPULATION: A MULTI-OMIC STUDY	364,763.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI	115,500.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	3,690,035.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	95,277.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD	244,860.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	221,420.
CHEYENNE HEALTH & WELLNESS CENTER 2508 E FOX FARM RD, #1-1A CHEYENNE, WY 82007	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	78,892.
CHEYENNE REGIONAL MEDICAL CENTER FOUNDATION 214 EAST 23RD STREET CHEYENNE, WY 82001	N/A	PC	CHEYENNE REGIONAL MEDICAL CENTER WYOMING ULTRASOUND REVITALIZATION PROJECT	1,490,918.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	2,165,669.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)	665,654.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)	666,216.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES	1,399,726.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	1,255,105.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	1,072,041.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	679,025.

Total from continuation sheets

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	1,009,535.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS	88,791.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	402,142.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE	1,421,241.
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	1,399,624.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN FUND	305,108.
CIVICA FOUNDATION 2912 WEST EXECUTIVE PARKWAY LEHI, UT 84043	N/A	PC	AFFORDABLE INSULIN	2,500,000.

Total from continuation sheets .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CIVICA FOUNDATION 2912 WEST EXECUTIVE PARKWAY LEHI, UT 84043	N/A	PC	AFFORDABLE INSULIN	2,500,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	MEDICAL EQUIPMENT FOR EMEK MEDICAL CENTER	1,103,070.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	138,626.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	EMERGENCY SUPPORT FOR SOROKA MEDICAL CENTER: MEDICAL EQUIPMENT	2,000,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A PHOTON COUNTING DETECTOR-CT DEVICE FOR SOROKA MEDICAL CENTER	2,159,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	418,217.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	452,465.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION	667,139.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION	243,216.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	1,243,053.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION	3,057,795.
COMMONWEALTH HEALTHCARE CORPORATION 1178 HINEMLU ST. GARAPAN SAIPAN, NORTHERN MARIANA ISLANDS 96950	N/A	GOV	CNMI CHCC MRI/MEDICAL EQUIPMENT UPGRADE PROJECT	6,440,191.
COMMUNITY CENTERS INC/DBA BARBARA'S HOUSE 2 ST ROCH AVENUE GREENWICH, CT 06830	N/A	PC	GENERAL OPERATING SUPPORT	45,000.
COMMUNITY SERVICE SOCIETY OF NEW YORK (CSS) 633 THIRD AVENUE NEW YORK, NY 10017	N/A	PC	KEEP NEW YORK COVERED (KNYC)	550,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING	261,570.
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	1,795,546.
CORK UNIVERSITY FOUNDATION WESTERN ROAD CORK, IRELAND	N/A	PC	ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS	642,744.
CORNELL UNIVERSITY PO BOX 22 ITHACA, NY 14851-0022	N/A	PC	SPONSORSHIP FOR THE 25TH ANNIVERSARY ADHERENT INVASIVE E. COLI (AIEC) MEETING	15,000.
CORPORATION FOR SUPPORTIVE HOUSING 61 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	1,200,000.
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT	34,000.
COUNCIL ON THE ENVIRONMENT, INC. 100 GOLD ST., SUITE 3300 NEW YORK, NY 10038	N/A	PC	GENERAL OPERATING SUPPORT	15,000.

**Total from continuation sheets** .....



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COZAD HOSPITAL DISTRICT NO. 2 300 EAST 12TH STREET COZAD, NE 69130	N/A	GOV	TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM	141,545.
CRITICAL PATH INSTITUTE 1840 E. RIVER ROAD TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,180,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	TRAINING AWARDS PROGRAM - CLASS OF 2021	1,067,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS	712,850.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE	595,677.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	588,266.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE	588,266.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SPONSORSHIP FOR THE 2024 CROHNS & COLITIS CONGRESS PRESENTED BY THE CROHNS & COLITIS FOUNDATION AND THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION	200,000.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	284,646.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA	562,426.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 & 2022 OPERATING SUPPORT FOR CROHN'S AND COLITIS UK: KNOWLEDGE AND EVIDENCE PERSONNEL	75,900.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF "CCCARE-P", A PEDIATRIC-SPECIFIC CROHNS DISEASE ELECTRONIC MEDICAL RECORD TO DRIVE CARE CONSISTENCY AND ENHANCE TRANSITIONS IN CARE	115,418.
CROOK COUNTY MEDICAL SERVICES DISTRICT 713 W. OAK ST. SUNDANCE, WY 82729	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	437,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	509,790.
DE LA SALLE SOLIDARIETA INTERNAZIONALE - E.T.S. VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	94,780.
DE LA SALLE SOLIDARIETA INTERNAZIONALE - E.T.S. VIA AUREALIA, 476 ROME, ITALY	N/A	PC	EXPAND DEVELOPMENT OF LASALLIAN UNIVERSITY OF AFRICA	784,080.
DIABETES NSW 26 ARUNDEL ST SYDNEY, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES	1,700,835.
DREAMED DIABETES LTD. 14 KAPLAN ST PETAH TIKVA, ISRAEL	N/A	NC	INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES	1,350,000.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	UTILIZING AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS TO PREVENT INSULIN-INDUCED HYPOGLYCEMIA IN T1D	203,497.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	UTILIZING AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS TO PREVENT INSULIN-INDUCED HYPOGLYCEMIA IN T1D	71,503.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	29,310.
EHLERS-DANLOS RESEARCH FOUNDATION 1829 REISTERSTOWN ROAD PIKESVILLE, MD 21208	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	313,686.
EZRATH NASHIM SARAH HERZOG MEMORIAL HOSPITAL 92 GIVAT SHAUL ST. JERUSALEM, ISRAEL	N/A	PC	CONSTRUCTION OF A NEW MENTAL HEALTH FACILITY AT HERZOG MEDICAL CENTER	2,384,174.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	1,960,000.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	4,889,200.
FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ RAMISTRASSE 101 ZURICH, SWITZERLAND	N/A	PC	SPATIAL BIOLOGY OF CROHNS COLITIS	536,228.

Total from continuation sheets

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	NYC FUND TO END YOUTH & FAMILY HOMELESSNESS, A PROJECT OF FJC.	300,000.
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS	1,000,000.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CAMPUS BIOTECH GENEVA, SWITZERLAND	N/A	PC	ACCESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	1,275,100.
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	17,093.
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	42,729.
FRIENDS OF CRAWFORD PARK, INC. 7 RYE RIDGE PLAZA RYE BROOK, NY 10573	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	IMPACT! SCHOLARSHIP PROGRAM	503,200.
FUENTE LATINA INC 7300 BISCAYNE BLVD, SUITE 200 MIAMI, FL 33138	N/A	PC	MEDIA FELLOWSHIPS TO ISRAEL	200,000.
FUND FOR PUBLIC HOUSING, INC. 90 CHURCH STREET NEW YORK, NY 10007	N/A	PC	DEVELOPING AND ACTIVATING GREENSPACE USING THE CONNECTED COMMUNITIES' PARTICIPATORY PROCESS AT FOUR NYCHA DEVELOPMENTS	1,630,000.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	PURCHASING A CT SCANNER FOR GALILEE MEDICAL CENTER	991,768.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	2,200,000.
GATES PHILANTHROPY PARTNERS PO BOX 60555 CITY OF INDUSTRY, CA 91716	N/A	PC	POLIO ERADICATION FUND SUPPORT	1,000,000.
GEISINGER CLINIC 100 NORTH ACADEMY AVE DANVILLE, PA 17822-3057	N/A	PC	STUDY OF PRE-IMPLEMENTATION OUTCOMES REQUIRED TO IMPLEMENT PREVENTIVE SCREENING AT WELL-CHILD VISITS	72,007.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	397,123.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	251,522.
GEORGETOWN UNIVERSITY 37TH O STREET NW WASHINGTON, DC 20057	N/A	PC	ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION	418,301.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	485,617.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	480,848.
GHANA RURAL INTEGRATED DEVELOPMENT 7774 10 SIDEROAD MILTON, CANADA	N/A	PC	LEYAATA HOSPITAL MEDICAL HOUSING	751,636.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 & 2022 OPERATING SUPPORT TO PROVIDE POST-OPERATIVE AND INFUSION KITS FOR WOMEN WITH INFLAMMATORY BOWEL DISEASE	77,164.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GLENROCK HOSPITAL DISTRICT 925 WEST BIRCH GLENROCK, WY 82637	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	63,635.
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.
GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS 1310 L. STREET NW WASHINGTON, DC 20005	N/A	PC	GENERAL OPERATING SUPPORT	18,920.
GRANTMAKERS IN HEALTH 1100 CONNECTICUT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GENERAL OPERATING SUPPORT	24,640.
GUARDIAN ORG FOUNDATION 900 17TH STREET NW, SUITE 250 WASHINGTON, DC 20006	N/A	PC	A GROWING CRISIS: NON-COMMUNICABLE DISEASES, AN INDEPENDENT JOURNALISM SERIES BY THE GUARDIAN	625,000.
HADASSAH MEDICAL ORGANIZATION EIN KEREM ADDRESS: KALMAN YA'AKOV MAN STREET JERUSALEM, ISRAEL	N/A	PC	EQUIPPING HADASSAH HOSPITAL'S OPERATING ROOMS	2,000,000.
HADASSAH MEDICAL ORGANIZATION EIN KEREM ADDRESS: KALMAN YA'AKOV MAN STREET JERUSALEM, ISRAEL	N/A	PC	CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER	1,136,000.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HEALTH ADVOCACY SUMMIT, INC. 1962 DOCKSIDE DRIVE GREENWOOD, IN 46143	N/A	PC	CROHNS AND COLITIS YOUNG ADULTS NETWORK LEARNING COMMUNITY, ROUNDTABLE ON ADOLESCENTS AND YOUNG ADULTS WITH IBD	60,060.
HEALTH RESEARCH ALLIANCE, INC. 65 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK, NC 27709	N/A	PC	GENERAL OPERATING SUPPORT	44,300.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE	362,703.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,441,293.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,652,490.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	778,887.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	745,207.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	1,310,340.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,240,499.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,956,717.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,849,482.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,044,591.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,114,441.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,929,862.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET, NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KAISER HEALTH NEWS RURAL HEALTH DESK	1,458,159.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	145,339.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	81,534.
HOLY ROSARY HEALTHCARE FOUNDATION 2600 WILSON STREET MILES CITY, MT 59301	N/A	PC	HOLY ROSARY HEALTHCARE COMPREHENSIVE CANCER CENTER	2,000,000.
HOT SPRINGS COUNTY HOSPITAL DISTRICT 150 E ARAPAHOE ST THERMOPOLIS, WY 82443	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	346,794.
HUMAN CELL ATLAS, INCORPORATED 415 MAIN ST CAMBRIDGE, MA 02142	N/A	PC	2023 HUMAN CELL ATLAS GENERAL MEETING	50,000.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	117,600.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	305,349.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	404,688.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT	1,623,623.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS	1,085,802.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE MELODY TRIAL: MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHN'S DISEASE	759,619.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	672,617.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	PROVIDING SUPPORT FOR EMERGENCY PREPAREDNESS	600,000.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	EMERGENCY FUNDING FOR RESPONSE TO ATTACKS ON ISRAEL	1,300,000.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	PROVIDING SUPPORT, RECOVERY AND RESPECTFUL HANDLING OF FALLEN WAR VICTIMS	350,000.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL	114,569.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	11,424.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	60,914.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT	749,790.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	341,606.
INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC 75 STATE STREET BOSTON, MA 02109	N/A	PC	SEED FUNDING SUPPORT	714,053.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)	379,100.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)	672,500.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CD. USE-IT: A PROSPECTIVE, MULTICENTER STUDY	375,221.
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA	1,999,629.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	58,968.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ISRAEL EMERGENCY ALLIANCE P.O. BOX 341069 LOS ANGELES, CA 90034	N/A	PC	SUPPORT OF LEGAL EFFORTS TO COMBAT ANTISEMITISM, AND SOCIAL MEDIA EXPANSION	250,000.
IVINSON MEMORIAL HOSPITAL 255 N 30TH ST LARAMIE, WY 82070	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	550,348.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	283,542.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)	620,243.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)	1,449,344.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	49,192.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES	500,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	AUTOIMMUNITY SCREENING FOR KIDS (ASK) PROGRAM TRANSITION TOWARDS A SUSTAINABLE SCREENING FOR T1D AND CELIAC DISEASE IN COLORADO (ASK RENEWAL 2022)	555,046.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING	1,300,000.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.	500,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	567,091.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	568,782.
JOHNSON COUNTY HOSPITAL DISTRICT 497 WEST LOTT STREET BUFFALO, WY 82834	N/A	GOV	JOHNSON COUNTY HEALTHCARE CENTER ULTRASOUND EQUIPMENT	476,613.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	941,354.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	19,000.
KAISER FOUNDATION HEALTH PLAN OF GEORGIA, INC. 1375 PEACHTREE STREET NE ATLANTA, GA 30309	N/A	PC	EXPANSION OF THE TIDES PILOT TO A PUBLIC HOSPITAL	291,280.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	855,018.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	246,662.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY	770,816.
KIMBALL COUNTY HOSPITAL 505 S BURG STREET KIMBALL, NE 69145	N/A	GOV	PINE BLUFFS HEALTH CLINIC: WYOMING ULTRASOUND REVITALIZATION PROJECT	5,252.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.	447,521.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL	531,295.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL	195,494.
KMR ADVANCEMENT OF MEDICAL CENTERS LTD. 8 HA'ALIYAH ST. HAIFA, ISRAEL	N/A	PC	PROPOSAL FOR BUILDING OF PRINCIPAL INFRASTRUCTURE FOR ALL 20 FLOORS OF THE HELMSLEY HEALTH DISCOVERY TOWER	1,000,000.
LIFESCAPE FOUNDATION 2011 W 26TH ST, SUITE 201 SIOUX FALLS, SD 57105	N/A	PC	GENERAL OPERATING SUPPORT	7,500.
LIVING GOODS 1423 BROADWAY, #1054 OAKLAND, CA 94612	N/A	PC	DIGITIZING COMMUNITY HEALTH	1,100,222.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, TX 77477	N/A	PC	SCALING INTEGRATED WASH SERVICES	2,838,602.
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	17,970.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	URGENT PROCUREMENT OF MEDICAL EQUIPMENT FOR WOUNDED SOLDIERS AND CIVILIANS	492,958.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	15,187.
MARY C. WHEELER SCHOOL, INC. 216 HOPE STREET PROVIDENCE, RI 02906	N/A	PC	GENERAL OPERATING SUPPORT: THE WHEELER FUND.	10,000.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	9,013,397.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	2023 WOMEN'S HEALTH LUNCHEON	20,000.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE	499,459.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	BUILDING A GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND OTHER SEVERE CHRONIC NONCOMMUNICABLE DISEASES	1,785,375.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE	1,728,414.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	WIRELESS INFRARED IMAGING CAPSULE FOR PINPOINTING INFLAMMATION IN CROHNS DISEASE	752,326.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHN'S DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION AND BETTER TREATMENT	705,894.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	251,447.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MILITARY SCIENCES MEDICAL TRAINING 2022-2024	250,000.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	334,407.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MDECINS SANS FRONTIERES USA, INC. 40 RECTOR STREET NEW YORK, NY 10006	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	412,500.
MEDICINE BOW RURAL HEALTH CARE DISTRICT 514 IDAHO DR MEDICINE BOW, WY 82329	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	19,017.
MEDICINES DEVELOPMENT FOR GLOBAL HEALTH (MDGH) 18 KAVANAGH STREET SOUTHBANK SOUTHBANK, AUSTRALIA	N/A	PC	ADVANCING THE FIGHT AGAINST ONCHOCERCIASIS	1,014,170.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	436,472.
MEMORIAL HOSPITAL OF CARBON COUNTY 2221 W. ELM STREET RAWLINS, WY 82301	N/A	GOV	MEMORIAL HOSPITAL OF CARBON COUNTY ULTRASOUND EQUIPMENT	598,152.
MEMORIAL HOSPITAL OF CONVERSE COUNTY 111 S. 5TH STREET DOUGLAS, WY 82633	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	559,262.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MEMORIAL HOSPITAL OF SWEETWATER COUNTY FOUNDATION 1200 COLLEGE DRIVE ROCK SPRINGS, WY 82901	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	551,594.
MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC. PO BOX 27837 WASHINGTON, DC 20038	N/A	PC	HIRING ADDITIONAL TRANSLATORS/ANALYSTS	420,000.
MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC. PO BOX 27837 WASHINGTON, DC 20038	N/A	PC	THE INTERCONNECTED IRAN-RUSSIA-CHINA AXIS	300,000.
MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC. PO BOX 27837 WASHINGTON, DC 20038	N/A	PC	TARGETED ADS FOR UNIVERSITY CAMPUS NEWSPAPERS	108,500.
MINERAL COUNTY HOSPITAL DISTRICT 200 SOUTH A STREET HAWTHORNE, NV 89415	N/A	GOV	USDA COMMUNITY FACILITY DIRECT LOAN PROGRAM APPLICATION	350,000.
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS	7,031.
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	PC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	1,086,286.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MONUMENT HEALTH STURGIS HOSPITAL 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	16,568.
MONUMENT HEALTH, INC. 353 FAIRMONT BLVD RAPID CITY, SD 57701	N/A	SOIII FI	NICU EQUIPMENT	2,066,019.
NATIONAL ASSOCIATION OF SCHOOL NURSES INC 1100 WAYNE AVE SILVER SPRING, MD 20910	N/A	PC	PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT	891,762.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	885,819.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	1,163,270.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER	1,850,000.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER	869,558.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)	336,672.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	1,911,525.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	GENERAL OPERATING SUPPORT - NCD ALLIANCE SUPPORTERS GROUP	42,500.
NEBRASKA METHODIST HOSPITAL FOUNDATION 8701 WEST DODGE ROAD OMAHA, NE 68114	N/A	PC	NICU EQUIPMENT	290,000.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	309,887.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,230,038.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	223,920.
<b>Total from continuation sheets</b> .....				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	81,967.
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	27,500.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS	398,456.
NEW GROUND INC. 70 ACORN LANE LEVITTOWN, NY 11756	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
NEW VENTURE FUND 1828 L STREET NW WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	1,468,813.
NEW YORK CITY BALLET, INC. DAVID H. KOCH THEATER NEW YORK, NY 10023	N/A	PC	GENERAL OPERATING SUPPORT FOR NEW COMBINATIONS FUND	15,000.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	867,832.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	3,692,303.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	100,123.
NIOBRARA COUNTY HOSPITAL DISTRICT 921 S BALLANCEE AVE LUSK, WY 82225	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	147,400.
NORTH BIG HORN HOSPITAL 1115 LANE 12 LOVELL, WY 82431	N/A	PC	NORTH BIG HORN HOSPITAL WYOMING ULTRASOUND REVITALIZATION PROJECT	153,800.
NORTH DAKOTA DEPARTMENT OF HEALTH 600 E BOULEVARD AVENUE BISMARCK, ND 58505-0200	N/A	GOV	NORTH DAKOTA LAW ENFORCEMENT AED PROJECT	27,500.
NURU INTERNATIONAL 2020 PENNSYLVANIA AVE NW WASHINGTON, DC 20006	N/A	PC	EXPANSION OF AGRIBUSINESS COOPERATIVES	2,250,000.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 1)	738,313.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	NICH BAY AREA EXPANSION	749,644.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	NICH BAY AREA EXPANSION	654,234.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	292,821.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	292,821.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	1,167,087.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	64,900.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	967,457.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	7,139.
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	1,000,000.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	36,761.
PHILANTHROPY NEW YORK, INC. 320 EAST 43RD STREET NEW YORK, NY 10017	N/A	PC	GENERAL OPERATING SUPPORT	39,250.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	64,193.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	24,968.
PLATTE VALLEY HEALTHCARE PROJECT 1300 W. MAIN ST. SARATOGA, WY 82331	N/A	PC	NORTH PLATTE VALLEY MEDICAL CENTER ULTRASOUND PROJECT	64,362.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PORT CHESTER CARVER CENTER INC 400 WESTCHESTER AVE PORT CHESTER, NY 10573	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
POWELL VALLEY HEALTH CARE INC 777 AVE H POWELL, WY 82435	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	349,300.
PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02138- 5366	N/A	PC	PRE-SYMPTOMATIC AUTOANTIBODY AND VIRAL PROFILE OF US MILITARY PERSONNEL WITH ADULT-ONSET TYPE 1 DIABETES	146,368.
PROJECT CONCERN ZAMBIA LIMITED PLOT 37/1P LUSAKA, ZAMBIA	N/A	PC	EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS	975,702.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	310,123.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S	1,186,800.
REACHANOTHER FOUNDATION 1900 NE 3RD ST., STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	2,667,559.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	403,877.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	A SYSTEM BIOLOGY APPROACH TO UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE	142,264.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	187,370.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USING NATURAL LANGUAGE PROCESSING OF CLINICAL DOCUMENTATION TO IMPROVE PERSONALIZATION OF CARE IN CROHN'S DISEASE	369,880.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	4,885,390.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D	272,555.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13	308,267.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.	988,042.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	DEVELOPING OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES	190,677.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)	502,750.
REGENTS OF UNIVERSITY OF CALIFORNIA, BERKELEY 190 DOE BERKELEY, CA 94720	N/A	PC	DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE	1,225,929.
RENOWN HEALTH FOUNDATION 1155 MILL ST RENO, NV 89502	N/A	PC	RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA	2,211,453.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	43,913.
ROUNDAABOUT THEATRE COMPANY, INC. 231 W 39TH STREET, 1200 NEW YORK, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	1,552,050.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES	73,424.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	608,000.
SAVE A LAB RESCUE 165 ELLERY AVE MIDDLETOWN, RI 02842	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
SCHWARTZ/REISMAN SCIENCE EDUCATION CENTER, REHOVOT, (R.A.) HERZL ST. 234 REHOVOT, ISRAEL	N/A	PC	THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT	1,500,000.
SCHWARTZ/REISMAN SCIENCE EDUCATION CENTER, REHOVOT, (R.A.) HERZL ST. 234 REHOVOT, ISRAEL	N/A	PC	THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT	1,982,305.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S: S-200 SEATTLE, WA 98145-5005	N/A	PC	EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)	602,243.
<b>Total from continuation sheets</b> .....				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	5,000,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	LINEAR ACCELERATORS FOR THE RADIOTHERAPY INSTITUTE	5,200,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK: THE PIONIR TRIAL (PREVENTING IBD ONSET IN INDIVIDUALS AT RISK)	174,719.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	934,083.
SHALVA - ISRAEL ASSOC TO RELIEVE THE HANDICAPPED CHILD AND FAMILY 1 SHALVA ROAD JERUSALEM, ISRAEL	N/A	PC	EQUIPMENT AND INFRASTRUCTURE FOR NATIONAL CRISIS CENTER	100,000.
SHARE TRUST INC. 310 DEDHAM ST DOVER, MA 02030	N/A	PC	BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION	1,114,361.
SHERIDAN COUNTY MEMORIAL HOSPITAL FOUNDATION 1401 WEST 5TH ST SHERIDAN, WY 82801	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	675,676.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHERIDAN COUNTY MEMORIAL HOSPITAL FOUNDATION 1401 WEST 5TH ST SHERIDAN, WY 82801	N/A	PC	SHERIDAN MEMORIAL HOSPITAL EMPATH AND CRISIS STABILIZATION UNIT	2,500,000.
SIGHTSAVERS INC 1 BOSTON PLACE BOSTON, MA 02108	N/A	PC	TRACHOMA ELIMINATION IN ZAMBIA	2,193,748.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	400,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL (HF4A) IMPROVING WATER, SANITATION, HYGIENE AND NUTRITION	962,857.
SOCIAL SCIENCE RESEARCH COUNCIL ONE PIERREPONT PLAZA, 15TH FLOOR BROOKLYN, NY 11201	N/A	PC	DATA2GO.NYC REVAMP AND DATA CLINIC	261,421.
SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES 151 ESSEX STREET HAVERHILL, MA 01832	N/A	PC	GENERAL OPERATING SUPPORT	35,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SOLIDARIDAD NETWORK FOUNDATION LIMITED 163 KUDU ROAD LUSAKA, ZAMBIA	N/A	PC	HOOVES FOR SUSTAINABILITY (H4S)	795,998.
SOUTH BIG HORN COUNTY HOSPITAL DISTRICT 388 US HWY 20 SOUTH BASIN, WY 82410	N/A	GOV	THREE RIVERS HEALTH ULTRASOUND PROJECT	199,845.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION PROJECT	291,933.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	26,976.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AL 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	903,283.
SPLASH INTERNATIONAL 7511 GREENWOOD AVE NORTH SEATTLE, WA 98103	N/A	PC	WASH IN SCHOOLS FOR EVERYONE	597,840.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	3,026,254.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ST. JOHN'S HOSPITAL FOUNDATION 555 E. BROADWAY JACKSON, MS 83001	N/A	PC	WYOMING ULTRASOUND REVITALIZATION PROJECT	273,054.
ST. PETER'S HEALTH FOUNDATION 2475 BROADWAY STREET HELENA, MT 59601	N/A	PC	TRANSCRANIAL MAGNETIC STIMULATION (TMS) SUITE	288,057.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM	4,925,243.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT	1,443,217.
STAR VALLEY MEDICAL CENTER CHARITABLE FOUNDATION 901 ADAMS AFTON, WY 83110	N/A	PC	STAR VALLEY HEALTH ULTRASOUND PROJECT	320,890.
STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS 901 S. STEWART ST., SUITE 5005 CARSON CITY, NV 89701	N/A	GOV	VALLEY OF FIRE VISITOR CENTER	3,500,000.
STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS 901 S. STEWART ST., SUITE 5005 CARSON CITY, NV 89701	N/A	GOV	ICE AGE FOSSIL STATE PARK TRAILS AND OUTDOOR AMENITIES	3,500,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227, SUITE A AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	875,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE III	1,245,075.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY	774,350.
STICHTING THE OCEAN CLEANUP BATAVIERENSTRAAT 15 ROTTERDAM, NETHERLANDS	N/A	PC	DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS	5,000,000.
SUBLETTE COUNTY HEALTH FOUNDATION PO BOX 627 PINEDALE, WY 82941	N/A	SOI	SUBLETTE COUNTY HOSPITAL DISTRICT RADIOLOGY EQUIPMENT PROJECT	1,017,308.
SUPPORTIVE HOUSING NETWORK OF NEW YORK INC 247 W 37TH ST NEW YORK CITY, NY 10018	N/A	PC	TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS	300,000.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY	650,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY	2,567,417.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY	1,920,614.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLAB. AND REGISTRY	1,283,708.
TECHNISCHE UNIVERSITAET MUENCHEN ARCISSTRABE 21 MUNCHEN, GERMANY	N/A	GOV	COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES	127,031.
TECHNISCHE UNIVERSITAT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	FR1DA IN SACHSEN	60,079.
TECHNISCHE UNIVERSITAT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	GENOMIC INFLUENCE OF MATERNAL TYPE 1 DIABETES - UNDERSTANDING PROTECTION AGAINST TYPE 1 DIABETES	210,829.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	346,330.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TEL-AVIV UNIVERSITY TEL AVIV UNIVERSITY TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	3,000,000.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.	900,000.
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	BUILDING VISIONARY AND EFFECTIVE TEAMS TO ACCELERATE PROGRESS AGAINST TYPE 1 DIABETES (T1D) AND OTHER NON-COMMUNICABLE DISEASES (NCDS)	998,081.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEDEV 2012100 HALUTZ RAMAT HANEDEV, ISRAEL	N/A	PC	RAMAT HANEDEV SENIOR CITIZEN CENTER	136,393.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEDEV 2012100 HALUTZ RAMAT HANEDEV, ISRAEL	N/A	PC	EMERGENCY PREPAREDNESS FOR COMMUNITIES IN THE RAMAT HANEDEV COUNCIL REGION OF SOUTHERN ISRAEL	432,000.
THE BANQUET 900 E 8TH ST SIOUX FALLS, SD 57103	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE BINYAMIN FUND INC 445 CENTRAL AVENUE CEDARHURST, NY 11516	N/A	PC	EMERGENCY PREPAREDNESS FOR COMMUNITIES IN BINYAMIN REGIONAL COUNCIL	500,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE CENTER FOR EFFECTIVE PHILANTHROPY, INC. 675 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	GENERAL OPERATING SUPPORT	49,800.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY	249,337.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	GENETIC PROTECTION BY HLA-DQ6 IN T1D	116,445.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY	165,000.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	400,000.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	1,031,896.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE	429,712.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	331,133.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	1,355,310.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND INDEX AND A HISTOPATHOLOGY INDEX FOR STRICTURING SMALL BOWEL CROHNS DISEASE	111,750.
THE DIATRIBE FOUNDATION 804 HAIGHT STREET SAN FRANCISCO, CA 94117	N/A	PC	DIATRIBE LEARN MENTAL HEALTH SERIES	100,285.
THE END FUND, INC. 2 PARK AVENUE, 18TH FLOOR NEW YORK, NY 10016	N/A	PC	REACHING THE LAST MILE FUND EXPANSION	4,130,500.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	QUANTITATIVE PROTEOMIC PROFILING OF FIBROSTENOTIC CROHNS DISEASE PATIENTS	247,654.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CROHNS DISEASE: A KNOWLEDGE TRANSLATION STRATEGY	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	137,153.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	126,154.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE	121,036.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE	191,883.
THE HEALTH & HOUSING CONSORTIUM, INC. STADIUM STATION BRONX, NY 10452	N/A	PC	NYC HEALTH & HOUSING CONSORTIUM: STRATEGIZING FOR SUSTAINABILITY	150,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE HOLE IN THE WALL GANG FUND, INC. 555 LONG WHARF DRIVE NEW HAVEN, CT 06511	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
THE HOPE CENTER 615 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	548,276.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	380,592.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	THE JEWISH AGENCY SECURITY FUND (THE FUND)	161,477.
THE LANIADO KIRIAT SANZ HOSPITAL DIVREI KHAYIM ST 16 NATANIYA, ISRAEL	N/A	PC	NEW MATERNITY FLOOR C	2,150,000.
THE LEGATUM INSTITUTE FOUNDATION C/O GENEVA GLOBAL 1536 E LANCASTER AVE. PAOLI, PA 19301	N/A	PC	TO CONCLUDE PHASE TWO OF THE PROJECT: THE PRODUCTION, DISSEMINATION AND PROMOTION OF THE UNITED STATES PROSPERITY INDEX	71,831.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. (CC) YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN-ISRAELIS PURSUING NURSING DEGREES	220,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE NATURE CONSERVANCY 4245 NORTH FAIRFAX DRIVE, SUITE 100 ARLINGTON, VA 22203	N/A	PC	FUTURE FOREST NYC PHASE III	352,196.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	206,088.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	461,893.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	568,851.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN	545,759.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	241,173.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	241,173.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS	648,749.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA BARBARA UC SANTA BARBARA SANTA BARBARA, CA 93106	N/A	PC	EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES	832,906.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS	575,810.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	413,258.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	266,200.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	453,311.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	676,014.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	179,943.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES	501,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	1,441,282.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	DIABETIC KETOACIDOSIS TRENDS AND RESOURCE UTILIZATION AT DIAGNOSIS OF TYPE 1 DIABETES IN THE UNITED STATES	157,700.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA, CA 92037	N/A	PC	GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD	2,265,175.
THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA, CA 92037	N/A	PC	TRANSLATION OF MICROBIOTA MECHANISMS ON NOD2 FOR CROHNS DISEASE THERAPIES	494,231.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT	2,421,222.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	EMERGENCY FUNDING FOR EQUIPMENT	976,000.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	THE HELMSLEY CENTER FOR INNOVATIVE SURGICAL TRAINING	4,395,700.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	704,764.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	PROJECT BODA-BODA	184,889.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS	266,667.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX (HAREDI) MEN PURSUING B.S. DEGREES IN NURSING	253,818.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	334,798.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	351,258.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THE HEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOME NEW YORKERS	143,021.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA EXPANDED SUPPORT	163,010.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA SCIENCE CONTINUATION	181,471.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN	217,136.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO-PHARMACOGENOMICS TO UNDERSTAND AND PREDICT RESPONSE TO BIOLOGICS IN CROHN'S DISEASE	106,296.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO-PHARMACOGENOMICS TO UNDERSTAND AND PREDICT RESPONSE TO BIOLOGICS IN CROHN'S DISEASE	106,296.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	784,751.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	212,881.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	444,246.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.	159,623.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.	179,714.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)	172,204.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	1,113,915.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	NC	LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES	1,261,871.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	NC	GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY	156,746.
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BOULEVARD DALLAS, TX 75390-9020	N/A	GOV	IMMUNE CHECKPOINT ENGINEERED BETA CELL AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF TYPE I DIABETES	275,000.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	58,241.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	1,750,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE	3,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	DECODING THE CLINICAL IMPACT OF HOST AND MICROBIAL INTESTINAL PROTEOMIC LANDSCAPE IN CROHNS DISEASE	961,620.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	DECODING PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IMPACTING CLINICAL AND PROGNOSTIC FEATURES IN CROHNS DISEASE	947,483.
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	15,112.
TRICKLE UP PROGRAM, INC. 104 WEST 27TH STREET, 12TH FLOOR NEW YORK, NY 10001	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
TROPICAL GASTROENTEROLOGY AND NUTRITION LIMITED 26 COPPER ROAD LUSAKA, ZAMBIA	N/A	PC	1ST CONVENING OF THE IBD AFRICA GENETICS CONSORTIUM	29,471.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TRUSTEES AND FRIENDS OF AGRICULTURAL RESEARCH AT THE VOLCANI CENTER HA MACABIM 68, P.O. BOX 15159 RISHON LEZION, ISRAEL	N/A	PC	PROTECTING FARMERS AND AGRICULTURAL WORKERS ACROSS THE WESTERN NEGEV	1,000,000.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, IN 47401-3654	N/A	GOV	MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES	1,128,685.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, IN 47401-3654	N/A	GOV	COLLABORATIVE EFFORT TO VALIDATE MICRORNA AS BIOMARKERS OF T1D	426,380.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	293,370.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES PHILADELPHIA, PA 19104-6205	N/A	PC	THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE	285,079.
TZAFON MEDICAL CENTER THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	VASCULAR ANGIOGRAPHY INSTITUTE	752,574.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TZAFON MEDICAL CENTER THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	5,431,730.
UNITED JEWISH APPEAL FEDERATION 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
UNITED JEWISH APPEAL FEDERATION 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	INCREASING ACCESS TO HEALTHCARE FOR PEOPLE LIVING WITH DIABETES AND OTHER NCDS	339,777.
UNITED STATES AFRICAN DEVELOPMENT FOUNDATION 1400 I STREET NW WASHINGTON, DC 20005	N/A	GOV	LIVELIHOOD IMPROVEMENT PROGRAM	1,283,255.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	784,421.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM	450,921.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITE DE GENEVE RUE MICHEL SERVET 1 GENEVE, SWITZERLAND	N/A	GOV	PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES	1,373,247.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	213,582.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	272,233.
UNIVERSITY COLLEGE LONDON GOWER STREET LONDON, UNITED KINGDOM	N/A	PC	SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE	60,000.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	707,339.
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA 1800 W CHARLESTON BLVD LAS VEGAS, NV 89102	N/A	GOV	DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	719,072.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	506,886.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY	80,506.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?	1,045,519.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?	583,311.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	500,000.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	713,088.
UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE, SUITE 500 CINCINNATI, OH 45221	N/A	GOV	STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE	416,500.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	251,607.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES	669,554.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	307,674.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM	345,527.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES	54,094.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT	741,600.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY	1,231,291.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	33,833.
<b>Total from continuation sheets</b> .....				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	881,959.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR	880,551.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D	203,056.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS	893,092.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	149,796.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	581,625.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CROHN'S-LIKE DISEASE OF THE POUCH	260,103.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	14,808.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	373,873.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	143,127.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	137,453.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	280,115.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	243,196.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS: A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL)	998,931.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	198,646.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	196,411.
UNIVERSITY OF TOLEDO 3000 ARLINGTON AVENUE TOLEDO, OH 43614-2595	N/A	GOV	TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH	91,848.
UNIVERSITY OF TOLEDO 3000 ARLINGTON AVENUE TOLEDO, OH 43614-2595	N/A	GOV	TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH	18,632.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS	290,806.
UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION 580 MASSIE ROAD CHARLOTTESVILLE, VA 22903	N/A	PC	GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND	50,000.
UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION 580 MASSIE ROAD CHARLOTTESVILLE, VA 22903	N/A	PC	GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND	50,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS SEATTLE, WA 98195-9472	N/A	GOV	DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4	378,764.
UNIVERSITY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS SEATTLE, WA 98195-9472	N/A	GOV	SKIN PATHOLOGY IN PEOPLE WITH T1D: IMPACT OF INSULIN INFUSION VIA PUMP	111,932.
UNIVERSITY OF WESTERN ONTARIO 339 WINDERMERE RD. LONDON, CANADA	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	919,293.
UNIVERSITY OF WYOMING FOUNDATION 222 S 22ND ST LARAMIE, WY 82070	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN WYOMING	641,903.
UPPSALA UNIVERSITET BOX 256 UPPSALA, SWEDEN	N/A	GOV	ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION	229,347.
UPTIME GLOBAL 23-38 HYPHE BRIDGE STREET OXFORD, UNITED KINGDOM	N/A	PC	RESULTS-BASED SAFE WATER SERVICES	350,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	MRI OF THE PANCREAS IN T1D	196,582.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	MRI OF THE PANCREAS IN T1D	176,459.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	200,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	36,595.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR A CROHN'S DISEASE GUT CELL ATLAS	290,049.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	68,349.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS	496,512.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	221,931.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	170,401.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY	145,749.
VANDERBILT UNIVERSITY SPONSORED PROGRAMS ADMINISTRATION NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	1,888,240.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D	705,194.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	30,504.
VILLAGES OF HOPE: AFRICA SOCIETY 2450 MILLTOWER COURT MISSISSAUGA, CANADA	N/A	PC	INFRASTRUCTURE IMPROVEMENTS AND EXPANSION	253,122.

Total from continuation sheets

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VIVLI, INC. 101 MIDDLESEX TURNPIKE, SUITE 6 BURLINGTON, MA 01803-4914	N/A	PC	DATA SHARING PLATFORM FOR T1-DEXTA DATASETS	120,000.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	25,335.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130-4862	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	338,970.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MO 63130-4862	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,673,164.
WEST PARK HOSPITAL DISTRICT 707 SHERIDAN AVENUE CODY, WY 82414	N/A	GOV	CODY REGIONAL HEALTH ULTRASOUND PROJECT	466,486.
WILDLIFE CONSERVATION SOCIETY 2300 SOUTHERN BOULEVARD BRONX, NY 10460	N/A	PC	GENERAL OPERATING SUPPORT FOR ELEPHANTS	10,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WIND RIVER FAMILY AND COMMUNITY HEALTH CARE SYSTEM 14 GREAT PLAINS RD ARAPAHOE, WY 82510	N/A	GOV	WYOMING ULTRASOUND REVITALIZATION INITIATIVE	391,802.
WNET FOR THE WLIW-21 PUBLIC BROADCASTING 825 EIGHTH AVENUE NEW YORK, NY 10019-7435	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA, SWITZERLAND	N/A	PC	STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS	2,862,039.
WYOMING COMMUNITY FOUNDATION 1472 NORTH 5TH STREET LARAMIE, WY 82072	N/A	PC	ENHANCING ULTRASOUND CAPABILITIES IN WYOMING	361,581.
WYOMING DEPARTMENT OF HEALTH 6101 YELLOWSTONE RD., SUITE 400 CHEYENNE, WY 82009	N/A	GOV	WYOMING FIRST RESPONDER AED PROJECT	16,000.
YAD SARAH 124 HERZL BLVD. JERUSALEM, ISRAEL	N/A	PC	EMERGENCY EQUIPMENT PURCHASES	300,000.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	414,595.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3a Grants and Contributions Paid During the Year**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	298,606.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE	792,237.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	SHAMIR UNDERGROUND EMERGENCY HOSPITAL EQUIPMENT	500,000.
YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND 120 BROADWAY NEW YORK, NY 10271	N/A	SOI	GENERAL OPERATING SUPPORT	7,500.
YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND 120 BROADWAY NEW YORK, NY 10271	N/A	SOI	GENERAL OPERATING SUPPORT	10,000.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET, #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2022	200,000.
ZIV MEDICAL CENTER, ZEFAT RAMBAM ST. ZEFAT, ISRAEL	N/A	GOV	EMERGENCY EQUIPMENT FOR ZIV MEDICAL CENTER	500,000.
<b>Total from continuation sheets</b>				



**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ACADEMISCH ZIEKENHUIS LEIDEN 2 ALBINUSDREEF LEIDEN, NETHERLANDS	N/A	GOV	SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)	93,238.
ACTION4DIABETES 9 PARKFIELD ROAD TAUNTON, UNITED KINGDOM	N/A	PC	PHILIPPINES T1D TASK FORCE	222,500.
ACTION4DIABETES 9 PARKFIELD ROAD TAUNTON, UNITED KINGDOM	N/A	PC	PHILIPPINES T1D TASK FORCE	284,390.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	ENHANCING THE COMMUNITY HEALTH WORKER MODEL TO PROMOTE DIABETES TECHNOLOGY USE IN ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY	173,613.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	259,951.
ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC 1825 EYE STREET NW, 401 WASHINGTON, DC 20006	N/A	SOI	COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION	539,349.
ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC 1825 EYE STREET NW, 401 WASHINGTON, DC 20006	N/A	SOI	COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION	500,000.
<b>Total from continuation sheets</b>				<b>584,996,461.</b>

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	225,500.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN	1,532,103.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN	1,476,985.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	306,900.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	1,200,436.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE 4930 DEL RAY AVE BETHESDA, MD 20814	N/A	PC	AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	64,189.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE IOWA	2,521,277.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA	379,458.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH	6,966,024.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	871,217.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH	4,816,553.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	850,098.
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	PROJECT IMPACT CGM: EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES	1,502,893.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	2,325,006.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	1,542,882.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	1,245,216.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	1,500,000.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	3,000,000.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	500,000.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	421,681.
ARAD MUNICIPALITY 6 HAPALMACH STREET ARAD, ISRAEL	N/A	GOV	ARAD OCCUPATIONAL REHABILITATION CENTER	106,764.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM	855,546.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	587,221.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	325,558.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	587,221.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.	209,377.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.	315,421.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.	315,421.
BALLAD RESEARCH INSTITUTE 3525 JOHN HOPKINS COURT SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN	315,380.
BALLAD RESEARCH INSTITUTE 3525 JOHN HOPKINS COURT SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN	243,390.
BAR ILAN UNIVERSITY MAX VE-ANNA WEBB ST. RAMAT GAN, ISRAEL	N/A	PC	THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY	3,348,125.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	547,540.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	288,200.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	5,785,714.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE.	765,436.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	10,542,857.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL	797,851.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,200,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	1,200,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	EXPANDING ECMO SERVICES AT BILLINGS CLINIC	449,629.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT	2,000,000.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	EXPANDING ECMO SERVICES AT BILLINGS CLINIC	485,826.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT	5,000,000.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW, #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES	609,887.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW, #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES	633,819.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,844.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,843.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	PC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,975,887.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	197,208.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	137,345.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D	758,218.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABETESWISE FOR EXERCISE	835,639.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABDOCS NATIONAL K12: SUPPLEMENT	402,980.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	1,006,687.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D	1,069,498.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABDOCS NATIONAL K12: SUPPLEMENT	193,790.
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	567,155.
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	585,924.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA	2,306,101.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA	2,359,636.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO TOMORROW'S TREATMENTS IN CROHN'S DISEASE	657,605.
CARDIFF UNIVERSITY 30-36 NEWPORT RD CARDIFF, UNITED KINGDOM	N/A	PC	T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	892,873.
CARDIFF UNIVERSITY 30-36 NEWPORT RD CARDIFF, UNITED KINGDOM	N/A	PC	T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	632,664.
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITAT MUNCHEN MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES	667,252.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,337,724.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	EXPANDING COMMUNITY RECOVERY AND RESILIENCE	1,808,630.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,273,764.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	EXPANDING COMMUNITY RECOVERY AND RESILIENCE	1,073,759.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	219,514.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	211,815.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	519,768.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION	733,694.
CENTER FOR HEALTH CARE STRATEGIES INC 300 AMERICAN METRO BLVD. HAMILTON, NJ 08619	N/A	PC	CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	1,002,514.
<b>Total from continuation sheets</b> .....				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTER FOR HEALTH CARE STRATEGIES INC 300 AMERICAN METRO BLVD. HAMILTON, NJ 08619	N/A	PC	IDENTIFYING OPPORTUNITIES TO SUPPORT T1D AUTOANTIBODY SCREENING IN MEDICAID PROGRAMS AND HEALTH CARE SYSTEMS THAT SERVE MEDICAID BENEFICIARIES	149,672.
CENTER FOR HEALTH CARE STRATEGIES INC 300 AMERICAN METRO BLVD. HAMILTON, NJ 08619	N/A	PC	CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	626,707.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	103,796.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT	153,102.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD	244,860.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	202,677.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	93,443.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	515,981.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	229,460.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	229,460.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES	1,470,081.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	684,686.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE	1,093,319.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES	439,601.

**Total from continuation sheets** .....



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	963,282.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	1,016,595.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	407,932.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	725,157.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D	228,375.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN FUND	500,000.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN FUND	500,000.

Total from continuation sheets

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IB D RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	145,605.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	1,472,591.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IB D RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	463,512.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	3,358,835.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	2,541,165.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION	2,811,261.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION	1,166,919.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	992,300.
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	1,212,300.
COREWELL HEALTH 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	3,104,271.
COREWELL HEALTH 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	2,081,202.
CORK UNIVERSITY FOUNDATION WESTERN ROAD CORK, IRELAND	N/A	PC	ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS	663,503.
CORK UNIVERSITY FOUNDATION WESTERN ROAD CORK, IRELAND	N/A	PC	ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS	941,943.
CORPORATION FOR SUPPORTIVE HOUSING 61 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	1,000,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CORPORATION FOR SUPPORTIVE HOUSING 61 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	800,000.
COZAD HOSPITAL DISTRICT NO. 2 300 EAST 12TH STREET COZAD, NE 69130	N/A	GOV	TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM	35,283.
COZAD HOSPITAL DISTRICT NO. 2 300 EAST 12TH STREET COZAD, NE 69130	N/A	GOV	TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM	17,570.
CRITICAL PATH INSTITUTE 1840 EAST RIVER ROAD TUCSON, AZ 85718	N/A	PC	TRANSLATIONAL THERAPEUTICS ACCELERATOR: DEVELOPING KINASE INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE TO TREAT T1D	500,000.
CRITICAL PATH INSTITUTE 1840 EAST RIVER ROAD TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,180,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE	342,493.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS	744,245.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE	626,728.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS	375,484.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA	374,912.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	297,612.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	525,177.
DIABETES NSW 26 ARUNDEL ST SYDNEY, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES	4,299,165.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	11,725.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	302,430.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	283,099.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	3,176,500.
FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ RAMISTRASSE 101 ZURICH, SWITZERLAND	N/A	PC	SPATIAL BIOLOGY OF CROHNS COLITIS	421,278.
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS	1,000,000.
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	NYC FUND TO END YOUTH & FAMILY HOMELESSNESS, A PROJECT OF FJC.	300,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS	1,000,000.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST) 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST) 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CAMPUS BIOTECH GENEVA, SWITZERLAND	N/A	PC	ACCESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	1,118,735.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	2,200,000.
GATES PHILANTHROPY PARTNERS PO BOX 60555 CITY OF INDUSTRY, CA 91716	N/A	PC	POLIO ERADICATION FUND SUPPORT	1,000,000.
GATES PHILANTHROPY PARTNERS PO BOX 60555 CITY OF INDUSTRY, CA 91716	N/A	PC	POLIO ERADICATION FUND SUPPORT	1,000,000.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	402,672.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	187,672.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	143,892.
GEORGETOWN UNIVERSITY 37TH O STREET NW WASHINGTON, DC 20057	N/A	PC	ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION	432,998.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	485,616.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	1,046,486.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	EUROPEAN PRE-T1D REGISTRY	196,089.
<b>Total from continuation sheets</b>				



**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,000,684.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,188,316.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	1,927,629.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,029,929.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	228,040.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,042,232.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,188,316.

**Total from continuation sheets** .....

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	2,348,061.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,466,113.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,500,510.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN	162,877.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	95,294.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,042,232.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,466,731.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,466,114.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,500,510.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,557,698.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,466,732.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,640,094.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,557,698.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,348,365.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,640,094.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,772,918.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,348,365.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,982,146.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,772,917.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,761,496.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,982,146.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,928,622.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,761,496.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,928,622.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,903,870.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	526,471.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,903,869.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	3,470,012.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	3,470,011.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,676,154.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,676,153.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	1,310,183.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	140,000.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	135,722.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	1,705,225.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	2,112,639.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	EYE INSTITUTE AND AMBULATORY SURGERY CENTER	3,158,400.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	39,438.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	15,775.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE, AN ADAPTATION FOR NYC'S COMMUNITY MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	779,716.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT	1,974,021.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS	920,802.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT	587,152.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL	44,685.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL	17,875.
INNODIA HERESTRAAT 49 LEUVEN, BELGIUM	N/A	PC	INNODIA NONPROFIT LAUNCH	434,183.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	108,203.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	164,873.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	113,757.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	109,309.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	114,864.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	112,522.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT	749,790.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT	749,790.
INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC 75 STATE STREET BOSTON, MA 02109	N/A	PC	SEED FUNDING SUPPORT	893,663.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC 75 STATE STREET BOSTON, MA 02109	N/A	PC	SEED FUNDING SUPPORT	971,684.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)	488,553.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)	645,000.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)	688,466.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)	296,500.
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA	2,449,440.
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA	1,550,680.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ISRAEL CENTER ON ADDICTION R.A. 2 HATZORAN ST NETANYA, ISRAEL	N/A	PC	ICA'S EMERGENCY MENTAL HEALTH SUPPORT	55,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY	159,838.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	410,774.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	273,882.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)	805,385.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	413,871.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)	1,256,044.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D	191,816.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	357,597.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)	1,223,066.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	188,007.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D	1,025,846.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	194,126.
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA	1,196,912.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF AUSTRALIA 80-84 CHANDOS STREET, ST LEONARDS, 2065, NSW, AUSTRALIA SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA	997,843.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,332.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A 3--HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR	200,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	105,404.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES	250,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,334.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	145,404.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES	250,000.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.	100,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE	750,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	742,901.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	571,287.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	287,280.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	569,990.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KAISER FOUNDATION HEALTH PLAN OF GEORGIA, INC. 1375 PEACHTREE STREET NE ATLANTA, GA 30309	N/A	PC	EXPANSION OF THE TIDES PILOT TO A PUBLIC HOSPITAL	255,687.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	FAT AS A VILLAIN IN CROHN'S DISEASE.	1,456,556.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	221,407.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	IDS 2024 BRUGES	50,000.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY	490,041.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	1,551,603.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	FAT AS A VILLAIN IN CROHN'S DISEASE.	1,344,948.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	199,460.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	205,983.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	1,574,759.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	1,018,620.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	T CELL RECEPTOR SEQUENCING IN TYPE 1 DIABETES - BIOMARKER DISCOVERY AND TECHNOLOGY DEVELOPMENT	115,097.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS	278,644.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	825,146.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.	384,292.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	369,984.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA	307,779.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,147,254.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,296,483.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,325,562.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS	208,787.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	778,535.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	781,151.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,069,889.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,079,926.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.	325,389.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	925,603.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	931,293.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, VA 77477	N/A	PC	SCALING INTEGRATED WASH SERVICES	2,574,349.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, VA 77477	N/A	PC	SCALING INTEGRATED WASH SERVICES	2,432,337.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	596,795.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	848,894.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE	1,722,621.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	348,553.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	FEASIBILITY OF OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS: A PILOT ANIMAL FEASIBILITY STUDY	385,906.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	151,705.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	275,000.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	137,500.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	322,909.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	17,020.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	6,809.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION 1400 VANBUREN ST., STE 215 MINNEAPOLIS, MN 55413	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	2,016,319.
MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION 1400 VANBUREN ST., STE 215 MINNEAPOLIS, MN 55413	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	1,801,545.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	318,700.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	378,700.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	217,428.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	205,285.
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	PC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	536,186.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NATIONAL ACADEMY OF SCIENCES 500 5TH STREET NW WASHINGTON, DC 20001	N/A	PC	STRENGTHENING MINORITY SERVING INSTITUTIONS	150,000.
NATIONAL ASSOCIATION OF SCHOOL NURSES INC 1100 WAYNE AVE. SILVER SPRING, MD 20910	N/A	PC	PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT	946,275.
NATIONAL ASSOCIATION OF SCHOOL NURSES INC 1100 WAYNE AVE. SILVER SPRING, MD 20910	N/A	PC	PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT	927,791.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	621,487.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	753,478.
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)	363,328.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	1,582,350.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,239,092.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	60,670.
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	14,249.
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	27,500.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS	183,350.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	614,668.
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	2,756,847.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVENUE NEW YORK, NY 10016	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	1,360,453.
NORTHERN WESTCHESTER HOSPITAL ASSOCIATION 400 EAST MAIN STREET MOUNT KISCO, NY 10549	N/A	PC	EMERGENCY DEPARTMENT RAPID ACCESS EXPANSION	400,000.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,139,629.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,019,181.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,129,765.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,783,316.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,795,816.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	318,978.
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DRIVE SAN FRANCISCO, CA 94129	N/A	PC	UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.	358,140.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	871,123.
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	1,000,000.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	14,706.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	25,448.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	9,988.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PROJECT CONCERN ZAMBIA LIMITED PLOT 37/1P LUSAKA, ZAMBIA	N/A	PC	EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS	1,004,026.
PROJECT CONCERN ZAMBIA LIMITED PLOT 37/1P LUSAKA, ZAMBIA	N/A	PC	EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS	1,590,680.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S	746,990.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	627,684.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	190,186.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	458,831.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	1,296,918.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)	502,750.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.	1,454,586.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D	220,565.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)	502,750.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D	166,880.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455-2070	N/A	GOV	STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.	585,172.
REGENTS OF UNIVERSITY OF CALIFORNIA, BERKELEY 190 DOE BERKELEY, CA 94720	N/A	PC	DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE	1,054,179.
REGION HOVEDSTADEN KONGENS VNGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	375,228.
REGION HOVEDSTADEN KONGENS VNGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	113,358.
RENOWN HEALTH FOUNDATION 1155 MILL ST RENO, NV 89502	N/A	PC	RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA	1,091,987.
RENOWN HEALTH FOUNDATION 1155 MILL ST RENO, NV 89502	N/A	PC	RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA	243,019.
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY	1,110,288.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY	826,376.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	17,567.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES	75,165.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MI 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	608,523.
SANFORD RESEARCH 1305 W 18TH ST SIOUX FALL, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,118,635.
SANFORD RESEARCH 1305 W 18TH ST SIOUX FALL, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,086,430.
SAPIR ACADEMIC COLLEGE D.N. HOF ASHKELON REGIONAL COUNCIL SHAAR HANEDEV, ISRAEL	N/A	PC	PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING	303,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SCRIPPS HEALTH 10140 CAMPUS POINT DRIVE LA JOLLA, CA 92121	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	1,262,800.
SCRIPPS HEALTH 10140 CAMPUS POINT DRIVE LA JOLLA, CA 92121	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	1,636,800.
SCRIPPS HEALTH 10140 CAMPUS POINT DRIVE LA JOLLA, CA 92121	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	888,800.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S: S-200 SEATTLE, WA 98145-5005	N/A	PC	EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)	609,141.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S: S-200 SEATTLE, WA 98145-5005	N/A	PC	EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)	616,923.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	5,000,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	989,083.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	3,500,000.
SHARE TRUST INC. 310 DEDHAM ST DOVER, MA 02030	N/A	PC	BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION	1,540,658.
SHARE TRUST INC. 310 DEDHAM ST DOVER, MA 02030	N/A	PC	BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION	1,540,658.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	200,000.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	170,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SOCIAL SCIENCE RESEARCH COUNCIL ONE PIERREPONT PLAZA, 15TH FLOOR BROOKLYN, NY 11201	N/A	PC	DATA2GO.NYC REVAMP AND DATA CLINIC	336,025.
SOLIDARIDAD NETWORK FOUNDATION LIMITED 163 KUDU ROAD LUSAKA, ZAMBIA	N/A	PC	HOOVES FOR SUSTAINABILITY (H4S)	468,562.
SOLIDARIDAD NETWORK FOUNDATION LIMITED 163 KUDU ROAD LUSAKA, ZAMBIA	N/A	PC	HOOVES FOR SUSTAINABILITY (H4S)	273,384.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	10,791.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	818,171.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	5,201,874.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	4,790,316.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM	124,981.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT	172,840.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM	101,195.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT	87,671.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	298,224.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	255,857.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS 901 S. STEWART ST., SUITE 5005 CARSON CITY, NV 89701	N/A	GOV	VALLEY OF FIRE VISITOR CENTER	3,500,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	1,300,026.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	998,988.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	1,200,977.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY	686,565.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY	538,692.
STICHTING THE OCEAN CLEANUP BATAVIERENSTRAAT 15 ROTTERDAM, NETHERLANDS	N/A	PC	DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS	5,000,000.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STICHTING THE OCEAN CLEANUP BATAVIERENSTRAAT 15 ROTTERDAM, NETHERLANDS	N/A	PC	DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS	5,000,000.
STIFTELSEN FOR UTBILDNING (IOIBD) DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
STIFTELSEN FOR UTBILDNING (IOIBD) DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
SUPPORTIVE HOUSING NETWORK OF NEW YORK INC 247 W 37TH ST NEW YORK CITY, NY 10018	N/A	PC	TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS	300,000.
SUPPORTIVE HOUSING NETWORK OF NEW YORK INC 247 W 37TH ST NEW YORK CITY, NY 10018	N/A	PC	TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS	200,000.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	633,709.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	2,567,417.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	650,000.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	1,917,417.
TECHNISCHE UNIVERSITAET MUENCHEN ARCISSTRABE 21 MUNCHEN, GERMANY	N/A	GOV	COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES	151,947.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	1,118,516.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	268,340.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMAN 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	1,420,270.
TEL-AVIV UNIVERSITY TEL AVIV UNIVERSITY TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	6,828,500.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TEL-AVIV UNIVERSITY TEL AVIV UNIVERSITY TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	1,524,350.
TEL-AVIV UNIVERSITY TEL AVIV UNIVERSITY TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	1,324,350.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.	2,600,000.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	2,664,333.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	2,078,769.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEDEV 2012100 HALUTZ RAMAT HANEDEV, ISRAEL	N/A	PC	RAMAT HANEDEV SENIOR CITIZEN CENTER	2,775,467.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEDEV 2012100 HALUTZ RAMAT HANEDEV, ISRAEL	N/A	PC	RAMAT HANEDEV SENIOR CITIZEN CENTER	699,190.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	971,014.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	1,129,976.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	300,000.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY	368,500.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	GENETIC PROTECTION BY HLA-DQ6 IN T1D	235,681.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY	371,800.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	1,321,210.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	236,313.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE	387,615.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	869,476.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE	342,955.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	719,051.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	127,077.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	137,417.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	555,480.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION	248,621.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION	250,415.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,032,574.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	391,212.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,081,289.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	340,788.
<b>Total from continuation sheets</b>				



**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE LANIADO KIRIAT SANZ HOSPITAL DIVREI KHAYIM ST 16 NATANIYA, ISRAEL	N/A	PC	NEW MATERNITY FLOOR	1,350,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE NATURE CONSERVANCY 4245 NORTH FAIRFAX DRIVE, SUITE 100 ARLINGTON, VA 22203	N/A	PC	FUTURE FOREST NYC PHASE III	347,804.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	115,896.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	1,729,516.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	568,027.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,091,471.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN	471,131.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,092,733.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS	433,333.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS	217,916.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA BARBARA UC SANTA BARBARA SANTA BARBARA, CA 93106	N/A	PC	EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES	1,027,327.

**Total from continuation sheets** .....

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA BARBARA UC SANTA BARBARA SANTA BARBARA, CA 93106	N/A	PC	EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES	1,116,996.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	124,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	200,584.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	994,996.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	809,568.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	1,023,372.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	1,945,286.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES	501,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	332,512.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	686,820.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	835,489.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	1,239,503.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	994,512.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	1,161,486.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES	501,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	506,760.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER UCD, GRANTS AND CONTRACTS, MAIL STOP F428 AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	598,309.
THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA, CA 92037	N/A	PC	GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD	1,836,022.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	993,626.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	756,699.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBF RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	188,118.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	514,210.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	578,470.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	482,110.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS	266,667.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS	266,666.
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT	1,536,740.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT	1,282,735.
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT	2,081,072.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	429,646.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	200,000.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THE HEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOME NEW YORKERS	146,689.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	413,263.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	150,000.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN	54,351.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN	44,540.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	333,042.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	209,222.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)	682,311.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	692,839.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	NC	GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY	69,271.

**Total from continuation sheets** .....



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	35,866.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE	3,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE	3,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	300,000.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, ID 47401-3654	N/A	GOV	TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES	58,372.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
<b>Total from continuation sheets</b> .....				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	869,232.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	LONGITUDINAL STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN AND ADOLESCENTS WITH NEW-ONSET T1D: CHARACTERISTICS AND PREDICTIVE BIOMARKERS	62,567.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM	304,033.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM	152,546.
UNIVERSITE DE GENEVE RUE MICHEL SERVET 1 GENEVE, SWITZERLAND	N/A	GOV	PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES	1,112,238.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	213,602.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	537,700.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	866,199.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	677,700.
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA 1800 W CHARLESTON BLVD LAS VEGAS, NV 89102	N/A	GOV	DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	387,094.
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA 1800 W CHARLESTON BLVD LAS VEGAS, NV 89102	N/A	GOV	DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	84,783.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	479,888.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY AND IMMUNOTHERAPY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY	152,801.
UNIVERSITY OF BRISTOL SENATE HOUSE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	431,779.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF BRISTOL SENATE HOUSE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	358,900.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	353,223.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?	808,734.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	718,215.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?	820,911.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?	726,752.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS OXFORD, UNITED KINGDOM	N/A	PC	DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?	851,645.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE, SUITE 500 CINCINNATI, OH 45221	N/A	GOV	STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE	416,500.
UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE, SUITE 500 CINCINNATI, OH 45221	N/A	GOV	STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE	429,700.
UNIVERSITY OF DUNDEE NETHERGATE DUNDEE, UNITED KINGDOM	N/A	PC	HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA	133,804.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM	672,028.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	ADVANCING -CELL SPECIFIC THERAPY BY IDENTIFYING -CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS	126,104.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	235,821.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES	692,073.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	95,777.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES	189,671.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	313,168.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	665,910.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES	64,043.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT	757,160.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	569,086.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY	176,239.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	199,968.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	204,566.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	714,411.
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. 2385 IRVING HILL ROAD LAWRENCE, KS 66045	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	579,370.
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. 2385 IRVING HILL ROAD LAWRENCE, KS 66045	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	706,324.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	473,409.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D	405,066.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D	490,922.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	326,055.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	328,238.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	286,197.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	242,826.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,027,184.
<b>Total from continuation sheets</b>				



**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS	1,038,654.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,116,830.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD OF THE POUCH	336,550.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS	1,058,738.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	149,796.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD OF THE POUCH	71,233.
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	74,153.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE & HEALTH SCIENCES GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	27,496.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, ID 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	671,881.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, ID 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	705,510.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	135,549.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	274,391.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	237,102.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	198,646.
<b>Total from continuation sheets</b>				

**Part XIV Supplementary Information** (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LANE AUSTIN, TX 78759-5316	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS	290,806.
UNIVERSITY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS SEATTLE, WA 98195-9472	N/A	GOV	DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4	387,576.
UNIVERSITY OF WESTERN ONTARIO 339 WINDERMERE RD. LONDON, CANADA	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	756,873.
UNIVERSITY OF WESTERN ONTARIO 339 WINDERMERE RD. LONDON, CANADA	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	606,448.
UNIVERSITY OF WYOMING FOUNDATION 222 S 22ND ST LARAMIE, WY 82070	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN WYOMING	458,857.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF WYOMING FOUNDATION 222 S 22ND ST LARAMIE, WY 82070	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN WYOMING	458,857.
UPPSALA UNIVERSITY HOSPITAL BOX 256 UPPSALA, SWEDEN	N/A	PC	IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION	1,139,284.
UPPSALA UNIVERSITY HOSPITAL BOX 256 UPPSALA, SWEDEN	N/A	PC	IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION	360,374.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY	513,936.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	121,999.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	163,405.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	275,000.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	232,525.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	104,599.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	182,168.
VANDERBILT UNIVERSITY SPONSORED PROGRAMS ADMINISTRATION NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	2,978,657.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D.	318,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	3,039,905.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	4,336,124.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	2,203,040.
VIVLI, INC. 101 MIDDLESEX TURNPIKE, SUITE 6 BURLINGTON, MA 01803-4914	N/A	PC	DATA SHARING PLATFORM FOR T1-DEXI DATASETS	74,348.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	11,027.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MI 63130-4862	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	488,300.
WASHINGTON UNIVERSITY CAMPUS BOX 1054 SAINT LOUIS, MI 63130-4862	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	863,618.
<b>Total from continuation sheets</b>				

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	202,620.
WEIZMANN INSTITUTE OF SCIENCE POB 26 REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	2,700,000.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA, SWITZERLAND	N/A	PC	STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS	3,477,889.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA, SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	3,521,461.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA, SWITZERLAND	N/A	PC	STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS	2,658,639.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA, SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	2,738,915.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE	599,035.

**Total from continuation sheets** .....

**Part XIV** Supplementary Information (continued)

**3b Grants and Contributions Approved for Future Payment**

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE	605,522.
YEHUDA ABARBANEL GOVERNMENT HOSPITAL 15 KEREN KAYEMET ST. BAT YAM, ISRAEL	N/A	GOV	MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS	454,960.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER	1,978,286.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET, #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2024-2026	200,000.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET, #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2024-2026	200,000.

**Total from continuation sheets** .....



**Part XIV** Supplementary Information

**3a Grants and Contributions Paid During the Year Continuation of Purpose of Grant or Contribution**

NAME OF RECIPIENT - ACADEMISCH ZIEKENHUIS LEIDEN

SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC

DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)

NAME OF RECIPIENT - ACUMEN AMERICA, LLC

SUPPLEMENTAL SUPPORT TO ADDRESS SOCIAL DETERMINANTS OF HEALTH FOR

PEOPLE WITH INSULIN REQUIRING DIABETES

**Part XIV** Supplementary Information

**3b Grants and Contributions Approved for Future Payment Continuation of Purpose of Grant or Contribution**

NAME OF RECIPIENT - INSTITUTE FOR MONITORING PEACE AND CULTURAL

TOLERANCE IN SCHOOL EDUCATION

TRANSFORMING EDUCATION FOR PEACE: A NATIONWIDE AWARENESS CAMPAIGN ON

INCITEMENT IN PALESTINIAN/UNRWA TEXTBOOKS.

NAME OF RECIPIENT - ACADEMISCH ZIEKENHUIS LEIDEN

SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC

DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)

**Schedule B**  
**(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Schedule of Contributors**

Attach to Form 990, 990-EZ, or 990-PF.  
Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for the latest information.

OMB No. 1545-0047

**2023**

Name of the organization THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	Employer identification number 13-7184401
------------------------------------------------------------------------------------	----------------------------------------------

Organization type (check one):

**Filers of:**

**Section:**

- Form 990 or 990-EZ  501(c)( ) (enter number) organization
- 4947(a)(1) nonexempt charitable trust **not** treated as a private foundation
- 527 political organization
- Form 990-PF  501(c)(3) exempt private foundation
- 4947(a)(1) nonexempt charitable trust treated as a private foundation
- 501(c)(3) taxable private foundation

Check if your organization is covered by the **General Rule** or a **Special Rule**.

**Note:** Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

**General Rule**

- For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling \$5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

**Special Rules**

- For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of **(1)** \$5,000; or **(2)** 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.
- For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than \$1,000 *exclusively* for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.
- For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions *exclusively* for religious, charitable, etc., purposes, but no such contributions totaled more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an *exclusively* religious, charitable, etc., purpose. Don't complete any of the parts unless the **General Rule** applies to this organization because it received *nonexclusively* religious, charitable, etc., contributions totaling \$5,000 or more during the year ..... \$ \_\_\_\_\_

**Caution:** An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it **must** answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

For Paperwork Reduction Act Notice, see the instructions for Form 990, 990-EZ, or 990-PF.

Schedule B (Form 990) (2023)

Name of organization THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	<b>Employer identification number</b>  13-7184401
--------------------------------------------------------------------------------	---------------------------------------------------------

**Part I Contributors** (see instructions). Use duplicate copies of Part I if additional space is needed.

(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
1	ESTATE OF LEONA M. HELMSLEY  230 PARK AVENUE, SUITE 659  NEW YORK, NY 10169	\$ 20,000,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
_____	_____  _____  _____	\$ _____	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)

Name of organization THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	<b>Employer identification number</b>  13-7184401
--------------------------------------------------------------------------------	---------------------------------------------------------

**Part II Noncash Property** (see instructions). Use duplicate copies of Part II if additional space is needed.

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____
	_____	\$ _____	_____

Name of organization THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	Employer identification number 13-7184401
--------------------------------------------------------------------------------	----------------------------------------------

**Part III** Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than \$1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of \$1,000 or less for the year. (Enter this info. once.) \$ \_\_\_\_\_  
Use duplicate copies of Part III if additional space is needed.

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
<b>(e) Transfer of gift</b>			
Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee	
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
<b>(e) Transfer of gift</b>			
Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee	
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
<b>(e) Transfer of gift</b>			
Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee	
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held
<b>(e) Transfer of gift</b>			
Transferee's name, address, and ZIP + 4		Relationship of transferor to transferee	

# Underpayment of Estimated Tax by Corporations

Attach to the corporation's tax return. FORM 990-PF

**2023**

Go to [www.irs.gov/Form2220](http://www.irs.gov/Form2220) for instructions and the latest information.

Name **THE LEONA M. AND HARRY B. HELMSLEY  
CHARITABLE TRUST**

Employer identification number  
**13-7184401**

**Note:** Generally, the corporation is not required to file Form 2220 (see Part II below for exceptions) because the IRS will figure any penalty owed and bill the corporation. However, the corporation may still use Form 2220 to figure the penalty. If so, enter the amount from page 2, line 38, on the estimated tax penalty line of the corporation's income tax return, but **do not** attach Form 2220.

**Part I Required Annual Payment**

1	Total tax (see instructions)		<b>1</b>	3,123,302.
2a	Personal holding company tax (Schedule PH (Form 1120), line 26) included on line 1			
2b	Look-back interest included on line 1 under section 460(b)(2) for completed long-term contracts or section 167(g) for depreciation under the income forecast method			
2c	Credit for federal tax paid on fuels (see instructions)			
2d	<b>Total.</b> Add lines 2a through 2c			
3	Subtract line 2d from line 1. If the result is less than \$500, <b>do not</b> complete or file this form. The corporation does not owe the penalty		<b>3</b>	3,123,302.
4	Enter the tax shown on the corporation's 2022 income tax return. See instructions. <b>Caution:</b> If the tax is zero or the tax year was for less than 12 months, skip this line and enter the amount from line 3 on line 5		<b>4</b>	1,659,683.
5	<b>Required annual payment.</b> Enter the <b>smaller</b> of line 3 or line 4. If the corporation is required to skip line 4, enter the amount from line 3		<b>5</b>	1,659,683.

**Part II Reasons for Filing** - Check the boxes below that apply. If any boxes are checked, the corporation **must** file Form 2220 even if it does not owe a penalty. See instructions.

- 6  The corporation is using the adjusted seasonal installment method.
- 7  The corporation is using the annualized income installment method.
- 8  The corporation is a "large corporation" figuring its first required installment based on the prior year's tax.

**Part III Figuring the Underpayment**

	(a)	(b)	(c)	(d)
9 <b>Installment due dates.</b> Enter in columns (a) through (d) the 15th day of the 4th (Form 990-PF filers: Use 5th month), 6th, 9th, and 12th months of the corporation's tax year	08/15/23	09/15/23	12/15/23	03/15/24
10 <b>Required installments.</b> If the box on line 6 and/or line 7 above is checked, enter the amounts from Sch A, line 38. If the box on line 8 (but not 6 or 7) is checked, see instructions for the amounts to enter. If none of these boxes are checked, enter 25% (0.25) of line 5 above in each column	414,921.	1,146,730.	780,826.	780,825.
11 <b>Estimated tax paid or credited for each period.</b> For column (a) only, enter the amount from line 11 on line 15. See instructions	7,023,536.	2,500,000.		
<b>Complete lines 12 through 18 of one column before going to the next column.</b>				
12 Enter amount, if any, from line 18 of the preceding column		6,608,615.	7,961,885.	7,181,059.
13 Add lines 11 and 12		9,108,615.	7,961,885.	7,181,059.
14 Add amounts on lines 16 and 17 of the preceding column				
15 Subtract line 14 from line 13. If zero or less, enter -0-	7,023,536.	9,108,615.	7,961,885.	7,181,059.
16 If the amount on line 15 is zero, subtract line 13 from line 14. Otherwise, enter -0-		0.	0.	
17 <b>Underpayment.</b> If line 15 is less than or equal to line 10, subtract line 15 from line 10. Then go to line 12 of the next column. Otherwise, go to line 18				
18 <b>Overpayment.</b> If line 10 is less than line 15, subtract line 10 from line 15. Then go to line 12 of the next column	6,608,615.	7,961,885.	7,181,059.	

Go to Part IV on page 2 to figure the penalty. Do not go to Part IV if there are no entries on line 17 - no penalty is owed.

For Paperwork Reduction Act Notice, see separate instructions.

Form 2220 (2023)

**Part IV Figuring the Penalty**

	(a)	(b)	(c)	(d)
<b>19</b> Enter the date of payment or the 15th day of the 4th month after the close of the tax year, whichever is earlier. <b>(C corporations with tax years ending June 30 and S corporations:</b> Use 3rd month instead of 4th month. <b>Form 990-PF and Form 990-T filers:</b> Use 5th month instead of 4th month.) See instructions .....	<b>19</b>			
<b>20</b> Number of days from due date of installment on line 9 to the date shown on line 19 .....	<b>20</b>			
<b>21</b> Number of days on line 20 after 4/15/2023 and before 7/1/2023 .....	<b>21</b>			
<b>22</b> Underpayment on line 17 x $\frac{\text{Number of days on line 21} \times 7\% (0.07)}{365}$ ...	<b>22</b> \$	\$	\$	\$
<b>23</b> Number of days on line 20 after 6/30/2023 and before 10/1/2023 .....	<b>23</b>			
<b>24</b> Underpayment on line 17 x $\frac{\text{Number of days on line 23} \times 7\% (0.07)}{365}$ ...	<b>24</b> \$	\$	\$	\$
<b>25</b> Number of days on line 20 after 9/30/2023 and before 1/1/2024 .....	<b>25</b>			
<b>26</b> Underpayment on line 17 x $\frac{\text{Number of days on line 25} \times 8\% (0.08)}{365}$ ...	<b>26</b> \$	\$	\$	\$
<b>27</b> Number of days on line 20 after 12/31/2023 and before 4/1/2024 .....	<b>27</b>			
<b>28</b> Underpayment on line 17 x $\frac{\text{Number of days on line 27} \times 8\% (0.08)}{366}$ ...	<b>28</b> \$	\$	\$	\$
<b>29</b> Number of days on line 20 after 3/31/2024 and before 7/1/2024 .....	<b>29</b>			
<b>30</b> Underpayment on line 17 x $\frac{\text{Number of days on line 29} \times \%}{366}$ .....	<b>30</b> \$	\$	\$	\$
<b>31</b> Number of days on line 20 after 6/30/2024 and before 10/1/2024 .....	<b>31</b>			
<b>32</b> Underpayment on line 17 x $\frac{\text{Number of days on line 31} \times \%}{366}$ .....	<b>32</b> \$	\$	\$	\$
<b>33</b> Number of days on line 20 after 9/30/2024 and before 1/1/2025 .....	<b>33</b>			
<b>34</b> Underpayment on line 17 x $\frac{\text{Number of days on line 33} \times \%}{366}$ .....	<b>34</b> \$	\$	\$	\$
<b>35</b> Number of days on line 20 after 12/31/2024 and before 3/16/2025 .....	<b>35</b>			
<b>36</b> Underpayment on line 17 x $\frac{\text{Number of days on line 35} \times \%}{365}$ .....	<b>36</b> \$	\$	\$	\$
<b>37</b> Add lines 22, 24, 26, 28, 30, 32, 34, and 36 .....	<b>37</b> \$	\$	\$	\$
<b>38 Penalty.</b> Add columns (a) through (d) of line 37. Enter the total here and on Form 1120, line 34; or the comparable line for other income tax returns .....	<b>38</b> \$			0.

\* Use the penalty interest rate for each calendar quarter, which the IRS will determine during the first month in the preceding quarter. These rates are published quarterly in an IRS News Release and in a revenue ruling in the Internal Revenue Bulletin. To obtain this information on the Internet, access the IRS website at [www.irs.gov](http://www.irs.gov). You can also call 800-829-4933 to get interest rate information.



Schedule A Adjusted Seasonal Installment Method and Annualized Income Installment Method

See instructions.

Form 1120-S filers: For lines 1, 2, 3, and 21, "taxable income" refers to excess net passive income or the amount on which tax is imposed under section 1374(a), whichever applies.

Part I Adjusted Seasonal Installment Method

Caution: Use this method only if the base period percentage for any 6 consecutive months is at least 70%. See instructions.

Table with 5 columns: (a) First 3 months, (b) First 5 months, (c) First 8 months, (d) First 11 months. Rows include taxable income for various periods (1a-1c, 2, 3a-3c, 4-6), calculations (7-13), and final tax amounts (14-19).

**Part II** Annualized Income Installment Method

		(a)	(b)	(c)	(d)
		First <u>2</u> months	First <u>3</u> months	First <u>6</u> months	First <u>9</u> months
20 Annualization periods (see instructions)	20				
21 Enter taxable income for each annualization period. See instructions for the treatment of extraordinary items	21	118,202,176.	172,774,794.	169,608,882.	397,109,094.
22 Annualization amounts (see instructions)	22	6.000000	4.000000	2.000000	1.333330
23a Annualized taxable income. Multiply line 21 by line 22	23a	709,213,056.	691,099,176.	339,217,764.	529,477,468.
23b Extraordinary items (see instructions)	23b				
23c Add lines 23a and 23b	23c	709,213,056.	691,099,176.	339,217,764.	529,477,468.
24 Figure the tax on the amount on line 23c using the instructions for Form 1120, Schedule J, line 1, or comparable line of corporation's return	24	9,858,061.	9,606,279.	4,715,127.	7,359,737.
25 Enter any alternative minimum tax (trusts only) for each payment period. See instructions	25				
26 Enter any other taxes for each payment period. See instr.	26				
27 Total tax. Add lines 24 through 26	27	9,858,061.	9,606,279.	4,715,127.	7,359,737.
28 For each period, enter the same type of credits as allowed on Form 2220, lines 1 and 2c. See instructions	28				
29 Total tax after credits. Subtract line 28 from line 27. If zero or less, enter -0-	29	9,858,061.	9,606,279.	4,715,127.	7,359,737.
30 Applicable percentage	30	25%	50%	75%	100%
31 Multiply line 29 by line 30	31	2,464,515.	4,803,140.	3,536,345.	7,359,737.

**Part III** Required Installments

		1st installment	2nd installment	3rd installment	4th installment
<b>Note:</b> Complete lines 32 through 38 of one column before completing the next column.					
32 If only Part I or Part II is completed, enter the amount in each column from line 19 or line 31. If both parts are completed, enter the <b>smaller</b> of the amounts in each column from line 19 or line 31	32	2,464,515.	4,803,140.	3,536,345.	7,359,737.
33 Add the amounts in all preceding columns of line 38. See instructions	33		414,921.	1,561,651.	2,342,477.
34 <b>Adjusted seasonal or annualized income installments.</b> Subtract line 33 from line 32. If zero or less, enter -0-	34	2,464,515.	4,388,219.	1,974,694.	5,017,260.
35 Enter 25% (0.25) of line 5 on page 1 of Form 2220 in each column. <b>Note:</b> "Large corporations," see the instructions for line 10 for the amounts to enter	35	414,921.	1,146,730.	780,826.	780,825.
36 Subtract line 38 of the preceding column from line 37 of the preceding column	36				
37 Add lines 35 and 36	37	414,921.	1,146,730.	780,826.	780,825.
38 <b>Required installments.</b> Enter the <b>smaller</b> of line 34 or line 37 here and on page 1 of Form 2220, line 10. See instructions	38	414,921.	1,146,730.	780,826.	780,825.

## FORM 990-PF INTEREST ON SAVINGS AND TEMPORARY CASH INVESTMENTS STATEMENT 1

SOURCE	(A) REVENUE PER BOOKS	(B) NET INVESTMENT INCOME	(C) ADJUSTED NET INCOME
INTEREST FROM SAVINGS	4,018,817.	4,018,817.	
TOTAL TO PART I, LINE 3	4,018,817.	4,018,817.	

## FORM 990-PF DIVIDENDS AND INTEREST FROM SECURITIES STATEMENT 2

SOURCE	GROSS AMOUNT	CAPITAL GAINS DIVIDENDS	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
DIVIDENDS AND INTEREST FROM SECURITIES	67,095,872.	0.	67,095,872.	132,636,674.	
TO PART I, LINE 4	67,095,872.	0.	67,095,872.	132,636,674.	

## FORM 990-PF OTHER INCOME STATEMENT 3

DESCRIPTION	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
FX TRANSACTION NET GAIN	75,679.	107,230.	
CLASS ACTION PROCEEDS, NET	27,425.	27,425.	
OTHER PARTNERSHIP INCOME	51,555,006.	18,797,169.	
SECTION 951(A) INCOME INCLUSION	0.	12,869,467.	
OTHER INVESTMENT INCOME	31.	31.	
GRANT RECOVERIES	7,742,742.	0.	
OTHER NON-TAXABLE INCOME	9,058.	0.	
TOTAL TO FORM 990-PF, PART I, LINE 11	59,409,941.	31,801,322.	

## FORM 990-PF

## LEGAL FEES

## STATEMENT 4

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
LEGAL FEES - INVESTMENTS	113,927.	113,927.		0.
LEGAL FEES - PROGRAMS	131,480.	0.		154,619.
LEGAL FEES - GENERAL ADMINISTRATIVE	177,853.	0.		173,296.
TO FM 990-PF, PG 1, LN 16A	423,260.	113,927.		327,915.

## FORM 990-PF

## ACCOUNTING FEES

## STATEMENT 5

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AUDIT AND TAX PREPARATION	250,826.	112,329.		160,305.
BOOKKEEPING	66,736.	3,901.		69,049.
OTHER ACCOUNTING SERVICES	109,527.	0.		116,371.
TO FORM 990-PF, PG 1, LN 16B	427,089.	116,230.		345,725.

## FORM 990-PF

## OTHER PROFESSIONAL FEES

## STATEMENT 6

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
GRANTS MANAGEMENT CONSULTING	187,909.	0.		169,633.
HUMAN RESOURCE CONSULTING	59,283.	6,250.		66,833.
INFORMATION TECHNOLOGY CONSULTING	431,360.	42,495.		390,141.
INVESTMENT ADVISORY	495,009.	495,009.		0.
INVESTMENT MANAGEMENT	3,744,150.	3,744,150.		0.
MANAGEMENT CONSULTING	53,667.	385.		23,291.
PROGRAM CONSULTING	1,401,182.	0.		1,313,020.
PUBLIC RELATIONS	537,596.	0.		502,546.
RECRUITMENT	236,412.	75,000.		166,096.
TO FORM 990-PF, PG 1, LN 16C	7,146,568.	4,363,289.		2,631,560.

## FORM 990-PF

## TAXES

## STATEMENT 7

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
STATE UBI AND OTHER TAXES	2,344,680.	0.		0.
FOREIGN TAXES WITHHELD	513,757.	2,384,774.		0.
FEDERAL EXCISE TAX	5,128,773.	0.		0.
FEDERAL UNRELATED BUSINESS INCOME TAX	1,600,000.	0.		0.
TO FORM 990-PF, PG 1, LN 18	9,587,210.	2,384,774.		0.

## FORM 990-PF

## OTHER EXPENSES

## STATEMENT 8

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AMERICAN DEPOSITARY RECEIPT FEE	16,670.	16,670.		0.
CONSULTING REIMBURSEMENTS CUSTODY, BANK, & PERFORMANCE REPORTING FEES	83,574.	0.		91,313.
STATE FILING FEES AND PENALTIES	577,640.	577,640.		0.
INFORMATION	1,550.	0.		1,500.
TECHNOLOGY/COMPUTERS	1,574,939.	242,796.		1,096,012.
INSURANCE	432,434.	39,929.		397,200.
OFFICE EXPENSES	1,330,082.	400,414.		841,353.
PORTFOLIO DEDUCTIONS	14,699,662.	55,993,792.		0.
TO FORM 990-PF, PG 1, LN 23	18,716,551.	57,271,241.		2,427,378.

## FORM 990-PF

## OTHER DECREASES IN NET ASSETS OR FUND BALANCES

## STATEMENT 9

DESCRIPTION	AMOUNT
UNREALIZED LOSS ON PRI	2,973,465.
PROVISION FOR DEFERRED FEDERAL EXCISE TAX	2,587,525.
PROVISION FOR CREDIT LOSSES - RELATED TO PROGRAM RELATED INVESTMENTS	8,923,492.
TOTAL TO FORM 990-PF, PART III, LINE 5	14,484,482.

## FORM 990-PF

## CORPORATE STOCK

## STATEMENT 10

DESCRIPTION	BOOK VALUE	FAIR MARKET VALUE
ALPHABET INC, 45,079 SHRS	6,863,729.	6,863,729.
AMAZON.COM INC, 62,440 SHRS	11,262,927.	11,262,927.
ANSYS INC, 16,010 SHRS	5,558,032.	5,558,032.
ATLASSIAN CORP, 7,353 SHRS	1,434,644.	1,434,644.
BIO-TECHNE CORP, 70,579 SHRS	4,968,056.	4,968,056.
CBRE GROUP INC, 65,438 SHRS	6,363,191.	6,363,191.
CARMAX INC, 22,974 SHRS	2,001,265.	2,001,265.
COSTAR GROUP INC, 37,037 SHRS	3,577,774.	3,577,774.
CROWDSTRIKE HOLDINGS INC, 4,441 SHRS	1,423,740.	1,423,740.
DANAHER CORP, 25,903 SHRS	6,468,497.	6,468,497.
ECOLAB INC, 20,961 SHRS	4,839,895.	4,839,895.
FASTENAL CO, 32,549 SHRS	2,510,830.	2,510,830.
GUIDEWIRE SOFTWARE INC, 45,210 SHRS	5,276,459.	5,276,459.
HEICO CORP, 40,957 SHRS	6,304,921.	6,304,921.
INTUIT INC, 5,110 SHRS	3,321,500.	3,321,500.
INTUITIVE SURGICAL INC, 12,879 SHRS	5,139,880.	5,139,880.
KINSALE CAPITAL GROUP INC, 6,921 SHRS	3,631,726.	3,631,726.
MARKEL GROUP INC, 2,553 SHRS	3,884,338.	3,884,338.
MASTERCARD INC, 17,212 SHRS	8,288,783.	8,288,783.
MICROSOFT CORP, 16,736 SHRS	7,041,170.	7,041,170.
MONOLITHIC POWER SYSTEMS INC, 5,448 SHRS	3,690,584.	3,690,584.
MOODY'S CORP, 11,080 SHRS	4,354,772.	4,354,772.
OLD DOMINION FREIGHT LINE INC, 24,254 SHRS	5,319,145.	5,319,145.
S&P GLOBAL INC, 16,804 SHRS	7,149,262.	7,149,262.
SHERWIN-WILLIAMS CO/THE, 11,066 SHRS	3,843,554.	3,843,554.
SITEONE LANDSCAPE SUPPLY INC, 21,900 SHRS	3,822,645.	3,822,645.
SPROUT SOCIAL INC, 41,508 SHRS	2,478,443.	2,478,443.
THERMO FISHER SCIENTIFIC INC, 9,077 SHRS	5,275,643.	5,275,643.
TRANSDIGM GROUP INC, 7,112 SHRS	8,759,139.	8,759,139.
VEEVA SYSTEMS INC, 24,036 SHRS	5,568,901.	5,568,901.
VERALTO CORP, 59,355 SHRS	5,262,414.	5,262,414.
VISA INC, 29,616 SHRS	8,265,233.	8,265,233.
VULCAN MATERIALS CO, 25,753 SHRS	7,028,509.	7,028,509.
WASTE CONNECTIONS INC, 28,597 SHRS	4,918,970.	4,918,970.
WEST PHARMACEUTICAL SERVICES I, 10,068 SHRS	3,984,008.	3,984,008.
WILLSCOT MOBILE MINI HOLDINGS, 63,928 SHRS	2,972,652.	2,972,652.
WORKIVA INC, 21,421 SHRS	1,816,501.	1,816,501.
ZOETIS INC, 14,278 SHRS	2,415,980.	2,415,980.

ASML HOLDING NV, 2,389 SHRS	2,318,453.	2,318,453.
ARCH CAPITAL GROUP LTD, 31,860 SHRS	2,945,138.	2,945,138.
SCHLUMBERGER LTD, 38,086 SHRS	2,087,494.	2,087,494.
FRESENIUS MEDICAL CARE AG, 105,911 SHRS	2,041,964.	2,041,964.
EATON CORP PLC, 7,035 SHRS	2,199,704.	2,199,704.
SONY GROUP CORP, 56,877 SHRS	4,876,634.	4,876,634.
FERGUSON PLC, 33,211 SHRS	7,254,279.	7,254,279.
KONINKLIJKE PHILIPS NV, 130,914 SHRS	2,618,280.	2,618,280.
SMITH & NEPHEW PLC, 89,859 SHRS	2,278,824.	2,278,824.
UNILEVER PLC, 81,279 SHRS	4,079,393.	4,079,393.
ALPHABET INC, 43,685 SHRS	6,593,377.	6,593,377.
AVERY DENNISON CORP, 25,477 SHRS	5,687,740.	5,687,740.
BERKSHIRE HATHAWAY INC, 15,142 SHRS	6,367,514.	6,367,514.
BLACKROCK INC, 3,156 SHRS	2,631,157.	2,631,157.
BOOKING HOLDINGS INC, 1,484 SHRS	5,383,774.	5,383,774.
CDW CORP/DE, 12,394 SHRS	3,170,137.	3,170,137.
CARLISLE COS INC, 13,377 SHRS	5,241,777.	5,241,777.
CARMAX INC, 62,091 SHRS	5,408,747.	5,408,747.
CARRIER GLOBAL CORP, 71,175 SHRS	4,137,403.	4,137,403.
DOLLAR GENERAL CORP, 25,941 SHRS	4,048,352.	4,048,352.
DOLLAR TREE INC, 23,960 SHRS	3,190,274.	3,190,274.
MASCO CORP, 72,819 SHRS	5,743,963.	5,743,963.
MICRON TECHNOLOGY INC, 43,584 SHRS	5,138,118.	5,138,118.
NORTHERN TRUST CORP, 39,309 SHRS	3,495,356.	3,495,356.
OMNICOM GROUP INC, 37,610 SHRS	3,639,144.	3,639,144.
PROGRESSIVE CORP/THE, 19,411 SHRS	4,014,583.	4,014,583.
QUEST DIAGNOSTICS INC, 29,141 SHRS	3,878,959.	3,878,959.
CHARLES SCHWAB CORP/THE, 92,922 SHRS	6,721,977.	6,721,977.
SYSCO CORP, 48,254 SHRS	3,917,260.	3,917,260.
TJX COS INC/THE, 15,463 SHRS	1,568,257.	1,568,257.
UNITEDHEALTH GROUP INC, 8,091 SHRS	4,002,618.	4,002,618.
RB GLOBAL INC, 197,129 SHRS	15,015,316.	15,015,316.
AON PLC, 34,711 SHRS	11,583,755.	11,583,755.
NINTENDO CO LTD, 165,000 SHRS	8,935,478.	8,935,478.
NOVARTIS AG, 92,230 SHRS	8,946,525.	8,946,525.
NESTLE SA, 52,246 SHRS	5,554,074.	5,554,074.
CIE FINANCIERE RICHEMONT SA, 46,562 SHRS	7,108,110.	7,108,110.
UNILEVER PLC, 149,110 SHRS	7,491,525.	7,491,525.
RECKITT BENCKISER GROUP PLC, 185,024 SHRS	10,545,968.	10,545,968.
INFORMA PLC, 903,750 SHRS	9,489,496.	9,489,496.
GSK PLC, 446,812 SHRS	9,643,941.	9,643,941.
BOOKING HOLDINGS INC, 2,779 SHRS	10,081,879.	10,081,879.
BRISTOL-MYERS SQUIBB CO, 208,007 SHRS	11,280,220.	11,280,220.
CORTEVA INC, 213,075 SHRS	12,288,035.	12,288,035.
EBAY INC, 151,642 SHRS	8,003,665.	8,003,665.
ELECTRONIC ARTS INC, 64,871 SHRS	8,606,436.	8,606,436.
FOX CORP, 243,057 SHRS	7,600,392.	7,600,392.
FOX CORP, 92,047 SHRS	2,634,385.	2,634,385.
INTERCONTINENTAL EXCHANGE INC, 87,691 SHRS	12,051,374.	12,051,374.
JOHNSON & JOHNSON, 60,279 SHRS	9,535,535.	9,535,535.
ESTEE LAUDER COS INC/THE, 35,524 SHRS	5,476,025.	5,476,025.
NEWS CORP, 422,306 SHRS	11,055,971.	11,055,971.
NEWS CORP, 151,503 SHRS	4,099,671.	4,099,671.
ORACLE CORP, 81,611 SHRS	10,251,158.	10,251,158.
REVVITY INC, 27,855 SHRS	2,924,775.	2,924,775.
TKO GROUP HOLDINGS INC, 39,152 SHRS	3,383,124.	3,383,124.
TRANSUNION, 114,304 SHRS	9,121,459.	9,121,459.
ZILLOW GROUP INC, 32,498 SHRS	1,555,354.	1,555,354.

ZILLOW GROUP INC, 180,747 SHRS	8,816,839.	8,816,839.
PDD HOLDINGS INC, 216,396 SHRS	25,156,035.	25,156,035.
STRUCTURE THERAPEUTICS INC, 1,336 SHRS	57,261.	57,261.
NU HOLDINGS LTD/CAYMAN ISLANDS, 708,356 SHRS	8,450,687.	8,450,687.
CHINA RENAISSANCE HOLDINGS LTD, 127,556 SHRS	118,487.	118,487.
YUBICO AB, 73,585 SHRS	1,311,683.	1,311,683.
AFFIRM HOLDINGS INC, 21,250 SHRS	791,775.	791,775.
AIRBNB INC, 89,793 SHRS	14,812,253.	14,812,253.
BILL HOLDINGS INC, 6,110 SHRS	419,879.	419,879.
COINBASE GLOBAL INC, 62,036 SHRS	16,446,984.	16,446,984.
CONFLUENT INC, 27,537 SHRS	840,429.	840,429.
CROWDSTRIKE HOLDINGS INC, 14,711 SHRS	4,716,199.	4,716,199.
DOORDASH INC, 22,663 SHRS	3,121,148.	3,121,148.
META PLATFORMS INC, 9,000 SHRS	4,370,220.	4,370,220.
FRESHWORKS INC, 2,700 SHRS	49,167.	49,167.
GUARDANT HEALTH INC, 4,000 SHRS	82,520.	82,520.
MAPLEBEAR INC, 13,360 SHRS	498,194.	498,194.
ROBLOX CORP, 72,000 SHRS	2,748,960.	2,748,960.
SNOWFLAKE INC, 57,211 SHRS	9,245,298.	9,245,298.
TOAST INC, 7,000 SHRS	174,440.	174,440.
UBER TECHNOLOGIES INC, 5,921 SHRS	455,858.	455,858.
UIPATH INC, 128,002 SHRS	2,901,805.	2,901,805.
TOTAL TO FORM 990-PF, PART II, LINE 10B	643,618,129.	643,618,129.

## FORM 990-PF

## OTHER INVESTMENTS

## STATEMENT 11

DESCRIPTION	VALUATION METHOD	BOOK VALUE	FAIR MARKET VALUE
JPM US LARGE CAP	FMV	177,279,037.	177,279,037.
SPDR TRUST SERIES I	FMV	115,257,951.	115,257,951.
JPM CORE BOND	FMV	1,228,783,297.	1,228,783,297.
JPM SHORT DURATION BOND	FMV	311,100,609.	311,100,609.
CHATHAM	FMV	119,844,821.	119,844,821.
CHATHAM OFFSHORE	FMV	118,008,474.	118,008,474.
CAMBER	FMV	136,629,017.	136,629,017.
ORBIMED GENESIS FUND	FMV	49,036,762.	49,036,762.
SEQUOIA CAP GLOBAL	FMV	189,217,984.	189,217,984.
ACADIAN FRONTIER	FMV	176,593.	176,593.
HIGHCLERE INTL SC	FMV	134,358,764.	134,358,764.
HIGHCLERE INTL SMID	FMV	66,330,787.	66,330,787.
LA CAPITAL GLOBAL	FMV	95,462,096.	95,462,096.
LACM WORLD SMALL CAP	FMV	97,962,582.	97,962,582.
MARATHON GLOBAL	FMV	181,832,660.	181,832,660.
SILCHESTER INTL	FMV	151,839,703.	151,839,703.
BLACKROCK US DEBT	FMV	141,112,373.	141,112,373.
BAYVIEW	FMV	856,754.	856,754.
EIG ENERGY FUND XVI	FMV	36,496,509.	36,496,509.
EIG ENERGY XV	FMV	3,317,372.	3,317,372.
FDAF DISLOCATED II	FMV	25,362,236.	25,362,236.
FDAF DISLOCATED III	FMV	35,430,388.	35,430,388.
FDAF DISLOCATED IV	FMV	30,533,776.	30,533,776.
GSO CAPITAL SOLS II	FMV	2,361,684.	2,361,684.
HIG BAYSIDE III	FMV	3,377,026.	3,377,026.



MHR AXIOM	FMV	243,605,491.	243,605,491.
MHR INST PARTNERS IV	FMV	63,010,246.	63,010,246.
NEWMARKET IIFC	FMV	19,137,487.	19,137,487.
ORBIMED ROYALTY II	FMV	1,544,922.	1,544,922.
ACCEL GROWTH FUND IV	FMV	17,738,020.	17,738,020.
ACCEL GROWTH II	FMV	13,189,479.	13,189,479.
ACCEL GROWTH III	FMV	11,522,052.	11,522,052.
ACCEL GROWTH V	FMV	28,308,899.	28,308,899.
ACCEL GROWTH VI	FMV	13,248,632.	13,248,632.
ACCEL INDIA V	FMV	12,618,661.	12,618,661.
ACCEL INDIA VI	FMV	7,927,095.	7,927,095.
ACCEL INDIA VII	FMV	2,587,355.	2,587,355.
ACCEL LEADERS 4	FMV	7,723,401.	7,723,401.
ACCEL LEADERS FUND	FMV	13,610,357.	13,610,357.
ACCEL LEADERS II	FMV	7,980,029.	7,980,029.
ACCEL LEADERS III	FMV	25,691,472.	25,691,472.
ACCEL XI	FMV	5,501,339.	5,501,339.
ACCEL XII	FMV	24,441,487.	24,441,487.
ACCEL XIII	FMV	12,686,251.	12,686,251.
ACCEL XIV	FMV	8,403,040.	8,403,040.
ACCEL XV	FMV	4,891,255.	4,891,255.
AH BIO FUND I	FMV	6,215,300.	6,215,300.
AH BIO FUND II	FMV	16,332,915.	16,332,915.
AH BIO III	FMV	17,539,078.	17,539,078.
AH BIO IV	FMV	5,164,862.	5,164,862.
AH CNK IV	FMV	9,973,313.	9,973,313.
AH CNK SEED I	FMV	1,812,964.	1,812,964.
AH FUND VII	FMV	10,637,499.	10,637,499.
AH FUND VIII	FMV	4,792,855.	4,792,855.
AH III	FMV	37,063,336.	37,063,336.
AH III PARALLEL	FMV	8,022,513.	8,022,513.
AH IV	FMV	42,823,557.	42,823,557.
AH IV PARALLEL	FMV	16,791,658.	16,791,658.
AH LSV FUND II	FMV	17,482,444.	17,482,444.
AH LSV FUND III	FMV	11,279,330.	11,279,330.
AH LSV I	FMV	18,669,497.	18,669,497.
AH V	FMV	41,678,594.	41,678,594.
AH V PARALLEL	FMV	27,081,839.	27,081,839.
AH VI	FMV	25,593,295.	25,593,295.
ANGELENO INV III	FMV	17,678,812.	17,678,812.
ARBORETUM III	FMV	2,731,511.	2,731,511.
ARBORETUM IV	FMV	9,848,177.	9,848,177.
ARBORETUM V	FMV	16,692,098.	16,692,098.
ARBORETUM VI	FMV	3,110,754.	3,110,754.
COLLER VI	FMV	3,508,788.	3,508,788.
COLLER VII	FMV	25,558,568.	25,558,568.
COLLER VIII	FMV	30,577,456.	30,577,456.
CONGRUENT CONTINUITY	FMV	5,628,815.	5,628,815.
CRESTVIEW ELO	FMV	7,079,890.	7,079,890.
CRESTVIEW III	FMV	38,332,056.	38,332,056.
CRESTVIEW IV	FMV	28,522,754.	28,522,754.
EIG ENERGY XVII	FMV	11,459,284.	11,459,284.
EMERGENCE III	FMV	49,402,869.	49,402,869.
EMERGENCE IV	FMV	22,667,037.	22,667,037.
EMERGENCE OPP I	FMV	6,474,026.	6,474,026.
EMERGENCE V	FMV	22,820,659.	22,820,659.
EMERGENCE VI	FMV	9,697,673.	9,697,673.
EPIRIS ELEC CO INV	FMV	12,983,712.	12,983,712.

EPIRIS II	FMV	24,549,597.	24,549,597.
EPIRIS III	FMV	9,507,394.	9,507,394.
FORTISSIMO IV	FMV	22,466,775.	22,466,775.
FORTISSIMO V	FMV	24,897,842.	24,897,842.
FORTISSIMO VI	FMV	2,052,354.	2,052,354.
FRAZIER GTH BUYOUT X	FMV	14,157,034.	14,157,034.
FRAZIER IX	FMV	8,527,401.	8,527,401.
FRAZIER OVERAGE	FMV	17,432,536.	17,432,536.
FRAZIER PUBLIC FUND	FMV	23,859,182.	23,859,182.
FRAZIER SUNMD CO INV	FMV	19,746,931.	19,746,931.
FRAZIER X	FMV	14,892,171.	14,892,171.
FRAZIER XI	FMV	7,591,048.	7,591,048.
GAVEA IV	FMV	1,493,387.	1,493,387.
GAVEA V	FMV	3,630,248.	3,630,248.
GAVEA V PLUS	FMV	423,181.	423,181.
GENERL ATLANTIC 2013	FMV	61,406,512.	61,406,512.
GENERL ATLANTIC 2018	FMV	80,379,997.	80,379,997.
HIG BIOVENTURE II	FMV	12,556,914.	12,556,914.
HIG BRAZIL	FMV	4,342,221.	4,342,221.
HIG BRAZIL LATAM B	FMV	18,846,817.	18,846,817.
HIG BRAZIL LATAM C	FMV	18,846,817.	18,846,817.
HIG CAPITAL V	FMV	9,219,459.	9,219,459.
HIG GROWTH B&E F II	FMV	16,876,670.	16,876,670.
HIG GROWTH III	FMV	5,450,751.	5,450,751.
HIG MID MARKET II	FMV	13,318,133.	13,318,133.
HIG MID MARKET III	FMV	18,405,040.	18,405,040.
HONGSHAN GROWTH III	FMV	86,634,726.	86,634,726.
HONGSHAN GROWTH IV	FMV	26,626,078.	26,626,078.
HONGSHAN GROWTH V	FMV	30,316,741.	30,316,741.
HONGSHAN GROWTH VI	FMV	19,761,283.	19,761,283.
HONGSHAN GROWTH VII	FMV	1,825,297.	1,825,297.
HONGSHAN VTR IV	FMV	10,645,322.	10,645,322.
HONGSHAN VTR IX	FMV	695,717.	695,717.
HONGSHAN VTR V	FMV	8,875,329.	8,875,329.
HONGSHAN VTR VI	FMV	8,235,075.	8,235,075.
HONGSHAN VTR VII	FMV	5,713,480.	5,713,480.
HONGSHAN VTR VIII	FMV	4,486,252.	4,486,252.
IDG BREYER	FMV	6,442,626.	6,442,626.
IDG CHINA CAP III	FMV	28,060,681.	28,060,681.
IDG CHINA VTR IV	FMV	24,022,389.	24,022,389.
IDG CHINA VTR V	FMV	37,326,845.	37,326,845.
IDG-ACCEL CHINA CAP	FMV	13,923,874.	13,923,874.
IDG-ACCEL CHINA GWTH	FMV	12,018,748.	12,018,748.
IRON POINT IV	FMV	17,995,936.	17,995,936.
JPM PEG SECONDRY III	FMV	5,480,557.	5,480,557.
ORBIMED ASIA III	FMV	51,045,883.	51,045,883.
ORBIMED ASIA IV	FMV	20,890,121.	20,890,121.
ORBIMED ISRAEL	FMV	3,103,591.	3,103,591.
ORBIMED ISRAEL II	FMV	22,413,588.	22,413,588.
ORBIMED PI IX	FMV	6,998,250.	6,998,250.
ORBIMED PI VI	FMV	11,171,826.	11,171,826.
ORBIMED PI VII	FMV	22,808,946.	22,808,946.
ORBIMED PI VIII	FMV	21,470,500.	21,470,500.
ORBMIED ASIA V	FMV	4,180,666.	4,180,666.
PEAK XV GWTH III	FMV	10,938,427.	10,938,427.
PEAK XV GWTH IV	FMV	955,224.	955,224.
PEAK XV SEA I	FMV	1,381,998.	1,381,998.
PEAK XV V	FMV	12,918,796.	12,918,796.

PEAK XV VI	FMV	12,207,222.	12,207,222.
PEAK XV VIII	FMV	758,109.	758,109.
PEAK XV VTR VII	FMV	3,097,553.	3,097,553.
PEP IV CORE	FMV	19,860.	19,860.
PEP IV SUPPL	FMV	4,324.	4,324.
PEP VI	FMV	19,858,804.	19,858,804.
PIATNGO VTR IX	FMV	447,234.	447,234.
PITANGO GROWTH	FMV	58,225,338.	58,225,338.
PITANGO GROWTH II	FMV	21,071,726.	21,071,726.
PITANGO HEALTH II	FMV	2,472,759.	2,472,759.
PITANGO HEALTHTECH I	FMV	12,704,126.	12,704,126.
PITANGO SPV	FMV	22,027,563.	22,027,563.
PITANGO VI, LP	FMV	28,484,864.	28,484,864.
PITANGO VTR VII	FMV	29,265,006.	29,265,006.
PITANGO VTR VIII	FMV	15,198,039.	15,198,039.
RIDGEWOOD III	FMV	39,922,324.	39,922,324.
RIDGEWOOD IV	FMV	28,352,131.	28,352,131.
S CAPITAL	FMV	23,742,984.	23,742,984.
S CAPITAL II	FMV	12,692,175.	12,692,175.
S CAPITAL III	FMV	2,427,909.	2,427,909.
SCF LIQUID PORTFOLIO	FMV	55,363,184.	55,363,184.
SEQUOIA GBL GRTH III	FMV	96,303,980.	96,303,980.
SEQUOIA GG 3 CH ANX	FMV	14,267,485.	14,267,485.
SEQUOIA GLB GROWTH	FMV	26,574,063.	26,574,063.
SEQUOIA GLB GRWTH II	FMV	39,413,558.	39,413,558.
SEQUOIA ISRAEL V	FMV	7,408,714.	7,408,714.
SEQUOIA SCOUT III	FMV	2,374,137.	2,374,137.
SEQUOIA SCOUT IV	FMV	1,103,113.	1,103,113.
SEQUOIA US ECO I	FMV	502,600.	502,600.
SEQUOIA US EXP I	FMV	5,623,411.	5,623,411.
SEQUOIA US GROWTH V	FMV	1,208,181.	1,208,181.
SEQUOIA US GRTH VIII	FMV	9,628,750.	9,628,750.
SEQUOIA US GRWTH VII	FMV	3,868,124.	3,868,124.
SEQUOIA US GWTH IX	FMV	7,461,815.	7,461,815.
SEQUOIA US GWTH VI	FMV	2,618,668.	2,618,668.
SEQUOIA US GWTH X	FMV	1,377,016.	1,377,016.
SEQUOIA US SEED V	FMV	283,543.	283,543.
SEQUOIA US VENT XVI	FMV	7,864,806.	7,864,806.
SEQUOIA US VTR XIV	FMV	7,614,201.	7,614,201.
SEQUOIA US VTR XV	FMV	4,735,787.	4,735,787.
SEQUOIA US VTR XVII	FMV	4,034,175.	4,034,175.
SEQUOIA US VTR XVIII	FMV	408,452.	408,452.
SQUOIA GG 3 US IN AX	FMV	14,028,615.	14,028,615.
STARWOOD X	FMV	16,895,377.	16,895,377.
STARWOOD XI	FMV	43,811,791.	43,811,791.
STARWOOD XII	FMV	27,488,966.	27,488,966.
TAURUS RESOURCES II	FMV	36,588,660.	36,588,660.
WTI VLL IX	FMV	12,826,350.	12,826,350.
WTI VLL VII	FMV	7,696,800.	7,696,800.
WTI VLL VIII	FMV	11,849,425.	11,849,425.
WTI VLL X	FMV	6,300,263.	6,300,263.
YORK CO INVEST 1	FMV	1,002,040.	1,002,040.

TOTAL TO FORM 990-PF, PART II, LINE 13

6,446,813,297.

6,446,813,297.

---



---

**FORM 990-PF DEPRECIATION OF ASSETS NOT HELD FOR INVESTMENT STATEMENT 12**


---

DESCRIPTION	COST OR OTHER BASIS	ACCUMULATED DEPRECIATION	BOOK VALUE
FURNITURE, FIXTURES AND EQUIPMENT	3,070,395.	1,934,123.	1,136,272.
LEASEHOLD IMPROVEMENTS	7,420,501.	1,927,641.	5,492,860.
WORK IN PROGRESS	41,130.	0.	41,130.
<b>TOTAL TO FM 990-PF, PART II, LN 14</b>	<b>10,532,026.</b>	<b>3,861,764.</b>	<b>6,670,262.</b>

---



---

**FORM 990-PF OTHER ASSETS STATEMENT 13**


---

DESCRIPTION	BEGINNING OF YR BOOK VALUE	END OF YEAR BOOK VALUE	FAIR MARKET VALUE
ACCRUED INCOME RECEIVABLE DUE FROM BROKER	1,995,290.	1,416,200.	1,416,200.
RETIREMENT PLAN ASSET	12,161,295.	25,945,689.	25,945,689.
ADVANCES AND OTHER RECEIVABLES	1,969,036.	2,162,642.	2,162,642.
PREPAID FEDERAL EXCISE TAX	64,252.	6,037.	6,037.
PROGRAM RELATED INVESTMENTS	5,573,002.	0.	0.
OPERATING LEASE RIGHT OF USE ASSET	25,653,304.	18,971,538.	18,971,538.
	8,596,861.	7,359,283.	7,359,283.
<b>TO FORM 990-PF, PART II, LINE 15</b>	<b>56,013,040.</b>	<b>55,861,389.</b>	<b>55,861,389.</b>

---



---

**FORM 990-PF OTHER LIABILITIES STATEMENT 14**


---

DESCRIPTION	BOY AMOUNT	EOY AMOUNT
DEFERRED FEDERAL EXCISE TAX	22,248,640.	24,836,165.
RETIREMENT PLAN LIABILITY	2,748,166.	2,432,030.
ACCRUED VACATION	890,327.	1,168,550.
GRANT REFUNDS PENDING MODIFICATION	6,355,762.	3,852,387.
OPERATING LEASE LIABILITIES	9,441,992.	8,365,590.
FEDERAL EXCISE TAX PAYABLE	0.	4,555,771.
ALLOWANCE FOR CREDIT LOSSES	0.	646,935.
<b>TOTAL TO FORM 990-PF, PART II, LINE 22</b>	<b>41,684,887.</b>	<b>45,857,428.</b>

FORM 990-PF

NAME OF FOREIGN COUNTRY IN WHICH  
ORGANIZATION HAS FINANCIAL INTEREST

STATEMENT 15

NAME OF COUNTRY

AUSTRALIA  
AUSTRIA  
BELGIUM  
CANADA  
DENMARK  
FINLAND  
FRANCE  
GERMANY  
HONG KONG  
INDONESIA  
ITALY  
JAPAN  
NETHERLANDS  
NEW ZEALAND  
NORWAY  
PORTUGAL  
SINGAPORE  
SOUTH AFRICA  
KOREA (SOUTH)  
SPAIN  
SWEDEN  
SWITZERLAND  
TAIWAN  
UNITED KINGDOM

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST

61-1915057

ADDRESS

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE  
LONDON, UNITED KINGDOM WC2H 9EA

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT  
OF TRANSFER

50,000,000.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR  
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT  
OF TRANSFER

60,730,000.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY  
FEEDER, L.P.

98-1142649

ADDRESS

2929 ARCH STREET 17TH FLOOR  
PHILADELPHIA, PA 19104

DESCRIPTION OF TRANSFER

MANAGEMENT FEE

AMOUNT  
OF TRANSFER

720,114.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

PITANGO SPV

98-1492234

ADDRESS

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.  
HERZLIYA, ISRAEL

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT  
OF TRANSFER

377,510.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

STARTUP HEALTH T1D PRI LP

93-2618051

ADDRESS

2000 BROADWAY, 18TH FLOOR  
NEW YORK, NY 10023

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT  
OF TRANSFER

5,000,000.

TOTAL AMOUNT OF TRANSFERS TO CONTROLLED ENTITIES

116,827,624.

FORM 990-PF

TRANSFERS FROM CONTROLLED ENTITIES  
PART VI-A, LINE 11

STATEMENT 17

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

CHATHAM CO-INVEST

85-0651355

ADDRESS

26 MAIN STREET, SUITE 204  
CHATHAM, NJ 07928

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT  
OF TRANSFER

11,475,370.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

ESTATE OF LEONA M. HELMSLEY

20-7535047

ADDRESS

230 PARK AVENUE, SUITE 659  
NEW YORK, NY 10169

DESCRIPTION OF TRANSFER

CONTRIBUTION

AMOUNT  
OF TRANSFER

20,000,000.



THE LEONA M. AND HARRY B. HELMSLEY CHARI

13-7184401

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR  
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT  
OF TRANSFER

24,829,704.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY  
FEEDER, L.P.

98-1142649

ADDRESS

2929 ARCH STREET 17TH FLOOR  
PHILADELPHIA, PA 19104

DESCRIPTION OF TRANSFER

DISTRIBUTION

AMOUNT  
OF TRANSFER

13,422,216.

TOTAL AMOUNT OF TRANSFERS FROM CONTROLLED ENTITIES

69,727,290.

FORM 990-PF

SCHEDULE OF CONTROLLED ENTITIES  
PART VI-A, LINE 11

STATEMENT 18

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

CHATHAM CO-INVEST

85-0651355

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

26 MAIN STREET, SUITE 204  
CHATHAM, NJ 07928

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

ESTATE OF LEONA M. HELMSLEY

20-7535047

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

230 PARK AVENUE, SUITE 659  
NEW YORK, NY 10169

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

HELMSLEY ENTERPRISES, INC.

13-2665914

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

230 PARK AVENUE, SUITE 659  
NEW YORK, NY 10169

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM WORLD SMALL CAP EQUITY FUND, L.P.

83-2888004

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

11150 SANTA MONICA BLVD., STE. 200  
LOS ANGELES, CA 90025

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST

61-1915057

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE  
LONDON, UNITED KINGDOM WC2H 9EA

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

1345 AVENUE OF THE AMERICAS 42ND FLOOR  
NEW YORK, NY 10105

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY  
FEEDER, L.P.

98-1142649

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

2929 ARCH STREET 17TH FLOOR  
PHILADELPHIA, PA 19104

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

PITANGO SPV

98-1492234

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.  
HERZLIYA, ISRAEL

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

STARTUP HEALTH T1D PRI LP

93-2618051

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

2000 BROADWAY, 18TH FLOOR  
NEW YORK, NY 10023

FORM 990-PF

PART VII - LIST OF OFFICERS, DIRECTORS  
TRUSTEES AND FOUNDATION MANAGERS

STATEMENT 19

NAME AND ADDRESS	TITLE AND AVRG HRS/WK	COMPEN- SATION	EMPLOYEE BEN PLAN CONTRIB	EXPENSE ACCOUNT
SANDOR FRANKEL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 25.00	150,000.	0.	0.
DAVID PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 35.00	150,000.	0.	0.
WALTER PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 32.00	150,000.	0.	0.
SARAH E. PAUL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF EXECUTIVE OFFICER 40.00	918,521.	213,448.	0.
JACQUELINE F. BAUSCH C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	GENERAL COUNSEL 40.00	592,495.	94,658.	0.
ROSALIND M. HEWSENIAN C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF INVESTMENT OFFICER THRU 12/31/23 40.00	1,148,308.	175,873.	0.
JOSHUA W. FENTON C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF INVESTMENT OFFICER FROM 1/1/24 40.00	794,891.	190,587.	0.
NICHOLAS J. SCHIAVO C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF FINANCIAL OFFICER 40.00	472,114.	121,468.	0.
TOTALS INCLUDED ON 990-PF, PAGE 6, PART VII		4,376,329.	796,034.	0.

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

3103 BEE CAVES ROAD, SUITE 201  
AUSTIN, TX 78746

GRANT AMOUNT

5,000,000.

DATE OF GRANT

02/20/18

AMOUNT EXPENDED

5,000,000.

PURPOSE OF GRANT

INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA

DATES OF REPORTS BY GRANTEE

1/2019, 1/2020, 2/2021, 1/2022, 1/2023, 1/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

3103 BEE CAVES ROAD, SUITE 201  
AUSTIN, TX 78746

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
7,923,870.	09/09/19	7,923,870.

PURPOSE OF GRANT

INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA

DATES OF REPORTS BY GRANTEE

PRIOR+7/2021, 1/2022, 7/2022, 1/2023, 1/2024, 4/2024, 5/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

3103 BEE CAVES ROAD, SUITE 201  
AUSTIN, TX 78746

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,800,000.	12/20/22	968,479.

PURPOSE OF GRANT

EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY

DATES OF REPORTS BY GRANTEE

1/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ABVANCE THERAPEUTICS, INC.

GRANTEE'S ADDRESS

38 BENNINGTON COURT  
RENO, NV 89511

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,920,820.	06/18/24	0.

PURPOSE OF GRANT

DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON TO IMPROVE THE LIVES OF THOSE LIVING WITH T1D.

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE



GRANTEE'S NAME

AKSTON BIOSCIENCES CORPORATION

GRANTEE'S ADDRESS

100 CUMMINGS CENTER, SUITE 454C  
BEVERLY, MA 01915

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
6,194,000.	03/01/17	5,843,336.

PURPOSE OF GRANT

PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY & IMPROVE QUALITY OF LIFE FOR PEOPLE LIVING WITH T1D

DATES OF REPORTS BY GRANTEE

PRIOR+2/2021, 6/2022, 3/2023, 6/2023, 12/2023, 3/2024, 6/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBERTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET  
LONDON, ONTARIO, CANADA

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,390,428.	11/20/18	2,751,742.

PURPOSE OF GRANT

STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM TO IMPROVE CARE OF CD PATIENTS

DATES OF REPORTS BY GRANTEE

PRIOR+6/2021, 12/2021, 6/2022, 2/2023, 7/2023, 11/2023, 3/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET  
LONDON, ONTARIO, CANADA

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
894,043.	02/10/22	287,504.

PURPOSE OF GRANT

DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES FOR PATIENTS

DATES OF REPORTS BY GRANTEE

2/2023, 6/2023, 3/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600  
CHICAGO, IL 60606

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,500,000.	11/20/21	1,270,333.

PURPOSE OF GRANT

EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE

DATES OF REPORTS BY GRANTEE

1/2022, 5/2022, 12/2022, 1/2023, 12/2023, 1/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

55 VICTORIA PARADE, LEVEL 2  
FITZROY, AUSTRALIA

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,560,371.	07/23/20	2,296,388.

PURPOSE OF GRANT

FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES

DATES OF REPORTS BY GRANTEE

PRIOR +2/2022, 7/2022, 8/2022, 2/2023, 8/2023, 3/2024, 8/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BIORASIS, INC.

GRANTEE'S ADDRESS

1392 STORRS RD U4213, ATL ROOM 106  
STORRS, CT 06269

GRANT AMOUNT

3,016,000.

DATE OF GRANT

02/06/18

AMOUNT EXPENDED

1,988,500.

PURPOSE OF GRANT

EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D

DATES OF REPORTS BY GRANTEE

PRIOR+ 2/2021, 7/2021, 5/2022, 11/2022, 5/2023, 6/2024, 7/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BREAKTHROUGH T1D (FKA JDRF INTERNATIONAL)

GRANTEE'S ADDRESS

200 VESEY STREET, 28TH FLOOR  
NEW YORK, NY 10281

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
8,200,000.	05/21/12	8,200,000.

PURPOSE OF GRANT

ORTHOGONALLY REDUNDANT GLUCOSE SENSOR TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 7/2016, 6/2017, 6/2019, 11/2019, 5/2020, 8/2020

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

CAPILLARY BIOMEDICAL, INC.

GRANTEE'S ADDRESS

2 WRIGLEY  
IRVINE, CA 92617

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,500,000.	09/02/20	1,428,325.

PURPOSE OF GRANT

ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 1/2022, 5/2022, 6/2022, 3/2023, 8/2023, 8/2024

ANY DIVERSION BY GRANTEE

NONE



GRANTEE'S NAME

DIABETOMICS, INC.

GRANTEE'S ADDRESS

2345 NE OVERLOOK DRIVE, SUITE #140  
HILLSBORO, OR 97006

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,031,900.	01/11/18	4,031,900.

PURPOSE OF GRANT

POINT-OF-CARE RAPID TESTS FOR T1D SCREENING AND INTERVENTION

DATES OF REPORTS BY GRANTEE

PRIOR+ 4/2022, 9/2022, 10/2022, 7/2023, 10/2023, 7/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DREAMED DIABETES LTD.

GRANTEE'S ADDRESS

14 KAPLAN ST  
PETAH TIKVA, TEL AVIV, ISRAEL

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,850,000.	02/23/23	0.

PURPOSE OF GRANT

INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES

DATES OF REPORTS BY GRANTEE

5/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

FEROX THERAPEUTICS

GRANTEE'S ADDRESS

111 TOWN SQUARE PLACE, SUITE 1203 PMB 1034  
JERSEY CITY, NJ 07310

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
872,300.	11/20/18	872,300.

PURPOSE OF GRANT

INSULIN INDUCED HYPOGLYCEMIA PREVENTION PROGRAM TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 4/2020, 7/2020, 12/2020, 1/2021, 4/2021, 7/2021

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

GRAND CANYON UNIVERSITY

GRANTEE'S ADDRESS

3300 WEST CAMELBACK ROAD  
PHOENIX, AZ 85017

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,274,027.	06/26/19	2,274,027.

PURPOSE OF GRANT

DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR TO IMPROVE T1D CARE

DATES OF REPORTS BY GRANTEE

6/2020, 7/2020, 7/2021, 4/2022, 1/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1  
MUNSTER, GERMANY

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,614,000.	11/08/23	0.

PURPOSE OF GRANT

DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF  
INTESTINAL ULTRASOUND EDUCATION.

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1  
MUNSTER, GERMANY

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,752,086.	10/22/20	2,141,708.

PURPOSE OF GRANT

DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.

DATES OF REPORTS BY GRANTEE

6/2021, 12/2021, 8/2022, 11/2022, 12/2022, 8/2023, 2/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1  
MUNSTER, GERMANY

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
342,387.	03/23/22	172,967.

PURPOSE OF GRANT

POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES:  
INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY FOR CD PATIENTS

DATES OF REPORTS BY GRANTEE

3/2023

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1  
MUNSTER, GERMANY

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,556,119.	06/22/23	338,377.

PURPOSE OF GRANT

THE EXTENT STUDY TO IMPROVE THE CARE OF CROHN'S DISEASE.

DATES OF REPORTS BY GRANTEE

5/2024, 8/2024

ANY DIVERSION BY GRANTEE

NONE



GRANTEE'S NAME

PERCUSENSE, INC,

GRANTEE'S ADDRESS

25134 RYE CANYON LOOP  
VALENCIA, CA 91355

GRANT AMOUNT

2,500,000.

DATE OF GRANT

09/02/20

AMOUNT EXPENDED

1,850,000.

PURPOSE OF GRANT

DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 4/2023, 5/2023, 7/2023, 8/2023, 10/2023, 6/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

STARTUP HEALTH T1D PRI LP

GRANTEE'S ADDRESS

2000 BROADWAY, 18TH FLOOR  
NEW YORK, NY 10023

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
5,000,000.	01/30/23	2,573,260.

PURPOSE OF GRANT

CATALYZING SEED AND EARLY-STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS

DATES OF REPORTS BY GRANTEE

3/2023, 11/2023, 6/2024, 9/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND  
BRISBANE, QUEENSLAND, AUSTRALIA

GRANT AMOUNT

2,493,864.

DATE OF GRANT

09/08/21

AMOUNT EXPENDED

865,466.

PURPOSE OF GRANT

LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES

DATES OF REPORTS BY GRANTEE

1/2023, 3/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND  
BRISBANE, QUEENSLAND, AUSTRALIA

GRANT AMOUNT

226,017.

DATE OF GRANT

05/22/23

AMOUNT EXPENDED

45,564.

PURPOSE OF GRANT

GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF  
ISLET AUTOIMMUNITY

DATES OF REPORTS BY GRANTEE

3/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THETIS PHARMACEUTICALS, LLC

GRANTEE'S ADDRESS

54 DANBURY ROAD, SUITE 285  
RIDGEFIELD, NJ 06877

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
5,069,660.	02/24/22	3,934,500.

PURPOSE OF GRANT

DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE

DATES OF REPORTS BY GRANTEE

PRIOR+5/2023, 9/2023, 12/2023, 2/2024, 4/2024, 6/2024, 7/2024

ANY DIVERSION BY GRANTEE

NONE

FORM 990-PF

OTHER PROGRAM-RELATED INVESTMENTS

STATEMENT 21

DESCRIPTION

AMOUNT

BIORASIS, INC. - EARLY FEASIBILITY STUDIES OF THE  
GLUCOWIZZARD IN CARE FOR T1D

687,500.

DESCRIPTION

AMOUNT

PERCUSENSE, INC. - DEVELOPMENT OF CONTINUOUS GLUCOSE AND  
KETONE METER TO IMPROVE CARE OF T1D

500,000.

TOTAL TO FORM 990-PF, PART VIII-B, LINE 3

1,187,500.

990-PF

INVOLVEMENT WITH NONCHARITABLE ORGANIZATIONS  
PART XVI, LINE 1, COLUMN (D)

STATEMENT 22

NAME OF NONCHARITABLE EXEMPT ORGANIZATION

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

DESCRIPTION OF TRANSFERS, TRANSACTIONS, AND SHARING ARRANGEMENTS

GRANT IN SUPPORT OF EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE

## GENERAL EXPLANATION

STATEMENT 23

## FORM/LINE IDENTIFIER AND DESCRIPTION/RETURN REFERENCE

FORM 990-PF, PART VI-A, LINE 11: - CONTROLLED ENTITIES

## EXPLANATION:

THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:

CHATHAM CO-INVEST  
26 MAIN STREET, SUITE 204  
CHATHAM, NJ 07928  
EIN# 85-0651355

ESTATE OF LEONA M. HELMSLEY  
230 PARK AVENUE, SUITE 659  
NEW YORK, NY 10169  
EIN# 20-7535047

HELMSLEY ENTERPRISES, INC.  
230 PARK AVENUE, SUITE 659  
NEW YORK, NY 10169  
EIN# 13-2665914

LACM WORLD SMALL CAP EQUITY FUND, L.P.  
11150 SANTA MONICA BLVD., STE. 200  
LOS ANGELES, CA 90025  
EIN# 83-2888004

MARATHON-LONDON GLOBAL SELECT  
ORION HOUSE, 5 UPPER ST. MARTIN'S LANE  
LONDON, UK WC2H 9EA  
EIN# 61-1915057

MHR LONGEVITY PARTNERS  
1345 AVENUE OF THE AMERICAS 42ND FLOOR  
NEW YORK, NY 10105  
EIN# 98-1471155

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.  
2929 ARCH STREET 17TH FLOOR  
PHILADELPHIA, PA 19104  
EIN# 98-1142649

PITANGO SPV  
BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.  
HERZLIYA, ISRAEL  
EIN# 98-1492234

STARTUP HEALTH T1D PRI LP  
2000 BROADWAY, 18TH FLOOR  
NEW YORK, NY 10023  
EIN# 93-2618051

---

---

GENERAL EXPLANATION

STATEMENT 24

---

FORM/LINE IDENTIFIER

---

FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:

EXPLANATION:

ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.